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ABSTRACT
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Title: Novel Tools to Study Modulation of Adenylyl Cyclase Isoforms
Committee Chair: Val J. Watts

Adenylyl cyclases (AC) are a major component of the cAMP signaling pathway. The
differential regulatory properties and tissue expression patterns of the nine transmembrane AC
isoforms provide unique mechanisms to regulate cAMP signaling in a precise and organized
manner. However, the understanding of the individual roles of AC isoforms in the overall cellular
response presents considerable challenges due to the expression of multiple AC isoforms in cells,
and the lack of available tools to accurately detect isoform-specific AC expression or selectively
modulate its catalytic activity. For these reasons, the research aims of this study were to develop a
series of tools to characterize isoform-specific AC responses. In the first approach, a cell line with
low cAMP levels in response to drug-stimulated conditions was developed by disrupting the
expression of two of the most abundant ACs (i.e. AC3 and AC6) expressed in HEK293 cells using
the CRISPR-Cas9 gene editing technology. Our HEK-ACΔ3/6 cell line displayed a substantially
reduced cAMP response to forskolin (less than 95%) and to endogenous Gαs-coupled receptors,
β2AR and EP2R (75% and 85% reduction respectively), compared to the cAMP responses of the
parental HEK293 cells. Characterization of the cAMP responses of the nine membrane-bound AC
isoforms to stimulatory and inhibitory paradigms in the HEK-ACΔ3/6 knockout cell line indicated
that the regulatory properties of the AC isoforms previously reported in the literature were
recapitulated. Furthermore, a comparison of the cAMP responses of a series of AC1 mutants
demonstrated that the HEK-ACΔ3/6 cell line provided an enhanced signal window over the
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parental HEK293 cells to characterize AC constructs with reduced catalytic activity. A second
approach to better understand the individual role of AC isoforms in biological responses is by
exploiting isoform-specific interactions with AC regulators to modulate AC activity. Thus, it was
also determined in these studies that juxtamembrane domains derived from AC2 could modulate
Gβγ-mediated AC activity. Based on the high degree of sequence homology between the
juxtamembrane region of the C2a domain of Gβγ-stimulated cyclases, AC2, AC4, and AC7,
together with surface plasmon resonance analysis with a C2a derived peptide (C2-20), it was
demonstrated that Gβγ subunits bind with high affinity to this C2a juxtamembrane region. In
addition, a minigene expressing the C2-20 peptide downstream of a membrane-anchoring domain,
CD8, abolished Gβγ-mediated potentiation of PMA-stimulated AC2 activity. Mutagenesis studies
indicated that several residues towards the middle of the sequence of the C2-20 peptide mediated
the inhibitory activity on Gβγ-signaling, and the inhibitory effects of the minigene appeared to be
selective for Gβγ-mediated stimulation of AC2. In the last approach to study isoform-specific AC
responses, a series of structure activity relationship (SAR) studies were carried out towards the
development of potent and selective AC1 and AC8 inhibitors. Initial SAR studies included analogs
of the selective AC1 inhibitor, ST034307, that revealed a structure relationship between AC1 and
AC8 selective inhibition. Furthermore, two new scaffolds were identified from a 10,000compound screening campaign from the Life Chemicals compound collection, that showed dual
inhibitory activity of calcium-stimulated AC1 and AC8 activity or selective inhibition of AC1
activity with sub-micromolar potency. Preliminary SAR analysis of various analogs of the dual
AC1/AC8 inhibitory scaffold led to analogs with differential selectivity profiles for AC1 and AC8
and improved potency on both Ca2+/calmodulin-stimulated AC isoforms. In conclusion,
throughout this work, a cellular model, a peptide/minigene, and a series of inhibitor scaffolds were
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developed as cellular and pharmacological tools to facilitate the study of the individual responses
and respective roles of AC isoforms in cellular signaling.
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CHAPTER 1. INTRODUCTION

1.1

Cyclic AMP(cAMP) Signaling Pathway

Cyclic adenosine monophosphate (cAMP) is one of the major secondary messengers of
cellular signaling. At the molecular level, cAMP is responsible for multiple biological processes
because it plays a critical role in the mechanism by which extracellular signals are translated into
cellular responses. The cAMP signaling cascade initiates when an extracellular stimulus in the
form of a photon, hormone, neurotransmitter, odorant, or lipid is recognized by the cell-surface
receptors, G-protein coupled receptors (GPCR) (Ji et al., 1998). Ligand-activated GPCR associates
to the heterotrimeric G-protein and promotes the dissociation of the Gαs-subunit from the
heterotrimeric complex (Mahoney and Sunahara, 2016). The Gαs-subunit subsequently modulates
the activity of the enzyme adenylyl cyclase (AC) which is responsible for the catalytic conversion
of ATP into cAMP (Sunahara and Insel, 2016). Dynamic equilibrium between AC activation and
cAMP degradation by cyclic nucleotide phosphodiesterase enzymes (PDEs) determines the
duration of the cAMP signal in a given cell (Sassone-Corsi, 2012). An increase of intracellular
cAMP levels then leads to the activation of three main cAMP effectors: protein kinase A (PKA),
the exchange proteins activated by cAMP (EPAC), and/or cyclic-nucleotide-gated ion channels
(reviewed in Cheng et al., 2008; Kaupp and Seifert, 2002; Skalhegg and Tasken, 2000). Fig. 1.1
provides an overview of the cAMP signaling pathway. The cAMP effectors ultimately mediate a
myriad of cellular responses by activating several other enzymes, changing membrane potential or
regulating gene expression.
When cAMP was discovered in 1958 by Nobel laureate Earl W. Sutherland, it was thought
impossible that numerous physiological changes in response to various hormones other than

An extracellular signal is recognized by G protein-coupled receptors (1), triggering the dissociation of the heterotrimeric Gprotein into a GTP-bound Gαs subunit and the Gβγ complex. Subsequently, the Gαs subunit activates the membrane-bound
enzyme, adenylyl cyclase (2) which is responsible of synthesizing cAMP from ATP (3). An increase of intracellular levels
activates the cAMP effectors: protein kinase A (PKA) (4), Epac (5) or cyclic-nucleotide-gated ion channels (CNGs) (6),
ultimately leading to a cellular response.

Figure 1.1 Overview of the cAMP signaling pathway.

2

3
epinephrine were mediated intracellularly by a common secondary messenger (Sutherland and
Rall, 1958). Sutherland and Rall initially proposed that hormones did not cross the plasma
membrane, thus, receptors at the cell surface recognized the extracellular stimuli and translated
into cAMP. Decades later, in the laboratory of Nobel laurate Alfred Gilman it was determined
that the surface receptor and adenylyl cyclase were separate proteins, and that the receptor triggers
AC activation via an intermediary, the GTP-dependent G-protein (Ross et al., 1978). Upon
recognition of an extracellular stimuli by the GPCR, the G-protein couples to the receptor, and the
receptor promotes the exchange of GDP for GTP to activate the G-protein (Sprang, 1997). GPCRs
can be linked to three major classes of Gα-proteins that not only stimulate (Gαs) or inhibit (Gαi)
AC activity, but also activate (Gαq) phospholipase C (PLC) which can mediate the release of Ca2+
from intracellular stores (reviewed in McCudden et al., 2005). GPCRs are the largest family of
surface receptors and because of their versatile mechanisms of activation, they have been a
therapeutic target of great interest for numerous human diseases (Sriram and Insel, 2018).
However, the cAMP signaling cascade has demonstrated not to be a simple chain reaction
downstream of GPCRs. Since the discovery of cAMP more than 60 years ago, our understanding
of the cAMP signaling pathway has evolved from a linear signaling cascade to a dynamic network
of signaling events. Emerging evidence supports that the regulatory properties and the
spatiotemporal distribution of the cAMP network components (AC, PDE, cAMP effectors) create
local cAMP domains that orchestrate organized and precise cellular processes (Arora et al., 2013).
As mentioned earlier, the propagation of the cAMP signal within the cell results from the balance
of cAMP synthesis and degradation by ACs and PDEs (Sassone-Corsi, 2012). Ten different AC
isoforms have been cloned, and 21 isoforms of PDEs exist. AC isoforms are regulated by various
mechanisms other than G-protein activation, and PDE isoforms also exhibit different regulatory
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properties and binding affinities for cAMP (Dessauer et al., 2017; Maurice et al., 2014). Hence,
multiple signal inputs besides GPCRs can trigger or prevent an increase of intracellular cAMP
levels, and isoform-specific regulatory properties along with specific cell and tissue expression
patterns of AC and PDE isoforms are additional mechanisms by which a given cell can mediate
specific cAMP responses (Bender and Beavo, 2006; Hanoune and Defer, 2001).
High resolution microscopy and fluorescence sensors most recently have allowed precise
monitoring of the different components of the cAMP signaling pathway (Calebiro and Maiellaro,
2014). It has become apparent that the cAMP signal does not spread uniformly across the cell, and
distinct cAMP pools act in subcellular microdomains. Cyclic AMP diffuses freely in the cytosol;
however, distinct GPCRs, ACs or PDEs sequestered at these subcellular compartments create a
localized increase of cAMP levels that only causes selective activation of nearby effectors and
does not allow the cAMP signal to rapidly diffuse (Arora et al., 2013). As more evidence for the
existence of subcellular pools of cAMP is emerging, the roles of scaffolding/anchoring proteins
such as caveolin and A-kinase anchoring proteins (AKAPs) in cAMP compartmentalization is also
becoming more evident (Kapiloff et al., 2014; Ostrom and Insel, 2004). Specific interactions
between ACs and/or cAMP effectors with anchoring/scaffolding proteins mediate the formation
of signalosome complexes that coordinate the effects of cAMP (Dessauer, 2009). Therefore,
localized cAMP signaling is another mechanism by which cAMP levels in the cell are fine-tuned
to induce a precise cellular response.
In conclusion, the diversity of GPCR signaling is not the only basis that controls cAMP
signaling and determines the signaling outcome. Intracellular inputs mediated by adenylyl cyclases
and PDEs in combination with the spatiotemporal control of the cAMP signal, also enables finetuning of the cAMP-mediated cellular responses. Hence, further understating of the interplay
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between the cAMP network components opens novel avenues that should be explored for the
development of therapeutic agents that can modulate cAMP signaling.

1.2

Adenylyl Cyclases (AC), a key determinant of cAMP-mediated cellular responses

The term of adenyl cyclase was first introduced by Sutherland in 1962 when describing the
enzyme responsible for cAMP production (Sutherland et al., 1962). It was not until 1989 that the
first mammalian AC (mAC) was cloned by Krupinski in the Gilman laboratory, and since then
additional 8 membrane-bound ACs and one soluble AC have been characterized in mammals
(Bakalyar and Reed, 1990; Buck et al., 1999; Defer et al., 1994; Feinstein et al., 1991; Gao and
Gilman, 1991; Ishikawa et al., 1992; Katsushika et al., 1992; Krupinski et al., 1989; Paterson et
al., 1995; Watson et al., 1994). All membrane-bound mACs share an N-terminus and two
transmembrane regions (M1 and M2) of six-spanning helices that are connected by two
cytosolic/catalytic domains (C1 and C2) and comprise the enzyme’s active site (Hurley, 1999)
(Fig.1.2). The soluble AC (sAC) shares homologous cytosolic/catalytic domains to the mACs,
except they are connected by a cytosolic linker instead of the transmembrane domains (Steegborn,
2014).
Adenylyl cyclases catalyze the formation of cAMP from ATP by removing the two terminal
phosphates groups from the triphosphate “tail” and linking the remaining phosphate to the sugar
ring of the ATP molecule (Tang and Hurley, 1998). The catalytic site on the cyclase is formed
within a cleft at the interface of the C1 and C2 domain when the two domains heterodimerize
(Tesmer et al., 1997). On the opposite site of the ATP binding site, a pseudo symmetric site is also
formed at the interface where the diterpene forskolin or bicarbonate binds to tmAC 1-8 or sAC,

6

Figure 4.2 Topology of transmembrane adenylyl cyclases
The basic structure of membrane-bound adenylyl cyclases consist of a cytosolic N-terminus,
followed by two domains (M1 and M2) of six membrane-spanning α-helices and two highly
conserved catalytic domains (C1 and C2) that form the ATP-binding site at the C1-C2 interface.
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respectively (Kleinboelting et al., 2014; Tesmer et al., 1997). GPCR/G-protein activation has been
described as the major mechanism of AC regulation; however, ACs can also be regulated by
protein kinases, Ca2+/Calmodulin, divalent cations, ethanol, bicarbonate and nitric oxide
depending on the AC isoform (Dessauer et al., 2017). AC isoform-specific cAMP responses that
arise from the regulatory effects of the different AC modulators exemplifies another mechanism,
independent of GPCR activation, by which intracellular levels of cAMP mediate many different
signaling events (Hanoune and Defer, 2001). Despite the fact that ACs are ubiquitously expressed
and cells/tissues express more than one AC isoform, several AC isoforms have been associated
with specific physiological processes and emerge as interesting targets for cAMP modulation
(Pierre et al., 2009; Sadana and Dessauer, 2009).

1.3

Adenylyl cyclase Regulation

1.3.1 G protein-coupled receptors
G protein-coupled receptors are seven transmembrane receptors that comprise the largest
family of membrane proteins. Activated by a diverse class of ligands including photons, small
molecules, peptides, odorants, or lipids, GPCRs translate extracellular signals into intracellular
signals by coupling to G-proteins (Ji et al., 1998). The inactive G-protein complex is a
heterotrimeric structure composed of a Gα, Gβ, and Gγ subunits (Wall et al., 1995). The
heterotrimeric complex is localized at the plasma membrane in an inactive GDP-bound state, but
upon GPCR activation, the receptor undergoes a conformational change that promotes the
exchange of bound GDP to GTP on the Gα subunit causing the dissociation of Gα from the Gβγ
complex (reviewed by Oldham and Hamm, 2008). Both Gα and Gβγ are then free to activate their
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corresponding downstream targets such as protein kinases, ion channels, or membrane-bound
enzymes (Cabrera-Vera et al., 2003).
Depending on the Gα protein subtype that couples to the GPCR, receptor activation
primarily promotes the stimulation (Gαs) or inhibition (Gαi, Gαo) of adenylyl cyclase activity or
triggers the release of Ca2+ from intracellular stores by activating phospholipase C (PLC) via Gαq
(Exton, 1996; Taussig and Zimmermann, 1998). Once the G-protein has been activated, G proteincoupled receptor kinases (GRKs) translocate to the activated receptor and phosphorylate its Cterminus (Benovic et al., 1986). The phosphorylated C-terminus interacts with arrestins which
block further coupling of the receptor with the G-protein and mediates receptor internalization for
subsequent signal termination (Lohse et al., 1990). For a detailed review of the roles of GRKs and
arrestins in GPCR desensitization/trafficking, referred to Moore et al., 2007.
Over the past three decades, GPCRs have been a prominent target for treatment of a wide
range of diseases (Sriram and Insel, 2018). Exceptional progress has been done trying to elucidate
the pharmacology, structure and biology of more than 800 homologous GPCR genes identified in
humans (Fredriksson et al., 2003; Katritch et al., 2012). It has become clear that GPCRs functions
are not limited to G-proteins, and arrestins can mediate GPCR signaling as well (reviewed by
Smith and Rajagopal, 2016). Furthermore, certain ligands can induce specific receptor
conformations that activate a specific intracellular pathway (G-protein vs arrestin) and this
phenomenon is referred as functional selectivity or biased signaling (Goupil et al., 2012). Since
the breakthrough of the β2-adrenergic receptor crystal structure in 2011 that earned Brian Kolbika
the Nobel prize in 2012 (shared with Robert Lefkowitz), the number of GPCR crystal structures
solved also keeps increasing (Rasmussen et al., 2011). Ongoing efforts are trying to explore new
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GPCR targets (orphan receptors), develop GPCR-based drugs with fewer side effects, and decipher
GPCR signaling networks (Jacobson, 2015; Ngo et al., 2016).
G protein-coupled receptors linked to Gαs and Gαi proteins are the primary regulators of
mAC activity, whereas sAC is insensitive to GPCR activation. Gαs stimulates all nine
transmembrane AC isoforms by direct interaction with the C1-C2 catalytic domains of the AC,
and Gαi inhibits cAMP production of several AC isoforms, but its mechanism of action is not fully
understood yet (Taussig and Zimmermann, 1998; Tesmer et al., 1997). The Gβγ complex
conditionally modulates AC activity after GPCR activation, however depending on the isoform it
has stimulatory or inhibitory effects (Khan et al., 2013).
1.3.1.1 Gαs-protein
Activation of adenylyl cyclases by Gαs subunits was the first described mechanism
resulting from GPCR activation. Stimulation of the catalytic activity by Gαs protein has been
confirmed for all transmembrane adenylyl cyclases in vitro (Sunahara et al., 1996). Studies with
purified C1 and C2 catalytic domains were the first indication that Gαs triggers cAMP production
by promoting C1-C2 dimerization (Sunahara et al., 1997). The crystal structure of the heterodimer
of the C1 (AC5) and C2 (AC2) catalytic domains in complex with Gαs and forskolin, revealed that
the Gαs-protein primarily interacts with the C2 domain by inserting a switch helix motif into a
groove formed by two helices of the AC (Tesmer et al., 1997). The residues important for the
interaction with the AC are positioned on the surface of the Gαs protein that faces the plasma
membrane and that undergoes a conformational change upon GTP binding (Berlot and Bourne,
1992). In cells, the stimulatory effect of Gαs-coupled receptors is not uniform across AC isoforms,
and it is strictly dependent on expression levels of the GPCR and the subcellular localization of
the receptor and the AC (Ostrom and Insel, 2004).
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1.3.1.2 Gαi-protein
Inhibition of AC activity by Gαi has been demonstrated for AC1, AC5, and AC6 (Taussig
et al., 1993a). The degree of inhibition by Gαi depends on the stimulation mechanism, and high
concentrations of forskolin or Gαs can overcome the inhibitory effects of the G-protein (Taussig
et al., 1994). A Gαi-binding site has been characterized on the C1 domain of AC5 by mutagenesis
studies. Analogous to the Gαs-AC interaction, the Gαi-protein interacts with two alpha helices of
the C1 catalytic domain—directly opposite to the Gαs-binding site (Dessauer et al., 1998). In
contrast to Gαs, it appears that the interaction of Gαi with the AC inhibits catalytic activity by
decreasing the apparent affinity of C1 for C2 (Dessauer et al., 2002). It is worth noting that AC2
is insensitive to Gαi in vitro (Taussig et al., 1993a), but activation of Gαi-coupled receptors in cells
induces an enhancement of AC2 activity (Watts and Neve, 1997). However, the stimulatory effects
are mediated by Gβγ subunits, not by the Gαi-protein.
1.3.1.3 Gβγ subunits
The Gβγ complex can function independently from the Gα subunits and modulates a broad
range of downstream effectors (Khan et al., 2013). Depending on the AC isoform, Gβγ
conditionally stimulates or inhibits AC activity (Taussig et al., 1993b). AC2, AC4 and AC7 have
been described as Gβγ-stimulated cyclases, whereas AC1, AC3 and AC8 are inhibited by the Gβγ
complex (Diel et al., 2006; Sunahara et al., 1996). The regulation of AC5 and AC6 by Gβγ appears
to be complex since there are contradictory reports in the literature of both stimulatory and
inhibitory effects (Bayewitch et al., 1998; Gao et al., 2007). Isoform-specific binding sites have
been identified for Gβγ that are distributed across the N-terminus and the two catalytic domains of
the ACs (Boran et al., 2011; Brand et al., 2015; Chen et al., 1995; Diel et al., 2008), however it is
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not fully understood yet how the interaction of Gβγ with the cyclase distinctly promotes or
interferes with the catalytic activity.
1.3.2 Ca2+/Calmodulin (CaM)
Calcium is another critical secondary messenger that transmits signals throughout the cell.
Changes in cytosolic calcium concentrations result from ion channel activation or the opening of
intracellular Ca2+ stores triggered by GPCR (Gαq) and PLC activation. An increase of Ca2+ in the
cytosol of the cell is primarily detected by the calcium-binding protein, calmodulin (CaM), a small
and flexible protein that upon Ca2+ binding undergoes a conformational change that enables its
interaction with approximately 300 other proteins (Clapham, 2007). Major targets of calmodulin
include Ca2+/calmodulin-dependent protein kinase II (CaMKII), calcineurin, the myosin light
chain kinase (MLCK) and both bacterial (edema factor and CyaA) and mammalian (AC1 and
AC8) adenylyl cyclases (Tidow and Nissen, 2013). Calcium and cAMP signaling pathways are
not two isolated signaling events, and crosstalk between different components of each pathway
contributes to the complex and distinct cellular responses that arise from changes in cAMP or
calcium levels (Bruce et al., 2003). One mechanism by which Ca2+ regulates the cAMP pathway
is by regulating AC activity. Ca2+/calmodulin stimulates the catalytic activity of AC1 and AC8,
and high concentrations of intracellular Ca2+ inhibit AC5 and AC6 (Guillou et al., 1999; Halls and
Cooper, 2011). Similarly, Ca2+ can also indirectly modulate AC activity by inhibiting or activating
other AC regulators such as PKC and CaMKII.
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1.3.2.1 Calcium
Calcium sensitivity was one of the primary properties evaluated besides G-protein and
forskolin activation when AC isoforms were initially cloned and characterized (Choi et al., 1992;
Feinstein et al., 1991; Ishikawa et al., 1992; Katsushika et al., 1992). The stimulatory properties
of Ca2+ on membrane-bound AC activity are mediated by the calcium binding protein, calmodulin,
and the inhibitory properties are a direct consequence of Ca2+ (Halls and Cooper, 2011). When
AC5 and AC6 were first cloned, it was established in vitro that Ca2+ inhibited their catalytic
activities in a dose-dependent manner (Katsushika et al., 1992; Yoshimura and Cooper, 1992).
Later, when the crystal structure of the C1(AC5)-C2(AC2) heterodimer bound to Ca2+ was solved,
it revealed that the divalent cation competes for the binding site of the metal cofactor Mg2+ at the
active site and stabilizes an inactive conformation of the C1 and C2 domains that ATP can’t bind
to (Mou et al., 2009). Ca2+ inhibition appears to be biphasic, having a high-affinity binding site for
AC5 and AC6 and a low-affinity binding site for the rest of the isoforms (Guillou et al., 1999).
Soluble AC is insensitive to G-protein and forskolin activation, but is directly activated by Ca2+
(Litvin et al., 2003). In the crystal structure of sAC bound to Ca2+, the Ca2+ binding site was
localized at the interface of the catalytic domains and confirmed that the divalent cation promotes
catalytic activity by increasing the affinity of the active site for ATP (Kleinboelting et al., 2014).
1.3.2.2 Calmodulin
Changes in intracellular Ca2+ levels and subsequent activation of calmodulin, has stimulatory
effects on AC1 and AC8 activity (Cali et al., 1994; Tang et al., 1991). The responsiveness of AC1
and AC8 to Ca2+/calmodulin is a critical property of these two isoforms (Ferguson and Storm,
2004). In the case of AC1, Ca2+/calmodulin-stimulated activity can be observed in combination

13
with Gαs and forskolin, or it can be inhibited by Gαi and Gβγ subunits (Tang et al., 1991). Although
the exact mechanism of activation of Ca2+/calmodulin has not been established, it is known that
the stimulatory effects of calmodulin are mediated by a direct interaction with the catalytic
domains of AC1 and AC8 (Masada et al., 2012). For AC1, the Ca2+/calmodulin binding domain
was found in the C1b domain when domain swapping of the C1b region of AC2 for the C1b domain
of AC1 made AC2 responsive to Ca2+/calmodulin (Levin and Reed, 1995). In contrast, AC8 has
two binding domains for calmodulin, one in the N-terminus and one in the C2 domain that were
determined by GST pull-down and mutagenesis studies (Gu and Cooper, 1999). Adenylyl cyclase
type 3 (AC3) is also described as a Ca2+/calmodulin-sensitive cyclase based on a limited set of
studies. The activation of AC3 by Ca2+/calmodulin appears to be conditional because in order to
observe a stimulatory effect on AC3 activity, other mechanisms of activation such as Gαs and
forskolin must be present (Choi et al., 1992; Mamluk et al., 1999).
1.3.3 Protein Kinases
Protein kinases are cytosolic enzymes that regulate about 30% of the human proteome by
transferring a phosphate group from ATP onto a free hydroxyl group of its substrates (Cheng et
al., 2011). This reversible post-translational modification induces conformational changes that
alter the structure and function of the phosphorylated-protein. More than 500 protein kinases have
been identified in humans, and they all have precise mechanisms to recognize their specific
targets/substrates (Ubersax and Ferrell, 2007). Protein Kinase A (PKA) is the prominent effector
of cAMP. When there is an increase of intracellular cAMP levels, the regulatory subunits of PKA
bind cAMP causing a conformational change that provokes the release of the catalytic subunits
(Cheng et al., 2011).
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In addition, protein kinases also regulate the activity of several AC isoforms and phosphorylation
sites have been identified on AC2, AC3, AC5, AC6 and AC8 (Iwami et al., 1995; Jacobowitz and
Iyengar, 1994; Kawabe et al., 1994). PKA has an inhibitory effect on AC5 and AC6 activity by a
negative feedback loop mechanism, PKC displayed stimulatory and inhibitory effects on AC2 and
AC6, respectively (Jacobowitz et al., 1993; Lai et al., 1997), and Ca2+/calmodulin-dependent
protein kinase II (CaMKII) inhibits AC3 activity, but activates AC9 (Cumbay and Watts, 2005;
Wei et al., 1996) .
1.3.3.1 Protein Kinase A
Evidence with purified enzymes demonstrated that PKA phosphorylates AC5 and it
reduces AC activity by decreasing the catalytic rate of cAMP synthesis (Iwami et al., 1995).
Phosphorylation inhibits Gαs-mediated activation of AC6 but has no major effects on Gαsstimulated activity of AC1 and AC2 (Chen et al., 1997). PKA phosphorylates AC6 at Ser674, within
a region involved in Gαs activation; however, the phosphorylated residue is only conserved
between AC5 and AC6 (Chen et al., 1997). Most recently, a phosphorylation site on the N-terminus
of AC8 (Ser112) was identified that decreases the cAMP response of the cyclase to Ca2+
(Willoughby et al., 2012). Analogous to AC5 and AC6 phosphorylation by PKA, the interaction
with the A-kinase-anchoring protein, AKAP79/150, serves as platform for PKA to phosphorylate
AC8 by colocalizing it in close proximity to the cyclase (Bauman et al., 2006; Beazely and Watts,
2006; Willoughby et al., 2012).
1.3.3.2 Protein Kinase C
PKC enzymes are activated by Ca2+ or diacylglycerol (DAG), and they are not cAMPdependent (Huang, 1989). Enhancement of AC2 and AC7 activity by PKC has been demonstrated
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in membrane preparations and intact cells (Jacobowitz et al., 1993; Nelson et al., 2003; Watson et
al., 1994). Particularly, AC2 activity can be stimulated by PKC activators (PMA, TPA) alone or
in combination with Gβγ subunits, forskolin, or Gαs (Jacobowitz and Iyengar, 1994; Watts and
Neve, 1997; Yoshimura and Cooper, 1993). Three phosphorylation sites have been proposed on
AC2, two sites on the C1 domain at Ser490 and Ser543, and one site on the C2 domain at Thr1057
(Bol et al., 1997; Shen et al., 2012). Much less evidence exists for the regulation of other AC
isoforms by PKC. For instance, only one study has provided evidence for the inhibitory effects of
PKC on AC6 activity that appear to be through a calcium-independent mechanism (Lai et al.,
1997). However, after chronic activation of the dopamine D2 receptor and activation of the PKCRaf1 pathway, sensitization of AC6 activity is also potentiated (Beazely and Watts, 2005). In
addition, several other reports have had conflicting results about PKC regulation of AC1, AC3,
AC5 and AC9 activity (reviewed by Halls and Cooper, 2011).
1.3.3.3 Ca2+/calmodulin-dependent protein kinase II (CaMKII)
CaMKII is one of the main effectors of the calcium binding protein, calmodulin. Ca2+-bound
CaM activates CaMKII by displacing an autoinhibitory domain that prevents substrate binding
(serine/threonine residues) to the catalytic domain (Hanson and Schulman, 1992). Limited
evidence is available on CaMKII regulation of AC3 activity, and only one report has shown the
inhibitory effects of CaMKII on Gαs- and forskolin-stimulated AC3 activity (Wei et al., 1996).
Wei et al., 1996 showed that neither PKA nor PKC phosphorylated AC3, but rather CaMKII in a
calcium-dependent manner phosphorylated Ser1076 of the C2 domain of AC3. Particularly,
phosphorylation of Ser1076 was proved to be mediated by CaMKII in endogenous AC3 of mouse
olfactory cilia and primary olfactory neurons, suggesting a role of the Ca2+/calmodulin-dependent
kinase in the regulation of cAMP responses associated with olfactory signaling (Wei et al., 1998).
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CaMKII also appears to potentiate AC9 activity (Cumbay and Watts, 2005). By using the CaM
inhibitor W7 and the CaMKII inhibitor KN62, it was determined that the enhancement of Gαsmediated stimulation of AC9 activity after Gαq-coupled receptor activation, was induced by
CaMKII activation (Cumbay and Watts, 2005).
1.3.4 Additional Isoform-specific Regulators
AC isoforms are also regulated by chemical compounds such as bicarbonate, ethanol and nitric
oxide (Dessauer et al., 2017).
Bicarbonate: Although there is a high degree of homology between the catalytic domains of
transmembrane ACs and the soluble AC, sAC accommodates a bicarbonate ion at the pseudo
symmetric site rather occupied in the membrane-bound ACs by the diterpene forskolin
(Kleinboelting et al., 2014; Steegborn, 2014). Binding of bicarbonate ions increases the Vmax of
the enzyme but has no effect on the affinity for ATP (Litvin et al., 2003). The ability of bicarbonate
to directly regulate sAC depicts a mechanism by which changes in pH modulate cellular signaling.
Nitric oxide (NO): The inhibitory effects of nitric oxide on AC activity are selective for the closely
related cyclases, AC5 and AC6. The inhibitory actions of NO are directly on the catalytic domains
of the AC and are not a result of an indirect effect through other NO effectors such as G-proteins
or phosphodiesterases (Hill et al., 2000). Evidence with NO and AC6 suggests that NO inhibits
the catalytic activity of the AC by decreasing the Vmax of the enzyme, and that it preferably binds
to the inactive/basal conformation of the AC because occupancy of the active site by ATP
diminished the ability of NO to inhibit AC6 activity (McVey et al., 1999).
Ethanol: The regulatory properties of ethanol on AC activity so far have only been demonstrated
on AC7 (Nelson et al., 2003). Studies with purified catalytic domains or with cells overexpressing
AC7 showed that ethanol alone potentiated AC activity, but it decreased the cAMP responses
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induced by forskolin or/and Gαs (Qualls-Creekmore et al., 2017). The multiplicity of regulatory
mechanisms that modulate adenylyl cyclase activity are other effective ways that the cell finetunes its responses to an extracellular signal. The regulatory properties of the AC isoforms
previously described are summarized in Table 1.1.
To achieve a precise cellular response, the cAMP pathway requires additional levels of
complexity, despite the diversity of the human GPCR family and the variety of ligands/signals that
induce GPCR activation. Regulation of AC activity by a variety of intracellular agents also allows
the integration of signal inputs from inside and outside of the cell (crosstalk) (Yan et al., 2016). In
addition, identifying isoform specific responses to regulators is also critical to elucidate the
contribution of each AC isoform to a cellular response given that adenylyl cyclase expression is
ubiquitous across tissues, and cells tend to express more than one AC isoform. Furthermore, based
on these isoform-specific regulatory properties, membrane-bound adenylyl cyclase isoforms are
subdivided into 4 groups. Group 1 consists of the Ca2+/calmodulin responsive ACs, AC1, AC3,
and AC8, whereas the Gβγ-stimulated cyclases, AC2, AC4, and AC7 belong to Group 2. Group 3
include the Ca2+-inhibited ACs, AC5 and AC6, and the forskolin-insensitive AC9 is the only
member of Group 4 (Dessauer et al., 2017). Hence, the multiplicity of regulatory mechanisms that
modulate adenylyl cyclase activity is another effective way the cell fine-tunes its responses to an
extracellular signal.

1.4

Organization of Adenylyl Cyclases at the Cellular and Tissue levels

Apart from the diverse regulatory properties of the AC isoforms, their distinct subcellular
localization and tissue expression pattern adds another aspect to the cAMP signaling network that
enables the cell to tailor precise responses to an extracellular stimulus.
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Table 1.1 Regulatory properties of adenylyl cyclase isoforms
Differential effects of regulators on the catalytic activity of AC isoforms. (+) stimulation, (–)
inhibition, (⁺/₋) complex regulation, (+ +) conditional stimulation/potentiation.
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Although, the relative expression level of AC isoforms has been assessed in different cell models
and human tissues by quantifying mRNA and protein levels, the selectivity of commercially
available antibodies is not ideal to distinguish between AC isoforms, and mRNA levels don’t
always correlate with protein expression (Dessauer et al., 2017).
Furthermore, most cells express more than one AC isoform, implying a potential functional
redundancy in response to a shared stimulant/activator; however, different cAMP responses still
arise as a result of the subcellular organization into membrane microdomains of specific AC
isoforms (Ostrom and Insel, 2004). At these subcellular compartments, GPCRs, cAMP effectors,
phosphodiesterases and AKAPs are also confined, causing a local cAMP response with unique
cellular and physiological outcomes (reviewed in Halls and Cooper, 2017).
1.4.1 AC Subcellular Compartmentalization
At the cellular level, AC isoforms are found in lipid rafts and non-raft membrane domains
(Ostrom and Insel, 2004). The interactions of the AC isoforms with caveolin and/or AKAPs, or
post-translational modifications on the cytosolic domains of the ACs, determine their specific
cellular localization (Dessauer, 2009). For instance, caveolin serves as a scaffolding protein for
AC6 and β2AR in lipid raft domains of cardiac myocytes, and colocalization of AC6 and β2AR in
caveolin-rich domains appears to be the major determinant of AC6-selective coupling to β2AR in
these type of cells (Ostrom et al., 2002; Ostrom et al., 2000). Conversely, the EP2R localizes at
non-raft domains, and it exhibits a more efficient coupling to AC isoforms localized at non-raft
domains such as AC2 and AC4, than mediating the activation of other ACs localized in lipid-rafts
such as AC3 and AC6 (Bogard et al., 2012; Ostrom et al., 2001; Ostrom et al., 2002).
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Similarly, Ca2+/Calmodulin regulation of AC1 and AC8 can be restricted to a microdomain
because the source of intracellular Ca2+ that triggers AC activation may also be specific
(Willoughby et al., 2010). Indeed, stimulation of AC activity by capacitative Ca2+ entry (CCE) has
been shown to be selective for AC8 which localizes at lipid rafts, so when the microdomain is
disrupted by degrading sphingomyelins, CCE fails to stimulate AC8 activity (Pagano et al., 2009;
Smith et al., 2002).
AKAPs primary role is to scaffold PKA, and they not only restrict the movement of ACs, but
also anchored other signaling components of the cAMP pathway creating a platform for dynamic
interactions that facilitate selective coupling with distinct upstream and downstream effectors
(Johnstone et al., 2017; Logue and Scott, 2010). More than 50 different isoforms of AKAPs have
been identified and those that interact with ACs, have different specificities for different AC
isoforms. Some AC-AKAP interactions have been characterized for AKAP79/150 with AC5/6,
Yotiao with AC1, AC2, AC3 and AC9, and mAKAP with AC2 and AC5 (Dessauer, 2009). Most
recently, the advancement of imaging techniques and the development of sensors with high
spatiotemporal resolution have allowed a better characterization of these multiprotein complexes
and localized cAMP signaling networks in living cells (Paramonov et al., 2015). The importance
of cellular compartmentalization of the cAMP pathway is then an emerging concept; thus,
additional evidence is still needed in order to associate a specific cellular response with a
multicomponent complex of a unique GPCR-AC-AKAP-PDE combination. However, it is
becoming more evident that via these signaling complexes, a single cell can achieve
spatiotemporal control of its cellular responses.
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1.4.2 Tissue Pattern Expression of ACs
Quantification of AC isoform expression in tissues has been a challenging task for various
reasons. Commercially available antibodies are not specific enough to distinguish between AC
isoforms, and the protein expression level of endogenous ACs is near the limit of detection by
western blot and immunohistochemistry (Antoni et al., 2006). Hence, most of the studies that have
reported the relative gene expression of AC isoforms in mammalian tissues are based on RNA
quantification methods such as RT-qPCR, Northern analysis, in-situ hybridization and micro
arrays (Atwood et al., 2011; Defer et al., 2000; Ludwig and Seuwen, 2002; Sanabra and Mengod,
2011). Table 1.2 summarizes the relative expression of the AC isoforms in human tissues.
Although the relative mRNA levels may indicate gene expression, this data must be interpreted
cautiously because mRNA levels do not always reflect the protein expression levels due to the fact
other factors such as translation efficiency and protein turn-over are also significant determinants
of protein abundance (Maier et al., 2009).

1.5

Physiological Roles of Adenylyl Cyclase Isoforms

Despite the fact that cells and tissues express more than one adenylyl cyclase isoform, it is the
combination of the unique regulatory properties of the different AC isoforms with their subcellular
organization

and

tissue-specific

expression

patterns

that

distinct

physiological

and

pathophysiological conditions have been associated with particular AC isoforms (Dessauer et al.,
2017). Knockout and overexpression studies have been the main approaches utilized to determine
the physiological functions regulated by isoform-specific AC activities (Sadana and Dessauer,
2009).
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Table 1.2 Relative tissue distribution of AC isoforms
Expression profile for the nine membrane-bound AC isoforms in human tissues based on the
results of semi-quantitative RT-qPCR analysis carried out by Ludwig and Seuwen, 2002.
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Likewise, the identification of genetic polymorphisms in the adenylyl cyclase (ADCY) genes and
their association with a particular phenotype have also provided complementary evidence of the
isoform-specific contributions to a particular disease (Chen et al., 2012; Grarup et al., 2018; Pitman
et al., 2014). Consequently, AC isoforms have emerged as potential therapeutic targets for various
pathophysiological conditions, and isoform-selective modulation of AC activity becomes an
additional approach—besides modulating GPCRs—by which the cAMP signaling pathway can be
regulated (Pierre et al., 2009).
1.5.1 Group I: Adenylyl cyclases 1, 3 and 8
Ca2+/calmodulin-stimulated cyclases, AC1 and AC8, are highly expressed in the brain
(Sanabra and Mengod, 2011; Xia et al., 1991). Single and double knockout studies of AC1 and
AC8 have demonstrated that both cyclases play a critical role in learning and memory (reviewed
by Ferguson and Storm, 2004). AC1- and/or AC8-deficient mice exhibited impaired long-term
potentiation (LTP) in various regions of the brain including the hippocampus, cerebellum,
hypothalamus and thalamus (Schaefer et al., 2000; Storm et al., 1998; Villacres et al., 1998; Wang
et al., 2003; Wong et al., 1999). However, the role of these Ca2+/calmodulin-stimulated cyclases
in memory and learning appears to be redundant given that in the single-knockout mice of AC1 or
AC8, memory and learning were attenuated to a lesser extent than in the double-knockout mice
(Wong et al., 1999). Moreover, LTP can be reestablished by forskolin in AC1- and/or AC8deficient mice, suggesting that stimulation of AC activity compensates for AC1/AC8-induced
cAMP signaling (Villacres et al., 1998; Wong et al., 1999). Likewise, mice overexpressing AC1
in the forebrain also showed improved contextual memory—in accordance with its role in memory
formation—however over expression of AC1 has also impaired spatial memory in elderly mice
(Garelick et al., 2009; Wang et al., 2004). In addition, mice overexpressing AC1 were also
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hyperactive and displayed reduced sociability (Chen et al., 2015). Studies with double-knockout
mice of AC1 and AC8 have also associated both of these AC isoforms with opioid withdrawal and
hyperlocomotion produced by morphine (DiRocco et al., 2009; Li et al., 2006; Zachariou et al.,
2008). Single-knockout mice of AC1 and AC8 have also revealed specific functions for each AC
isoform (Sadana and Dessauer, 2009). For instance, AC1-deficient mice displayed reduced
responses to chronic and inflammatory pain (Vadakkan et al., 2006), advocating for selective AC1
inhibitors as non-opioid based strategies for chronic pain management (Skyba et al., 2004; Watts,
2018). Likewise, AC1-knockout mice showed reduced excitotoxicity to overactivation of the
NMDA and AMPA receptors (Wang et al., 2007; Watts, 2007). In contrast, AC8-knockout mice
failed to exhibit stress-induced anxiety-like behaviors, so this AC isoform has emerged as a
potential target to treat mood disorders (Bernabucci and Zhuo, 2016).
In the case of AC3, its high expression in the olfactory epithelium and olfactory sensory
neurons was the first indication of its role in olfaction (Bakalyar and Reed, 1990; Bishop et al.,
2007). AC3-deficient mice were unable to detect odorants and pheromones, and social, learning,
and sexual behaviors dependent on olfactory signals were also significantly altered (Cao et al.,
2016; Wang et al., 2006; Wang and Storm, 2011; Wong et al., 2000). In addition, AC3-knockout
mice became obese, exhibited diminished short-term memory for novel objects and were unable
to show extinction of contextual fear (Wang et al., 2009; Wang et al., 2011b). Most recently, the
identification of polymorphisms within the ADCY3 (AC3) gene that cause weight gain or weight
loss have provided converging evidence that implicates loss of AC3 activity with the development
of obesity and type 2 diabetes (Grarup et al., 2018; Pitman et al., 2014; Saeed et al., 2018). For
example, loss-of-function mutations in the ADCY3 gene have been associated with severe cases
of obesity in humans (Grarup et al., 2018; Saeed et al., 2018). Likewise, the characterization of a
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mouse strain that remains unaffected during high-fat diet consumption because of a single gainof-function mutation in the ADCY3 gene, also supports the role of AC3 activity in the mechanisms
of body weight regulation (Pitman et al., 2014), and suggests that AC3 activators could be used in
antiobesity therapies.
1.5.2 Group II: Adenylyl cyclases 2, 4 and 7
For the Gβγ-mediated cyclases, AC2 and AC4, there is no data available for knockout mice or
overexpression studies that link these two cyclases to a specific physiological condition (Sadana
and Dessauer, 2009). However, their high expression in airway smooth muscle cells may suggest
their involvement in pulmonary function (Bogard et al., 2012; Bogard et al., 2011). Only a single
study in a cellular model of Lesch-Nyhan syndrome, rat B103 neuroblastoma, has provided
evidence that implicates the disease with diminished AC2 activity (Kinast et al., 2012). In contrast,
the direct regulation of AC7 catalytic domains by ethanol (Yoshimura et al., 2006; Yoshimura and
Tabakoff, 1995), and behavioral studies with female mice that exhibited reduced AC7-expression
and consumed large volumes of ethanol, suggest that AC7 is linked to alcohol consumption
(Desrivieres et al., 2011). In addition, AC7 plays a critical role in the immune system given its
high expression levels in leukocytes, and its importance to increase cAMP levels in response to
pathogens and microbes in B and T cells (Duan et al., 2010).
1.5.3 Group III: Adenylyl cyclases 5 and 6
AC5 and AC6 are the most abundant AC isoforms expressed in the heart that play a critical
role in cardiac function (reviewed by Baldwin and Dessauer, 2018) . Despite these two cyclases
are closely related, AC5 and AC6 knockout mice showed different phenotypic changes in the heart,
implying specific roles of each isoform (Sadana and Dessauer, 2009; Vatner et al., 2013).
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AC5-knockout mice exhibited diminished responses to β-AR stimulation in the left ventricle
(Tang et al., 2006) , and decreased inhibition of cAMP production in response to Gαi-coupled
muscarinic receptors and Ca2+ (Okumura et al., 2003). Instead, cardiomyocytes from AC6deficient mice displayed reduced responsiveness to β-AR activation (Tang et al., 2008), but
overexpression of AC6 increased contractility of the cardiac muscle after persistent β2AR
activation (Roth et al., 1999; Tang et al., 2011; Tang et al., 2013; Wu et al., 2017). The beneficial
effects of AC6 overexpression appear not to be cAMP-dependent given that inactive catalytic
domains exerted the same effects as active C1 and C2 domains (Gao et al., 2011). Consequently,
overexpression of AC6 catalytic domains has been evaluated as a cardioprotective gene therapy
strategy to improve cardiac function (Gao et al., 2016; Hammond et al., 2016).
AC5-deficient mice also displayed increased life-span compared to wild-type subjects and
prevented the development of age-related cardiac myopathy (Chester and Watts, 2007; Vatner et
al., 2015; Vatner et al., 2009; Yan et al., 2007). Loss of AC5 had also additional metabolic benefits
such as decreased body weight under regular and high-fat diets (Ho et al., 2015), and abolished
the locomotive, addictive and analgesic effects of opioid receptor agonists (Kim et al., 2006). Also,
AC5 activity appears to be important for acute pain sensation in response to thermal and
mechanical stimuli (Kim et al., 2007). However, deletion of AC5 also resulted in increased alcohol
intake (Kim et al., 2011) and caused movement impairment syndromes such as bradykinesias
(Iwamoto et al., 2003). Furthermore, in agreement with the role of AC5 in motor functions,
ADCY5 polymorphisms within the catalytic domains of the cyclase have also been linked to the
autosomal-dominant movement disorder, familial dyskinesia with facial myokymia (FDFM)
(Chen et al., 2012). Besides the cardioprotective roles of AC6, this isoform is highly expressed in
the kidneys and based on studies with AC6-deficient mice, it plays a major role in water
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homeostasis (reabsorption) and renin secretion (Aldehni et al., 2011; Chien et al., 2010), and it
also mediates the development of renal cysts (Rees et al., 2014).
1.5.4 Group IV: Adenylyl cyclase 9
Initial attempts to generate an AC9-knockout mouse strain suggested that an AC9-deficient
phenotype was embryonic lethal, so the reports that have associated AC9 with the immune system
and myelogenous leukemia have been based on microRNA-mediated downregulation of AC9
expression (Huang et al., 2009; Risoe et al., 2011; Zhuang et al., 2014). However, an AC9deficient mice was recently developed by disrupting AC9 expression using a gene-trap
mutagenesis strategy (Li et al., 2017). The changes in phenotype associated with the loss of AC9
indicated that this forskolin-insensitive isoform is involved in cardiac function (Li et al., 2017).
Indeed, the protein-protein interactions between AC9 and the AKAP protein, Yotiao, or the heat
shock protein 20 (Hsp20) appear to mediate the cardioprotective role of AC9 (Baldwin and
Dessauer, 2018; Li et al., 2012).
Table 1.3 summarizes the major pathophysiological conditions associated with the
individual AC isoforms. A comprehensive understanding of the physiological roles of certain
isoforms is still elusive due to various challenges when studying adenylyl cyclases. As summarized
in Table 1.2, cells and tissues express more than one AC isoform, and some isoforms only respond
to general activators of adenylyl cyclase activity, making it difficult to tease out the contribution
of each specific AC. Likewise, the lack of good antibodies to accurately detect AC isoform protein
expression or the scarcity of selective AC modulators (Brand et al., 2013), also pharmacologically
limits the ability to study ACs at the molecular level.
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Table 1.3 Classification and major pathophysiological conditions associated with AC isoforms.
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Nonetheless, the existing reports with knockout mice and overexpressing animal models have
encouraged screening campaigns to develop selective AC modulators as new therapeutics for
various diseases (Brust et al., 2017; Conley et al., 2013; Pierre et al., 2009; Wang et al., 2011a).

1.6

Scope of the work

The objective of the work reported here was to develop a series of tools to characterize isoformspecific AC responses. In order to do so, three aims were achieved:

AIM #1: CRISPR/Cas9-based cell line (HEK-ACΔ3/6)

CHAPTER 2

Develop a HEK293 cell line with low cAMP levels through the use of CRISPR/Cas9
technology
Functional characterization of the cAMP responses of the nine membrane-bound ACs to forskolin,
G protein-coupled receptors, Ca2+ and protein kinase C in the HEK-ACΔ3/6 cells. Comparison of
the cAMP responses of AC1wt and AC1 mutant construct in the parental HEK293 cells and the
knockout cell line.

AIM #2: CD8-C2-20 minigene

CHAPTER 3

Determine whether juxtamembrane domains of adenylyl cyclase type 2 (AC2) could
modulate Gβγ activity
The binding affinity for Gβγ was determined for a peptide derived from the C2a domain of AC2
using SPR. A minigene was subsequently utilized to evaluate the biological activity of the C2a
domain on Gβγ-mediated pathways.

30
AIM #3: AC1 and AC8 Inhibitors

CHAPTER 4

Carry out structure activity relationship studies for inhibitors of type 1 and type 8 adenylyl
cyclases
A series of structure activity relationship (SAR) studies were carried out for a set of analogs of the
selective AC1 inhibitor, ST034307, and completion of a high-throughput screen of 10,000
compounds yielded two promising scaffolds that exhibit AC1 selective and dual AC1/AC8
activity.
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CHAPTER 2.
A NOVEL CRISPR/CAS9-BASED CELLULAR MODEL
TO EXPLORE ADENYLYL CYCLASE AND CYCLIC AMP
SIGNALING

Functional characterization of adenylyl cyclase isoforms has proven to be challenging in
mammalian cells due to the endogenous expression of multiple AC isoforms, and the high
background cAMP levels induced by non-selective AC activators. To simplify the characterization
of individual mAC isoforms, we generated a HEK293 cell line with low cAMP levels by knocking
out two highly expressed ACs, AC3 and AC6, using the clustered regularly interspaced short
palindromic repeats (CRISPR)-associated system (Cas) technology. Stable HEK293 cell lines
were generated lacking either AC6 (HEK-ACΔ6) or both AC3 and AC6 (HEK-ACΔ3/6). Knock
out was confirmed genetically and by comparing cAMP responses of the knockout cells to the
parental cell line. HEK-ACΔ6 and HEK-ACΔ3/6 cells revealed an 85% and 95% reduction in the
forskolin-stimulated cAMP response. Forskolin- and Gαs-coupled receptor-induced activation was
examined for the nine recombinant mAC isoforms in the HEK-ACΔ3/6 cells. Forskolin-mediated
cAMP accumulation for AC1-6 and AC8 revealed 10- to 250-fold increases over the basal cAMP
levels.. All nine mAC isoforms, except for AC8, also exhibited significantly higher cAMP levels
than the control cells following β2-adrenergic receptor (β2AR) and prostaglandin EP2 receptor
(EP2R) activation. Isoform specific AC regulation by Gαi-coupled receptors, protein kinases and
Ca2+/calmodulin was also recapitulated in the knockout cells. In addition, the HEK-ACΔ3/6 cells
allowed the characterization of the cAMP responses of novel AC1 constructs containing mutations
within the forskolin binding site. We have developed a HEK293 cell line deficient of endogenous
AC3 and AC6 with low cAMP background levels for future studies of cAMP signaling, AC
isoform regulation, and high throughput screening assays for AC modulators.Introduction
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Adenylyl cyclases are key transduction mediators of G-protein coupled receptor signaling
by catalyzing the conversion of ATP into the secondary messenger, cyclic AMP. Nine mammalian
mACs (AC1-AC9) have been cloned and one soluble mammalian AC has also been characterized.
Although mAC isoforms exhibit high structural homology, they are differentially regulated by Gproteins subunits, Ca2+/Calmodulin and protein kinases; and depending on these regulatory
properties, mACs are classified into four groups (reviewed in Dessauer et al., 2017). Group 1,
comprising AC1, AC3 and AC8 is characterized for being activated by Ca2+/Calmodulin. Group
2, which includes AC2, AC4 and AC7, is described to be conditionally stimulated by Gβγ subunits.
AC5 and AC6 belong to Group 3 and both are inhibited by Ca2+. Lastly, AC9, the only mAC that
is insensitive to the diterpene forskolin, is the sole member of Group 4. This differential regulation
of mAC isoforms, coupled with their tissue-specific expression patterns, correlates with knockout
and overexpression studies that have implicated particular mACs with various physiological
processes (Sadana and Dessauer, 2009). Consequently, adenylyl cyclase signaling dysfunction has
emerged as a potential therapeutic target, and considerable efforts have been made to identify
potent and selective AC modulators (Dessauer et al., 2017; Pierre et al., 2009; Seifert et al., 2012).
Overexpression of mAC isoforms in various cellular models such as HEK293, COS-7, and
CHO cells has allowed in vitro and in vivo characterization of AC activity (Brust et al., 2017;
Mann et al., 2009). However, mammalian cells usually express multiple AC isoforms, resulting in
high background cAMP responses arising from these endogenous ACs. Therefore, cautious
interpretation is required when evaluating Gαs-coupled receptor- and forskolin-mediated
stimulation of individual mAC isoforms in these heterologous systems. Other approaches to
examine mAC activity have also utilized the Sf9 cell line from Spodoptera frugiperda which has
been widely used to study membrane-bound proteins. This insect cell line expresses recombinant

33
proteins in high yields, exhibits low cAMP levels, and the recombinant proteins expressed undergo
similar folding and post-translational modifications to those observed in mammalian cellular
systems (Schneider and Seifert, 2010). In vitro studies to assess AC activity for all nine membrane
isoforms and to characterize mAC inhibitors’ activity and selectivity, have been successfully
performed in Sf9 cells (Brand et al., 2013; Pinto et al., 2008). However, Sf9 cells also express an
endogenous AC that is stimulated by forskolin and can be inhibited by P-site AC inhibitors (Gille
et al., 2004; Pinto et al., 2008). In addition, possible disadvantages of using these insect cells is the
difficulty of monitoring in real-time the spatiotemporal dynamics of the cAMP pathway, and the
potential lack of expression of key upstream regulators or downstream effectors of AC isoforms.
In an effort to facilitate the selective characterization of AC isoforms’ activity and
regulation, it was the objective of this study to generate an isolated mammalian cell model with
low cAMP production at drug-stimulated conditions. To do so, the CRISPR-Cas 9 technology was
employed to knockout, in HEK293 cells, two abundant endogenous ACs (AC3 and AC6) (Fig.
2.1). Our HEK-ACΔ3/6 cell line showed little to no response to forskolin and Gαs-coupled receptor
agonists and demonstrated to be a suitable cellular model to evaluate the individual responses of
the nine mammalian mAC isoforms to forskolin, G-protein coupled receptors, and other regulators
such as calcium and protein kinases. The HEK-ACΔ3/6 cells were also used to stably express
representative AC isoforms for membrane-based in vitro assays. Lastly, this new cellular model
proved to be a valuable tool to functionally characterize the activity profiles of a series of AC1
forskolin-binding site mutants that were difficult to interpret in the parental HEK293 cells due to
the high cAMP background.
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Figure 2.1 Schematic diagram of the CRISPR/Cas9 genome editing technology.
The CRISPR-Cas9 technology was engineered from the bacterial immune system to cut the DNA
at a desired location (Ran et al., 2013). The CRISPR-Cas9 endonuclease (1) recognizes the targeted
location within the genome based on the 20-nucleotide sequence of the single guide RNA (sgRNA)
(2). CRISPR-Cas9 cleaves the DNA (triangle) between a Protospacer Adjacent Motif (PAM)
sequence and the complimentary sequence to the sgRNA (3). The double-strand DNA break
(DSDB) event triggers a repair mechanism at the cleavage site that directly ligates the blunt ends
of the DNA, but due to the lack of a DNA template, generally leads to the insertion/deletion of
base pairs (4). The introduction of these indels at the repair site cause a frameshift mutation that
prompts a premature stop codon and subsequently causes loss of protein expression (5).
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2.2

Methods

2.2.1 Materials
The sgRNA oligos and primers for plasmid construction were synthesized by Integrated DNA
Technologies (IDT) (Coralville, IA). Dulbecco’s modified Eagle’s medium (DMEM), penicillinstreptomycin-amphotericin B solution (Antibiotic-Antimycotic), cell dissociation buffer,
phosphate-buffered saline (PBS), and OptiMEM were purchased from Life Technologies
(Carlsbad, CA). The HEK293 cell line was obtained from ATCC (Manassas, VA). Bovine Calf
serum (BCS), Fetal Clone I (FCI), and HEPES were obtained from Hyclone (GE Healthcare,
Pittsburgh, PA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA), and
XtremeGENE HP was obtained from Roche (Basel, Switzerland). A23187, adenosine 5′triphosphate (ATP) disodium salt hydrate, bovine serum albumin (BSA), 3-isobutyl-1methylxanthine (IBMX), (−)-Isoproterenol (+)-bitartrate salt, magnesium chloride (MgCl2)
anhydrous, puromycin, and Tween 20 were purchased from Sigma-Aldrich (St. Louis, MO). The
Pierce BCA protein assay kit was obtained from Thermo Fisher Scientific (Waltham, MA), and
forskolin, phorbol 12-myristate 13-acetate (PMA), and prostaglandin E2 (PGE-2) from Tocris
(Bio-Techne, Minneapolis, MN). The 384-well white opaque plates (Catalog# 6007680) were
from PerkinElmer (Waltham, MA), and the cAMP detection reagents, HTRF cAMP Dynamic 2,
were obtained from Cisbio (Bedford, MA). The QuickExtract DNA extraction solution was
purchased from Epicentre Biotechnologies (Illumina, Madison, WI), and the BbsI restriction
enzyme and Phusion High-Fidelity DNA polymerase were from New England Biolabs (Ipswich,
MA).

36
2.2.2 Plasmids
The CRISPR/Cas9 vector, pSpCas9(BB)-2A-Puro (PX459) was a gift from Feng Zhang
(Addgene plasmid # 62988). The plasmids encoding for human AC1, AC3, AC4 and AC7 genes
were synthesized, codon optimized for mammalian expression, and cloned into a pcDNA3.1+
expression

vector

by Genscript

Biotech

(Piscataway,

NJ).

The

pcDNA3.1+/hAC5,

pcDNA3.1+/hAC9, and pQE60/Gαs-His vectors were a gift from Carmen Dessauer. The
pReceiver/hAC8 vector was purchased from GeneCopoeia (Rockville, MD), and the
pcDNA3.1+/hAC2 plasmid was obtained from Genscript. The corresponding DNA mutations of
the

mutant

AC1

constructs

pcDNA3.1+/AC1-N878A,

and

(pcDNA3.1+/AC1-W419A,
pcDNA3.1+/AC1-S924P)

were

pcDNA3.1+/AC1-V423G,
incorporated

into

the

pcDNA3.1+/hAC1 plasmid by Genscript. All the adenylyl cyclase genes encoded for untagged
proteins.
2.2.3 Design and construction of CRISPR-Cas9 plasmids
Two abundant ACs in HEK293 cells are AC3 and AC6 encoded by the ADCY3 and ADCY6
genes respectively. To generate the HEK-ACΔ6 and HEK-ACΔ3/6 knockout cell lines we
utilized the CRISPR/Cas9 system developed by the Zhang lab in which the pSpCas9(BB)-2APuro (PX459) vector coexpresses the single guide RNA(sgRNA), the human-codon optimized
Cas9 nuclease, and a puromycin resistance gene (Ran et al., 2013). The specific sgRNAs for
each gene were selected from the CRISPR/Cas9 screening library designed by Wang. et al., and
these targeting sequences for the ADCY3 and ADCY6 genes were:
5’ GGGAGAAGACCAAGACTGGG 3’ and 5’ TGGGTGGCTCTGCATCCCGG 3’,
respectively (Wang et al., 2014). To insert the customized sgRNAs into the PX459 vector, two
oligos per sgRNA (ADCY3: 5’-CACC-GGGAGAAGACCAAGACTGGGG-3’ and

37
5’-AAAC-CCCCAGTCTTGGTCTTCTCCC-3’, ADCY6: 5’-CACCGTGGGTGGCTCTGCATCCCGG-3’ and 5’-AAAC-CCGGGATGCAGAGCCACCCAC-3’) were
synthesized by IDT, annealed according to the protocol by Ran et al., and cloned into the BbsI
site of the PX459 backbone vector. Correct insertion to the sgRNAs was confirmed by Sanger
sequencing.
2.2.4 Stable knockout cell lines generation and validation
HEK293 cells were transfected with either the sgRNA for AC6 (HEK-ACΔ6) or both AC3 and
AC6 sgRNAs (HEK-ACΔ3/6) using Lipofectamine 2000. After 24-hour transfection, the media
was replaced with puromycin (2mg/mL) containing media to select for sgRNA- and Cas9expressing cells. Transfected cells were then seeded sparsely into 10cm-dishes after they had been
exposed to puromycin for 72-hours, and cell colonies were allowed to form for 2-3 weeks in
regular HEK293 media consisting of DMEM supplemented with 5% bovine calf serum (BCS), 5%
fetal clone I (FCI) and 1% Penicillin-Streptomycin-Amphotericin B Solution. HEK-ACΔ6 and
HEK-ACΔ3/6 cell clones were screened for loss of function of AC3 and AC6 genetically, and by
comparing cAMP responses between the knockout cells and the parental HEK293 cell line. For
genotypic characterization of the clones, genomic DNA was extracted from the HEK-ACΔ6 and
HEK-ACΔ3/6 clones with QuickExtract DNA extraction solution according to the manufacturer’s
instructions. A portion of the ADCY3 and ADCY6 genes around the sgRNA site was amplified
by polymerase chain reaction (PCR) from the genomic DNA with the following AC3 and AC6 set
of

primers

(ADCY3:

5’-GTTAAAGCCCGTCTAGTATTG-3’

and

5’-

CATCAGTCGACCACACGTCG-3’, ADCY6: 5’-ATGTCATGGTTTAGTGGCCTCC-3’ and 5’CGTGTAGGCGATGTAGACAA-3’). The PCR conditions were as follows: after initial
denaturation at 98 °C for 30 seconds, 30 cycles were performed of denaturation at 98 °C for
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10 seconds, annealing at 52 °C for 30 seconds and extension at 72 °C for 30 seconds followed by
a final extension at 72°C for 10 minutes. The PCR products were analyzed by agarose gel
electrophoresis and by Sanger sequencing. The resulting gene mutation for the isolated HEKACΔ6 cell line was a single base pair insertion in both alleles of the ADCY6 gene that caused a
frame shift and subsequent disruption of ADCY6 protein expression (Fig.S1b). For the isolated
HEK-ACΔ3/6 cell line, ADCY3 expression was disrupted by a single base pair deletion for one
allele and two-base pair insertion for the other allele, whereas loss of function of ADCY6 was a
result of a single base pair deletion in both alleles of the gene (Fig. S1c). Phenotypic changes in
the HEK-ACΔ6 and HEK-ACΔ3/6 cell lines were assessed by comparing the forskolin- and Gαscoupled receptor-stimulated cAMP responses in the knockout cells and the parental HEK293 cell
line.
2.2.5 cAMP assays in cells
Parental HEK293, HEK-Δ6, and HEK-ACΔ3/6 cells were washed with PBS, dissociated from
the culture plate with cell dissociation buffer, and centrifuged twice at 150 x g for 5 minutes. The
cell pellet was resuspended in Opti-MEM, and cells were counted and seeded in a white opaque
384-well plate at a cell density of 15,000 cells per well for the functional characterization of the
knockout cells, and 10,000 cells per well for the experiments with the transient transfected HEKACΔ3/6 cells. Cells were incubated for 2 hours at 37°C with 5% CO2 before drug-treatment to
ensure cells had adhered to the plate.
2.2.5.1 Stimulation assays
HEK293, HEK-ACΔ6, HEK-ACΔ3/6 or transiently transfected HEK-ACΔ3/6 cells were
treated with forskolin for 1-hour, the EP2R agonist, PGE-2 for 15 minutes or the β2AR agonist,
isoproterenol, for 5 minutes. For Ca2+- and protein kinase C-mediated AC activation, and the
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synergistic experiments, cells were stimulated for 1-hour with 40 μM (4x) A23187 or 4 μM (4x)
PMA in the absence or presence of 40 μM (4x) PGE-2 or 200 μM (4x) forskolin respectively. AC
activity was triggered in HEK293 and HEK-ACΔ3/6 cells transiently expressing wild-type AC1
(AC1-WT) or mutant AC1 (AC1-W419A, AC1-V423G, AC1-N878A and AC1-S924P) cells with
increasing concentrations of forskolin in the presence or absence of 12μM (4x) A23187 for a
period of 1-hour. All the drug-treatments were performed in the presence of the phosphodiesterase
inhibitor, IBMX. Intracellular cAMP levels were detected after each corresponding incubation
period using the Cisbio HTRF cAMP detection kit as described below.
2.2.5.2 Acute Inhibition assay (Gαi-coupled receptors)
Transfected HEK-ACΔ3/6 cells transiently expressing D2R and mACs were treated with
vehicle or 12μM (4x) quinpirole followed by the addition of the corresponding stimulant for each
transfection condition in the presence of IBMX. Cyclic AMP was stimulated in Venus-, AC3-, and
AC5-transfected cells with forskolin, and AC1- and AC8-expressing cells were stimulated with
A23187. AC2-expressing cells were stimulated with PMA and cells expressing AC4 were treated
PGE-2. After 1-hour incubation with quinpirole and the corresponding stimulant, for all AC
conditions except AC4-expressing cells that were drug-treated for only 15 minutes, cAMP levels
were detected using the Cisbio HTRF cAMP detection reagents as described below.
2.2.5.3 Sensitization assay
Same transiently transfected cells used for the acute inhibition assays were incubated for
2-hours with 9μM (3x) quinpirole at 37°C with 5% CO2 prior stimulation of AC activity. Venus-,
AC3- and AC5-expressing cells were treated with forskolin to trigger AC activity, AC1- and AC8expressing cells were stimulated with A23187, and AC4 activity was induced with PGE-2.
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All drug-treatments were performed in the presence of IBMX and the D2R antagonist, spiperone.
After a period of incubation of 1-hour with the AC stimulants, except for AC4-expressing cells
that were incubated with PGE-2 for 15 minutes; cAMP levels were detected as described below.
2.2.5.4 cAMP Detection
Cisbio HTRF cAMP detection reagents, d2-labeled cAMP and anti-cAMP cryptate, were
added to all wells after the corresponding incubation times for the treatment conditions, and timeresolved fluorescence was measured at dual emission wavelengths (620nm and 665nm) after 1hour incubation at room temperature. Cyclic AMP accumulation per well was calculated using
GraphPad Prism by interpolating the 620/665 signal ratios from a cAMP standard curve ran in
parallel with every experiment.
2.2.6 ACs transient transfections
HEK293 or HEK-ACΔ3/6 cells were plated overnight prior transfection in a 12-well plate. The
cells were then transiently transfected with Lipofectamine 2000 in a 1:2 (DNA:Lipofectamine)
ratio or with XtremeGENE HP in a 1:1.5 or a 1:3 (DNA:XtremeGENE HP) ratio according to the
manufacturer’s protocol. Lipofectamine 2000 was used to transfect Venus, AC1-AC6, AC8, and
mutant AC1 constructs for the forskolin, A23187, and protein kinase C experiments. For the acute
and sensitization experiments, Lipofectamine 2000 was also used to cotransfect the Dopamine D2
receptor (D2R) and the corresponding mAC isoform into the HEK-ACΔ3/6 cells in a 1:2 DNA
ratio (receptor:mAC). XtremeGENE HP was used in a 1:1.5 ratio to transfect all mAC isoforms
for the calcium- and Gαs-mediated AC activation assays, and it was used in a 1:3 ratio to transfect
AC7 and AC9 in the forskolin experiments. After transfection, cells were cultured for 40 hours
before cAMP responses were measured as described above.
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2.2.7 AC1, AC2, AC5 and AC8 stable cell pool generation
HEK-ACΔ3/6 cells were seeded overnight in a 6-well plate to ensure that at the time of
transfection, the cells had recovered and had reached 70% confluency. XtremeGENE was used in
a 1:3 ratio (DNA:XtremeGENE) to transfect the pcDNA3.1+/hAC1, pcDNA3.1+/hAC2,
pcDNA3.1+/hAC5 and pReceiver/hAC8 constructs. Media was replaced after 48-hour transfection
to G418 (600ug/mL) or Puromycin (4μg/mL) containing media for the cells transfected with the
pcDNA3.1 or the pReceiver expression vectors, respectively. The HEK-ACΔ3/6-AC1-, HEKACΔ3/6-AC2, and HEK-ACΔ3/6-AC5 pool cell lines were maintained and proliferated for cellbased and cellular membrane assays in media containing G418 (300ug/mL), and the HEKACΔ3/6-AC8 pool cell line was maintained in media containing puromycin (2μg/mL).
2.2.8 Isolation of cellular membranes
HEK-ACΔ3/6, HEK-ACΔ3/6-AC1, HEK-ACΔ3/6-AC2, HEK-ACΔ3/6-AC5, and HEKACΔ3/6-AC8 cells were proliferated in 15-cm cell culture dishes to a 90% confluency. Media was
decanted and replaced with 10mL of ice cold lysis buffer containing: 1mM HEPES, 2 mM EDTA
and 1mM EGTA at pH 7.4. The cell culture dish was incubated for 10 minutes with the lysis buffer
on ice, and cells were scraped off using a disposable cell lifter. The cell suspension was transferred
to a high-speed centrifuge tube and centrifuged at 30,000 x g for 20 minutes at 4°C. Supernatant
was discarded, and the cell pellet was resuspended in binding buffer containing 4 mM MgCl2 and
50 mM Tris at pH 7.4. After the cell suspension was homogenized using a Kinematica
homogenizer, it was divided into 1mL-aliquots. Aliquots were centrifuged at 10,000 x g for 10
minutes at 4°C, supernatant was discarded, and membrane pellets were frozen and stored at -80°C
until the day of the assay.
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2.2.9 Gαs Purification and Activation
Recombinant Gαs-His protein was expressed and purified using immobilized metal affinity and
ion exchange chromatography as described previously (Lee et al., 1994) and stored at -80°C until
it was activated for membrane assays. The purified Gαs protein was activated by incubation on ice
in 50 mM HEPES, 2mM DTT, 250 μM GTPγS, and 1mM MgCl2 for 20 minutes, followed by a
30 minute incubation at 30°C (Chen-Goodspeed et al., 2005).
2.2.10 cAMP assays in membranes
Cells membranes were thawed on ice and resuspended in washing buffer containing 2 mM
Tris, 1mM EGTA and 1mg/mL of BSA. Membrane suspension was centrifuged at 10,000 x g for
10 minutes at 4°C, supernatant was aspirated, and the washing step was repeated two more times.
Following the final wash, the membrane pellet was resuspended in membrane buffer containing
33mM HEPES, 0.1% Tween 20, and 1 mM EGTA. Protein concentration of the membrane
suspension was measured using the Pierce BCA Protein assay kit, and the protein concentration
was adjusted to 250 μg/mL. Membrane suspensions were plated in a white opaque 384-well plate
at 10 μL/well followed by the addition of increasing concentrations of Gαs or forskolin—prepared
in membrane buffer without EGTA— and stimulation buffer containing: 33mM HEPES, 0.1%
Tween 20, 2.5mM MgCl2, 250 μM ATP and 500 μM IBMX at pH 7.4. Cellular membranes were
incubated with the stimulants for 45 minutes at room temperature and cAMP accumulation was
measured using the Cisbio HTRF cAMP detection kit as described above.
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2.3

Results

2.3.1 CRISPR/Cas9-based HEK-ACΔ6 and HEK-ACΔ3/6 cell lines display remarkably
low cAMP levels
HEK293 are a human expression system that is widely used to study recombinant proteins
because of their easy maintenance, rapid reproduction, and high transfection efficiency. HEK293
cells express multiple AC isoforms that when stimulated by forskolin and/or endogenous Gαscoupled receptors promote high levels of cAMP. It has been reported based on qPCR studies, along
with our own qPCR results (data not shown), that HEK293 cells express AC1, AC2, AC3, AC5,
AC6, AC7 and AC9 mRNA (Atwood et al., 2011; Ludwig and Seuwen, 2002; Yu et al., 2014).
Therefore, to decrease cAMP levels in HEK293 cells, we cloned sgRNA sequences that targeted
the two abundant endogenous ACs (AC3 and AC6) into a CRISPR/Cas9 expression system. HEKACΔ6 and HEK-ACΔ3/6 cell lines were generated lacking either AC6, or both AC3 and AC6,
respectively. We characterized the genotype of the knockout cells (Figure S1) and determined
loss-of-function of the ADCY3(AC3) and ADCY6(AC6) genes by comparing the drug-induced
cAMP responses of the knockout cells with the parental cell line. The activity of the endogenous
ACs was stimulated by two common mechanisms: direct AC activation with forskolin (Fig. 2.2a),
or Gαs subunit-mediated activation elicited by the β2AR agonist, isoproterenol (Fig. 2.2b) or the
EP2R agonist, PGE-2 (Fig. 2.2c). Knocking out the ADCY6 gene in the HEK-ACΔ6 cell line
reduced the cAMP response to forskolin by nearly 85%, and by an additional 10% when AC3
expression was also disrupted, resulting in an overall reduction of cAMP accumulation by 95% in
the HEK-ACΔ3/6 cells compared to the parental cell line (Fig. 2.2a). Likewise, HEK-ACΔ6 cells
exhibited 50% of the maximal response to isoproterenol (Fig. 2.2b), whereas the HEK-ACΔ3/6
cells displayed >75% lower cAMP accumulation than the HEK293 parental cell line.
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A.

B.

C.

Figure 2.2 Functional characterization of HEK-ACΔ6 and HEK-ACΔ3/6 cell lines.
Parental HEK293 cells and the CRISPR-Cas9 based HEK-ACΔ6 and HEK-ACΔ3/6 cells were
incubated at room temperature with increasing concentrations of the direct AC activator, forskolin
(A), or the Gαs-coupled receptors agonists, isoproterenol (B) or PGE-2 (C), and cAMP
accumulation was measured. *The HEK-ACΔ6 and HEK-ACΔ3/6 responses to PGE-2 are
overlapping in panel (C). Data represents the mean and SEM of at least three independent
experiments conducted in duplicate.

45
In the case of the EP2R-mediated activation, HEK-ACΔ6 cells showed >85% reduction of the
maximal response to PGE-2, but no significant differences in PGE-2-stimulated cAMP levels were
noted between the HEK-ACΔ6 and HEK-ACΔ3/6 cells (Fig. 2.2c).
2.3.2 Forskolin-mediated responses of the mAC isoforms in the knockout cells
Forskolin directly binds to a hydrophobic pocket at the interface between the AC catalytic
domains, and it elicits stimulatory effects on ACs 1 to 8 by promoting a conformational change
that facilitates cAMP synthesis (Tesmer et al., 1997). Hence, we employed our CRISPR-Cas9
based cell line to selectively assess forskolin-mediated responses in the nine mAC isoforms. Cyclic
AMP levels were evaluated for increasing concentrations of forskolin in the HEK-ACΔ3/6 cell
line expressing venus (control) or the or the individual mAC isoforms (Fig. 2.3). Forskolin induced
cAMP production at a wide range of efficacies in the knockout cells expressing ACs, except for
those transfected with AC7 and AC9. These forskolin-mediated responses ranged from 10- to a
250-fold increase over the basal cAMP levels for cells expressing AC1-AC6 and AC8, compared
to a 4-fold increase over basal of the Venus-transfected cells. In particular, cells overexpressing
AC5 and AC8 displayed the most robust cAMP response to forskolin relative to the other isoforms,
and AC9-expressing cells were unresponsive to forskolin as has been previously described (Yan
et al., 1998). Lack of selectivity of commercially available mAC antibodies or epitope tags on the
constructs used here prevented the assessment of protein expression for a more rigorous
comparison of forskolin-mediated cAMP responses across the other AC isoforms. Nonetheless,
forskolin is a useful tool to selectively examine the activity of AC isoforms 1-6, and 8 in our HEKACΔ3/6 cells, given the increase in the signal window upon forskolin stimulation of AC in these
knockout cells.
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Figure 2.3 Forskolin-stimulated cAMP responses for the nine mACs in the HEK-ACΔ3/6 cell line.

HEK-ACΔ3/6 cells were transiently transfected with Venus (black) or the individual mAC
isoforms (blue) as indicated. After 40 hours, cAMP accumulation was stimulated with increasing
concentrations of forskolin at room temperature. Data represents the mean and SEM of at least
three independent experiments conducted in duplicate.
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2.3.3 Gαs-protein coupled receptor signaling through mACs
Activation of GPCRs linked to Gαs is another major mechanism to activate ACs. Therefore,
we evaluated the specific AC isoform responses following activation of the endogenously
expressed β2AR and EP2R (Andressen et al., 2006; Atwood et al., 2011). HEK-ACΔ3/6 cells
transiently transfected with the different mACs were treated with a saturating concentration of
isoproterenol (Fig. 2.4a) or PGE-2 (Fig. 2.4b). Activation of both Gαs -coupled receptors triggered
a significant increase of cAMP levels in all AC isoforms, except for AC8, when compared to the
control-transfected cells. AC8-expressing cells displayed high basal and forskolin-mediated
activity, but cAMP levels did not increase significantly to Gαs stimulation above the basal
response. Surprisingly, cells expressing AC4 showed the highest cAMP response to receptor
activation—considering that this isoform was poorly activated by forskolin (Fig. 2.3). Knockout
cells transfected with AC7 and AC9 also showed a 2-fold increase over Venus-transfected cells
when stimulated by Gαs -coupled receptors. This suggest that both isoforms are being expressed,
and the lack of response of these isoforms to forskolin activation may reflect their unique
regulatory properties (Hacker et al., 1998; Yan et al., 2001).
2.3.4 Selective regulation of mAC isoforms in the CRISPR/Cas9-based cell line
In addition to activation by forskolin and Gαs -proteins, AC isoforms are selectively activated
by Ca2+ or protein kinases. Thus, we further explored AC1/AC8 and AC2/AC7 selective activation
in the HEK-ACΔ3/6 cells by Ca2+ or protein kinase C (PKC), respectively (Fig. 2.5). First, we
examined the response of Ca2+/calmodulin-stimulated cyclases, AC1 and AC8, in the HEKACΔ3/6 cell line (Fig. 2.5a). An increase in intracellular Ca2+ with the calcium ionophore,
A23187, elevated cAMP levels over basal in AC1-expressing cells by 5-fold and in AC8expressing cells by 8-fold,
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B.

Figure 2.4 Gαs-coupled receptor-mediated activation of the nine mACs in the HEK-ACΔ3/6 cells.
HEK-ACΔ3/6 cells were transiently transfected with venus or the individual mAC isoforms as
indicated. After 40 hours, cAMP accumulation was stimulated with 10 μM isoproterenol (A) or
10 μM PGE-2 (B). Data represents the mean and SEM of at least three independent experiments
conducted in duplicate. Statistical analysis was performed using paired t-test. *P < 0.05, **P <
0.01, ***P < 0.001, ****P < 0.0001 compared to the cAMP levels of the vehicle-treated cells.
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A.

B.

Figure 2.5 Ca2+/Calmodulin and PKC regulation of AC isoforms in the HEK-ACΔ3/6 cell line.
(A). HEK-ACΔ3/6 cells were transiently transfected with the venus control plasmid, AC1, AC2,
or AC8. Cells were incubated with the 10 μM A23187, 10 μM PGE-2, or a combination of both
as indicated, and cAMP accumulation was measured. (B). Venus, AC1, AC2 or AC7-transfected
HEK-ACΔ3/6 cells were incubated with 1 μM PMA, 50 μM forskolin, or a combination of both
as indicated, and cAMP accumulation was measured. Data represents the mean and SEM of at
least three independent experiments conducted in duplicate. Statistical analysis was performed
using one-way ANOVA followed by a Dunnett’s comparison. *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001 compared AC-transfected cAMP responses to the responses of the
Venus-transfected cells for each stimulation condition.
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whereas Venus (mock) or AC2 (negative control) transfected cells failed to respond to Ca2+ influx.
Additionally, we assessed whether Ca2+-induced AC1 and AC8 activation was differentially
modulated by simultaneous activation with Gαs. Stimulation with A23187 and PGE-2 (Gαs)
elicited an apparent synergistic effect on HEK-ACΔ3/6 cells expressing AC1, since the cAMP
response was greater for the combination of Ca2+ and Gαs stimulation than to the additive response
to both drugs. AC8-expressing knockout cells showed a minimal response to Gαs that modestly
potentiated Ca2+–induced cAMP accumulation.
Protein kinases are another set of important regulators of ACs. Particularly, activation of PKC
with the phorbol ester, PMA, directly stimulates AC2 and AC7 activity (Harry et al., 1997;
Jacobowitz and Iyengar, 1994). To determine whether AC2 and AC7 expression will give rise to
PKC-stimulated cAMP accumulation in the HEK-ACΔ3/6 cells, transiently transfected cells were
incubated with PMA (Fig. 2.5b). In the presence of the phorbol ester, AC2-expressing cells
showed a 3-fold increase over basal levels. In contrast, cells expressing AC7 (or AC1) showed no
significant response to PMA. However, when AC2 and AC7 activity was stimulated with PMA in
the presence of forskolin, both isoforms appeared to exhibit a robust synergistic response. In the
case of AC7, the PMA and forskolin combination was able to induce a cAMP signal that was
significantly higher than control cells, despite a minimal or absent response to forskolin or PMA
alone.
2.3.5 Regulation of mACs activity by Gαi-coupled receptors
GPCRs, besides stimulating mAC activity via Gαs-proteins, can also inhibit cAMP synthesis
via activation of the inhibitory G-proteins, Gαi/o. However, Gαi/o-mediated inhibition is not a
shared regulatory mechanism between all mAC isoforms, and inhibition of mAC activity has
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only been documented for AC1, AC3, AC5, AC6 and AC8 (Chen and Iyengar, 1993; Steiner et
al., 2005; Taussig et al., 1993a). Hence, to evaluate whether the HEK-ACΔ3/6 cellular model
could also be used to characterize negative regulators of mACs, knockout cells were transiently
co-transfected with the Gαi/o-coupled dopamine D2 receptor (D2R) and Venus, AC1, AC2, AC3,
AC4, AC5 or AC8. Cyclic AMP responses were examined in HEK-ACΔ3/6 cells in the presence
of forskolin (Venus, AC3 and AC5), PMA (AC2), PGE-2 (AC4), or A23187 (AC1 and AC8) in
combination with the D2R selective agonist, quinpirole (Fig. 2.6a). Acute activation of the D2R
reduced the cAMP responses to the corresponding stimulants of AC1, AC3 and AC5-expressing
cells by 56%, 50%, and 84% respectively. No significant differences were observed between the
cAMP levels of vehicle and quinpirole-induced responses of HEK-ACΔ3/6 cells expressing
AC8. In addition, quinpirole potentiated the response to the corresponding stimulation
conditions of AC2- and AC4-expressing cells by 70%. Activation of Gαi-coupled receptors have
also been implicated in another regulatory mechanism of mAC activity referred to as
superactivation or heterologous sensitization. This adaptive cellular response developed after
chronic activation of Gαi/o-coupled receptors, causes an enhancement of stimulated mAC
activity, contrary to the inhibitory effects observed after acute receptor activation. Although the
molecular mechanism underlying heterologous sensitization is not fully understood, it has been
established that sensitization is a pertussis toxin(PTX)-sensitive event in which Gαs and Gβγ
subunits are actively involved (Brust et al., 2015a). HEK-ACΔ3/6 transiently expressing the D2R
receptor and Venus, AC1, AC2, AC3, AC4, AC5 or AC8 were treated for 2-hours with
quinpirole followed by the stimulation of AC activity in the presence of the D2R antagonist,
spiperone, to assess the isoform specific cAMP responses resulting from the sensitization
paradigm (Fig. 2.6b).
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Figure 2.6 Regulation of AC isoforms after acute and chronic activation of Gαi-coupled
receptor, D2R, in the HEK-ACΔ3/6 cell line.
(A). HEK-ACΔ3/6 cells transiently coexpressing the Gαi/o-coupled D2R, and the Venus control
plasmid, AC1, AC2, AC3, AC4, AC5 or AC8 were treated with vehicle or 3 μM quinpirole in
combination with an adenylyl cyclase activator. Cyclic AMP accumulation was induced in Venus
and AC3-transfected cells with 10 μM forskolin; cells expressing AC2 and AC4 were activated
with 1 μM PMA and 10 μM PGE-2, respectively; AC5-expressing cells were stimulated with 300
nM forskolin and cells expressing AC1 and AC8 were activated with 10 μM A23187. All
transfection conditions were drug-treated for 1-hour, except for AC4-expressing cells that were
treated with quinpirole and PGE-2 for 15 minutes prior cAMP accumulation was measured (B).
Cotransfected HEK-ACΔ3/6 cells with the D2R and the corresponding AC were incubated with
vehicle or 3 μM quinpirole for 2-hours prior to stimulation of AC activity in the presence of 1 μM
spiperone to terminate the action of the D2R. Venus- and AC3-transfected cells were stimulated
with 10 μM forskolin; AC2-transfected cells were stimulated with 1μM PMA and AC4-expressing
cells were stimulated with 10 μM PGE-2; AC5-transfected cells were stimulated with 100 nM
forskolin, and AC1- and AC8- transfected cells were stimulated with 3 μM A23187. Cyclic AMP
accumulation was measured after the 1-hour incubation with the stimulants, except for AC4expressing cells that were treated with PGE-2 for 15 minutes. Data represents the mean and SEM
of at least three independent experiments conducted in duplicate. Statistical analysis was
performed using paired t-test. *P < 0.05, **P < 0.01, ****P < 0.0001 compared to the cAMP levels
of vehicle-treated cells.
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Chronic activation of the D2R led to an enhancement of the cAMP responses of the AC
isoforms, except for AC4 and AC8. PGE-2-mediated AC4 activity was inhibited after chronic
activation of the D2R receptor in AC4-expressing HEK-ACΔ3/6 cells, even though the action of
the D2R was blocked at the time of PGE-2 stimulation with spiperone (D2R antagonist). The
lower response of AC4 also referred as “super inhibition” has been previously reported after
chronic Gαi-coupled receptor activation (Nevo et al., 1998).
2.3.6 Adenylyl cyclase activity in cellular membranes
In vitro studies of native or overexpressed membrane-bound ACs in cellular membranes of
insect or mammalian cells have allowed the study of AC activity in a controlled environment
providing valuable information about their pharmacology, regulatory mechanisms, and kinetic
properties. Consequently, HEK-ACΔ3/6 pooled cell lines were generated that stably express
AC1, AC2, AC5 or AC8 to isolate cellular membranes for in vitro studies. Forskolin and Gαsmediated cAMP accumulation was examined on membrane preparations in the presence of the
metal ion cofactor, Mg2+, and the substrate ATP (Fig. 2.7). An increase of catalytic activity with
increasing concentrations of forskolin and Gαs was observed on cellular membranes
overexpressing mACs, and these cAMP responses were significantly higher than the cAMP
levels observed on the isolated membranes from untransfected HEK-ACΔ3/6 cells. Results with
the cellular membranes of the HEK-ACΔ3/6 cell lines were in accordance with the cAMP
responses observed with the intact cells. For instance, membranes isolated from HEK-ACΔ3/6AC5 and HEK-ACΔ3/6-AC8 cells exhibited a markedly increased cAMP response to forskolin.
The maximal extent of AC activation induced by forskolin or Gαs was similar on the membrane
preparations overexpressing AC1, AC5, and AC8. In contrast, Gαs appeared to be more
efficacious than forskolin in stimulating AC2.

B.

A.

Membranes isolated from HEK-ACΔ3/6 cells (black) or HEK-ACΔ3/6 cells stably expressing AC1, AC2, AC5, or AC8 (blue)
were stimulated with increasing concentrations of (A) forskolin or (B) purified Gαs, and cAMP accumulation was measured.
Data represents the mean and SEM of at least three independent experiments conducted in duplicate.

Figure 2.7 Forskolin and Gαs-induced cAMP responses of isolated membranes from HEK-ACΔ3/6 cells overexpressing mACs.
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2.3.7 HEK-ACΔ3/6 cellular model to study the activity of AC1 forskolin mutants
To further demonstrate that our HEK-ACΔ3/6 cell line is an improved cellular model to study
ACs, the cAMP responses of several mutant AC1 constructs were examined in the HEK-ACΔ3/6
and HEK293 cells. The mutant AC1 constructs were designed to incorporate single amino acid
mutations at the forskolin binding site. Mutants AC1-W419A, AC1-V423G and AC1-S924P
intended to have impaired the response to forskolin taking into consideration that Trp419 and Val423
(AC1 numbering) in the C1 domain directly interact with forskolin, and Ser924 (AC1 numbering)
in the C2 domain bridges a nearby water molecule with the diterpene. Mutant AC1-N878A was
also included in our mutagenesis studies given that this Asn878 residue is located within the
forskolin binding pocket of AC1, but it is not conserved across forskolin-sensitive isoforms
(Tesmer et al., 1997). Fig. 2.8 presents the location of the mutated amino acids within the forskolin
binding site at the interface of the C1-C2 catalytic domains.
Adenylyl cyclase activity triggered by forskolin, A23187 or a combination of both was
examined on transiently transfected HEK293 and HEK-ACΔ3/6 cells expressing Venus, AC1-WT
and the mutant AC1 constructs: AC1-W419A, AC1-V423G, AC1-N878A or AC1-S924P
(Fig.2.9). Venus-transfected HEK293 cells displayed higher cAMP levels to forskolin-induced
activation than the HEK-ACΔ3/6 cells as was expected. In the presence of the calcium ionophore,
A23187, the forskolin response of the HEK293 cells was reduced compared to the responses
mediated by forskolin alone. No difference was observed on forskolin activation of Venustransfected HEK-ACΔ3/6 cells in the presence of A23187. At the highest concentration of
forskolin (50 μM) a 3-fold difference between AC1-WT and mock-transfected cells was observed
for HEK293 cells compared to a 20-fold difference between HEK-ACΔ3/6 expressing AC1-WT
and Venus.
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Figure 2.8. Location of mutated amino acids on AC1 within the forskolin binding site.
Model of the catalytic domains of AC1 based on the crystal structure of the C1(AC5)-C2(AC2)
catalytic domains (PDB: 1AZS) (Tesmer et al., 1997). The model includes the ATP and forskolin
(FSK) molecules bound at their pseudo symmetric binding sites within the interface of the C1-C2
catalytic domains. The enlarge panel corresponds to the forskolin binding site, and the side chains
of the mutated amino acids on AC1 are represented in orange sticks. The amino acid numbering
corresponds to the numbering of the full amino acid sequence for human AC1. *In the crystal
structure, the Asn878 residue corresponds to Lys897 on the C2 domain of AC2.

B.

HEK293 (A) or HEK-ACΔ3/6 cells (B) were transiently transfected with venus, AC1-wt or a AC1 mutant construct as indicated.
After 40 hours, cAMP accumulation was stimulated with increasing concentrations of forskolin in the absence (blue) or presence
(orange) of 3 μM A23187. Black and open circles represent the forskolin response of venus-transfected cells in the presence or
absence of A23187, respectively. Data represents the mean and SEM of at least three independent experiments conducted in
duplicate.

Figure 2.9 Cyclic AMP responses to forskolin and A23187 of AC1 mutants expressed in HEK 293 and HEK-ACΔ3/6 cells.

A.
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Although both cell models revealed A23187 potentiation of forskolin-stimulated cyclic
AMP accumulation at lower forskolin concentrations, the response in the HEK-ACΔ3/6 cells was
more robust. The interpretation of the AC responses of the HEK293 cells overexpressing the AC1
mutants was rather complicated. At first glance, AC1-W419A and AC1-S924P mutants appeared
to be inactive in the HEK293 cells because neither forskolin, A23187, or a combination of both
had an effect on cAMP accumulation. The AC1-V423G mutant seemed to be insensitive to
forskolin but was responsive to A23187 (Fig. S2). Surprisingly, the effects of forskolin and
A23187 on the AC1-N878A mutant were substantially greater than those observed for AC1-WT
in the HEK293 cells. In contrast to the HEK293 cells, the expression of the AC1 mutants in the
HEK-ACΔ3/6 cells showed a more robust pharmacological profile.
AC1-W419A and AC1-S924P mutants showed little to no response when stimulated with
forskolin or A23187, but the combination of the two was able to induce a distinguishable cAMP
signal that was significantly higher than the control cells. In the case of the AC1-V423G mutant,
expression in the HEK-ACΔ3/6 cellular model revealed that this mutant was responsive to
forskolin, A23187, and a combination of both agents similar to AC1-WT. However, the extent of
AC activation in response to forskolin was vastly reduced in the AC1-V423G mutant in
comparison to AC1-WT. Although a stimulant-induced cyclic AMP response was observed for
the AC1-N878A mutant in the HEK293 cells, the dose response curves of forskolin in the
presence or absence of A23187 were shifted to the left in the HEK-ACΔ3/6 cells. Different
cAMP responses were observed for AC1-WT and the AC1 forskolin-binding site mutants in
response to A23187, but these distinct responses were the same when the AC1 constructs were
either expressed in the parental HEK293 or the HEK-ACΔ3/6 cells (Fig. S2).
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2.4

Discussion

The cAMP signaling pathway is a dynamic interplay between GPCRs, ACs,
phosphodiesterases, and downstream effectors, so a basic understanding of the individual roles of
each signaling component is critical to unravel how cAMP is ultimately necessary for multiple
cellular processes. In our continuing efforts to study AC function and regulation, we have
developed a HEK293 cell line with a minimal background level of intracellular cAMP by using
the CRISPR/Cas9 technology to disrupt the endogenous expression of AC3 and AC6. Functional
characterization of the HEK-ACΔ6 and HEK-ACΔ3/6 cell lines revealed that the cAMP responses
to forskolin and Gαs-coupled receptor activation were mediated predominantly by AC6 in HEK293
cells. Differences in the cAMP responses elicited by β2AR and EP2R activation of these knockout
cells also suggested that endogenous AC3 and AC6 contribute to a different extent to the overall
cAMP accumulation in HEK293 cells. Although it has been determined in vitro that Gαs activates
all AC isoforms (reviewed in Simonds, 1999), depending on the plasma membrane localization of
the receptor and/or the AC, different AC isoforms might also couple to specific GPCRs (Johnstone
et al., 2017). Thus, differences observed in the HEK-ACΔ6 and HEK-ACΔ3/6 cell lines might
reflect subcellular localization of the receptors and ACs.
Our results indicate that in these knockout cells, the individual activity of the nine mAC
isoforms could be characterized for general activators (forskolin and Gαs-coupled receptors) given
that the HEK-ACΔ3/6 cell line showed remarkably lower cAMP background levels for both
stimulatory mechanisms. It is becoming more apparent that forskolin and Gαs evoke varying
degrees of AC activation across the mAC isoforms even though their corresponding binding sites
within the AC catalytic domains are highly conserved. For instance, it was reported for Sf9
membranes expressing AC1, AC2, and AC5 that the potency and efficacy of forskolin and
forskolin analogs differs between isoforms (Pinto et al., 2008). Therefore, it was not surprising
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that forskolin elicited different cAMP outcomes on AC isoform-expressing HEK-ACΔ3/6 isolated
membranes and intact cells.
Activation of endogenous Gαs-coupled receptors also revealed varying responses on AC
isoform-expressing cells. The relative pattern of cAMP accumulation observed between isoforms
was the same when cells were stimulated with either isoproterenol or PGE-2, and as observed in
the parental HEK293 cell line, EP2R activation in the transfected HEK-ACΔ3/6 cells led to
higher cAMP levels than isoproterenol. All membrane-bound AC isoforms except for AC8 were
stimulated by Gαs-coupled receptor activation in the HEK-ACΔ3/6 cells. The absence of an AC8
response in cells was not explained by the inability of Gαs to bind or stimulate this isoform
because in vitro studies with the HEKΔ36-AC8 membrane preparations demonstrated that the
stimulatory Gα-subunit was able to activate AC8, and a the lack of a response in AC8-expressing
cells to Gαs-coupled receptor activation has been previously reported in HEK293 cells (Nielsen
et al., 1996).
Selective regulatory properties of AC isoforms were also recapitulated in the HEKACΔ3/6 cells. Consistent with previous reports in the literature, Ca2+ influx stimulated
Ca2+/Calmodulin-regulated mACs, AC1 and AC8 (Tang et al., 1991). Likewise, our results with
the AC1- and AC8-expressing cells for the cotreatments with the calcium ionophore, A23187,
and PGE-2 were also in accordance with previous reports in intact cells, where only AC1
displayed an apparent synergistic response to Ca2+ stimulation in the presence of activated Gαs
(Cumbay and Watts, 2001; Nielsen et al., 1996). In particular, by taking advantage of the unique
regulatory properties of each mAC isoform, we ultimately demonstrated specific mechanisms to
selectively activate all nine mACs with an improved signal window over basal levels.
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Specifically, subtle cAMP responses were unmasked for AC isoforms such as AC7 or AC9
that did not display a robust cAMP response to various stimulatory mechanisms in the HEKACΔ3/6 cell model. Acute and chronic activation of the Gαi-coupled receptor, D2R, elicited
opposing effects on AC activity in the HEK-ACΔ3/6 cells, and these inhibitory or sensitized
responses were AC isoform-dependent. Overall, the effects of acute and chronic Gαi-coupled
receptor activation in the D2R- and mAC-transfected HEK-ACΔ3/6 cells, were also consistent
with previous studies (Chen and Iyengar, 1993; Taussig et al., 1993a; Watts and Neve, 2005),
indicating that the HEK-ACΔ3/6 cell line can also be used to examine the unique inhibition or
adaptive responses of adenylyl cyclase isoforms.
In vitro studies with isolated membranes from HEK-ACΔ3/6 cells overexpressing mACs
also exhibited a suitable signal-to-background window for the characterization of isoformspecific basal and catalytic activities. The basal activity of the isolated membranes in the
presence of Mg2+ and ATP was also significantly higher for isolated membranes overexpressing
an AC isoform compared to the untransfected HEK-ACΔ3/6 cell membranes. Overall, the foldchange response to forskolin over the basal activity was significantly lower in the isolated
membranes than that in cells, whereas the fold-change over the basal response triggered by
purified Gαs was much higher in the membrane preparations. Particularly, these in vitro assays
are a more direct approach to discern the effects of forskolin, Gαs and other modulators on AC
activity. Therefore, our HEK-ACΔ3/6 cell line proved to be an adequate in vitro and in vivo
cellular model to study mAC responses.
By disrupting the expression of AC3 and AC6 in the HEK293 cells, the enhancement of the
signal window upon stimulation of AC activity in the knockout cells enable AC responses that
previously were masked by the high cAMP levels, to become noticeable. The cAMP responses
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detected for the uncharacterized AC1 constructs containing mutations within the forskolin-binding
pocket were significantly different when these constructs were expressed in HEK293 or HEKACΔ3/6 cells. Mutation of the Trp419 or Ser924 residues were predicted to disrupt forskolin activity
based on the binding interactions revealed by the crystal structure of the mAC catalytic domains
(Tesmer et al., 1997). Interpretation of the data with the AC1-W419A and AC1-S924P mutants in
the HEK293 cells suggested these two AC mutants were functionally inactive as indicated by the
lack of a response over the cAMP levels of Venus-transfected cells. In contrast, expression of
AC1-W419A and AC1-S924P in the HEK-ACΔ3/6 cells revealed a complete loss of forskolin
sensitivity, but in combination with A23187 induced a distinct increase of cAMP accumulation
higher than the drug-induced responses of the control-cells, demonstrating only a partial loss of
function. An analogous mutation on Ser942 of AC2 (AC2-S942P) is forskolin insensitive in the
absence or presence of Gαs despite showing similar Gαs-mediated stimulation to AC2-WT (Brand
et al., 2013), indicating that analogous mutations of conserved residues within the forskolin
binding site of AC isoforms may affect the distinct responses to other stimulatory agents in
different ways.
The crystal structure of the C1-C2 heterodimer also revealed that Val423 directly interacts
with forskolin. However, mutating this residue did not abolished forskolin stimulation, and
forskolin only showed diminished efficacy to activate AC1-V423G. No difference between the
potency of forskolin for AC1-V423G and AC1-WT, also implies that the interaction between
forskolin and Val423 is important to mediate its stimulatory effects but may not be essential for
forskolin binding. That there were no significant effects of the mutation on the cAMP response
mediated by A23187 alone also suggests that the AC1-WT and AC1-V423G constructs were
expressed at similar levels.
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The robust enhancement of cAMP accumulation detected for AC1-N878A in comparison to
AC1-WT when the cells were stimulated with forskolin or/and A23187, was unanticipated. All the
forskolin-sensitive mACs have a charged or polar residue at this position on the forskolin binding
site, except for AC3 and AC8 (Seifert et al., 2012). By mutating Asn878 in AC1 to the counterpart
Ala residue in AC8, it appears that the responses of AC1-N878A are comparable to the robust
cAMP responses elicited by forskolin and A23187 on AC8-expressing cells. Even though the
enhanced responses of the AC1-N878A construct were detected in both HEK293 and HEKACΔ3/6 cells, a shift to the left of the forskolin dose-response curves became apparent in the HEKACΔ3/6 cell model, besides the change in efficacy observed in both parental and knockout cells.
In conclusion, the HEK-ACΔ3/6 cell line is a useful tool that has several advantages over the
parental cell line for the study of mutant ACs with reduced catalytic activity and changes in
forskolin sensitivity. Our knockout model not only allowed for functional characterization of AC
mutants with diminished activity, but also revealed additional pharmacological effects on the AC1N878A mutant that exhibited an enhanced cAMP response to stimulatory conditions.
For future applications, the HEK-ACΔ3/6 cellular system provides a more controlled
environment for high throughput screening assays of selective AC modulators to ultimately lower
false-positives rates (non-selective compounds) and simplify hit validation. Although the scope of
the present work focused on mACs, our HEK-ACΔ3/6 cell line is also an appropriate cellular
model to study function and regulation of soluble AC. Overexpression of sAC in HEK293 cells
results in high cAMP levels in the presence of IBMX (Zippin et al., 2001) that reflects activity
from sAC as well as the endogenous ACs (e.g. AC3 and AC6). The use of the HEK-ACΔ3/6 cells
would presumably enhance the overall signal to noise window for evaluating modulators of AC10.
An additional advantage of the new cell model is the human genetic background that readily allows
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for a wider range of studies assessing cAMP signaling in intact cells. Our CRISPR/Cas-based cell
line is a valuable human cellular system to study AC isoforms in an unbiased manner and is a tool
that could simplify and aid future efforts to develop selective AC modulators.
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CHAPTER 3.

CHARACTERIZATION OF A PEPTIDE MODULATOR
OF Gβγ SIGNALING DERIVED FROM AC2

Conditional stimulation by Gβγ subunits is the main regulatory property that characterizes
adenylyl cyclases (AC) 2, 4, and 7. The objective of this study was to explore the modulatory
properties on Gβγ-mediated signaling of an uncharacterized C2a domain adjacent to the membrane
that displayed high degree of homology between Gβγ-stimulated cyclases. Surface plasmon
resonance determined that a peptide derived from this juxta membrane C2a domain, C2-20, binds
with high affinity to Gβγ subunits (KD ~2 nM). Subsequently, a minigene strategy was used to
characterize the activity of the C2-20 peptide on Gβγ-mediated conditional stimulation of AC2
activity. The minigene contained an N-terminal CD8 domain to localize the C2-20 peptide to the
membrane. Expression of the CD8-C2-20 minigene inhibited completely Gβγ-mediated
potentiation of AC2 following the activation of the dopamine D2 receptor (D2R). In addition, the
specificity of the CD8-C2-20 minigene was explored with a series of mutant minigenes containing
triple-alanine substitutions and their respective inhibitory activities suggested that the C2-20
domain interaction with Gβγ is mediated by multiple contact points given that none of the CD8C2-20 mutants were sufficient to abolish its inhibitory action. Furthermore, the effects of the CD8C2-20 minigene were evaluated on other Gβγ-mediated pathways such as ERK activation, βarrestin recruitment, and heterologous sensitization of AC2 and AC5. Interaction of the C2-20
domain with Gβγ successfully blocked potentiation of AC2 activity induced by the Gβγ complex
and attenuated β-arrestin recruitment to the D2R. However, it did not interfere with the role of Gβγ
subunits in heterologous sensitization of AC2 and AC5 or Gβγ-mediated stimulation of the MAPK
kinase cascade. The resulting studies suggest that specific regions of the C2a domain could be used
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to selectively modulate Gβγ signaling. These studies highlight further the complexities associated
with AC signaling and the unique ways in which isoforms are modulated by Gβγ subunits.

3.1

Introduction

Adenylyl cyclases (AC) play a vital role in many biological processes because they are the
enzymes responsible for the conversion of ATP into the secondary messenger cAMP. Nine
isoforms of membrane-bound ACs exist in mammals, and their structure consist of a cytosolic Nterminus, two helical membrane-spanning domains and two cytosolic regions (C1 and C2). The
C1 and C2 domains of transmembrane ACs dimerize to form the catalytic core upon AC activation.
Each cytosolic domain subdivides into a highly conserved region (C1a and C2a) that contains the
essential residues for catalytic activity, and a less conserved domain (C1b and C2b) that contains
several regulatory sites (Tang and Hurley, 1998).
Despite the high degree of structural and sequence homology of mAC isoforms, they
exhibit differential regulatory mechanisms to stimulatory and inhibitory Gα-proteins, Gβγ
subunits, protein kinases, and divalent cations. Thus, membrane-bound ACs are classified into 4
groups based on these regulatory properties. Calcium-stimulated cyclases, AC1, AC3, and AC8,
belong to Group I, and Gβγ-stimulated AC2, AC4, and AC7 comprise Group II. Group III consists
of AC5 and AC6 which are inhibited by sub micromolar concentrations of Ca2+, while AC9
belongs to Group IV as the only mAC insensitive to the diterpene, forskolin (reviewed in Dessauer
et al., 2017).

Specific AC isoforms have been associated with various physiological and

pathological conditions dictated by these isoform-specific regulatory properties and distinct tissue
distribution patterns (Sadana and Dessauer, 2009). Therefore, AC isoforms have emerged as
interesting drug targets for diseases ranging from cardiovascular disorders to pain and addiction
(Dessauer et al., 2017; Pierre et al., 2009; Seifert et al., 2012).
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The Gβγ complex is one of the mAC regulators that exerts either inhibitory or stimulatory
actions depending on the AC isoform. Once released from the heterotrimeric G-protein complex
after GPCR activation, the Gβγ dimer has the ability to conditionally stimulate AC2, AC4, and
AC7 or inhibit AC1 and AC3 (Khan et al., 2013). Multiple binding domains have been
characterized for Gβγ on the intracellular domains of the mAC isoforms. Unique sites have been
reported for AC1 and AC3 within the C1 region, for AC2 on both C1 and C2 domains, and for
AC5 and AC6 on the N-terminus (Boran et al., 2011; Brand et al., 2015; Wittpoth et al., 1999). In
particular, five Gβγ-binding domains have been identified on AC2 (Fig. 3.1): the QEHA region in
the C2 domain, the PFAHL region within the C1b domain, the KF loop—proximal to the QEHA
region—and two additional sites in the C1 domain (339-360 and 578-602, AC2 numbering) (Boran
et al., 2011; Chen et al., 1995; Diel et al., 2008; Diel et al., 2006). Several of these binding sites
are homologous between the Gβγ-stimulated cyclases (AC2, AC4 and AC7; Fig. 3.1), and it
appears, based on mutagenesis and domain swapping studies that the conditional stimulatory effect
of Gβγ on AC2 is mediated by a complex interaction with several of those shared binding sites
(Diel et al., 2006; Weitmann et al., 2001).
The involvement of the Gβγ complex in regulating important physiological processes
(Khan et al., 2013) has motivated interest to elucidate the potential of Gβγ subunits as a therapeutic
target (Smrcka et al., 2008). However, non-selectively inhibiting all Gβγ functions may cause
unwanted side effects, so understanding the protein-protein interaction dynamics between Gβγ and
its effectors is necessary to achieve selective modulation of Gβγ-mediated pathways. Gβγ subunits
are localized to membranes by prenylation of the Gγ subunit (Smrcka, 2008).
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Figure 3.1 Sequence alignment between AC2, AC4, and AC7 of the Gβγ-binding sites
The location of the Gβγ-binding sites identified on AC2 is indicated in the diagram by colored
boxes. Amino acid sequences of human AC2 (ADCY2), AC4 (ADCY4), and AC7 (ADCY7) were
aligned with the EMBL-EBI Clustal Omega software. For each corresponding Gβγ-binding site,
the overall score represents the sequence homology between AC2, AC4 and AC7, and the scores
reported for the AC4 and AC7 domains represent the sequence similarity between each AC and
AC2. Identical amino acids and amino acids with similar properties between AC2, AC4 and AC7
are highlighted in grey and light blue, respectively.
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Various strategies such as GPCR-derived pepducins—lipidated peptides corresponding to a
juxtamembrane region of the receptor’s intracellular loops—have emerged as novel mechanisms
to modulate membrane-bound proteins (Zhang et al., 2015). For example, a juxtamembrane
portion of an intracellular loop of the Glycine receptor (GlyR) interacts with the Gβγ complex, and
a peptide derived from this domain, interferes with Gβγ-mediated activation of the G-proteincoupled inwardly rectifying K+ channel (GIRK) (Guzman et al., 2009).
Consequently, the objective of this research was to determine whether juxtamembrane
domains of AC2 could also modulate Gβγ activity. To do so, we first evaluated the homology
between the cytosolic domains adjacent to the membrane of the Gβγ-stimulated cyclases: AC2,
AC4 and AC7, and identified an uncharacterized juxtamembrane segment on the C2a domain that
binds the Gβγ complex with high affinity. A minigene derived from this juxtamembrane C2a
segment, blocked Gβγ-potentiation of AC2 activity in cells, and showed a biased profile for
inhibition of AC2 potentiation over other Gβγ-mediated pathways.

3.2

Methods

3.2.1 Peptide synthesis
The C2-20 peptide (RQNEYYCRLDFLWKNKFKKE) and the scrambled version of the C220 peptide (LRNKEYRLDFKENYKFKWCQ) for the SPR experiments, were synthesized by
Genscript Biotech (Piscataway, NJ).
3.2.2 Surface Plasmon Resonance
SPR was performed as described in (Seneviratne et al., 2011; Surve et al., 2014), with
modifications. The C2-20 peptide or the scrambled peptide was immobilized on the surface of a
polyethylene glycol-coated gold sensor chip (Reichert, NY) using N′-ethylcarbodiimide
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hydrochloride (EDC) – N-Hydroxysuccinimide (NHS) chemistry, by injecting 10 μM C2-20 or
the scrambled peptide in 50 mM HEPES, pH 7.6, 1 mM EDTA, 200mM NaCl, 0.1%
polyoxyethylene 10 lauryl ether (C12E10), 1 mM dithiothreitol, and 0.1% DMSO. Gβγ was injected
and its binding was observed for 2 minutes followed by dissociation for 5 minutes, at a flow-rate
of 75 μL/min. After dissociation, the peptide surface was regenerated using 610 mM MgCl 2, 205
mM Urea, and 610mM Guanidine- HCl, followed by the second injection. The data was analyzed
using Scrubber and the BIAevaluation software (Biacore), and the KD was determined by globally
fitting the binding curves determined at several concentrations of compound with a 1:1 binding
model.
3.2.3 Constructs design
The pcDNA3.1+/CD8-C2-20 construct was designed based on the pcDNA3/CD8-βARKct
plasmid (Crespo et al., 1995). The CD8-C2-20 plasmid contains the transmembrane domain
portion of the CD8 lymphocyte-specific receptor (residues 1-209), followed by the restriction site
BamHI, and the C2-20 domain sequence: RQNEYYCRLDFLWKNKFKKE (residues 822-841,
AC2 numbering). For the scrambled CD8-C2-20 construct, the C2-20 peptide sequence was
randomly reorganized (LRNKEYRLDFKENYKFKWCQ), but charge distribution was
maintained. CD8-C2-20 and scrambled CD8-C2-20 plasmids were synthesized, and codon
optimized for human cell line expression by Genscript Biotech (Piscataway, NJ).
3.2.4 Site-directed mutagenesis of CD8-C2-20 minigene
Variants of the CD8-C2-20 minigene with triple alanine mutations or a C-terminal deletion
were generated using the Q5® Site Directed Mutagenesis kit. First, primers were designed to
replace in the C2-20 sequence a 9 bp segment that encodes for: RQN (CD8 (RQN 1-3)), EYY
(CD8 (EYY 4-6)), CRL (CD8 (CRL 7-9)), DFL (CD8 (DFL 10-12)), or WKN (CD8 (WKN 13-15)),
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with the codon sequence, gcc gcc gcc, that encodes for a triple AAA substitution (Table S1). In
the case of the C-terminal deletion for the CD8 (C2-17) minigene, the primers designed flanked
the 9bp codon sequence of the last three amino acids (KKE) of the C2-20 domain. PCR
amplification of the entire pcDNA3.1+/CD8-C2-20 plasmid using the corresponding forward and
reverse set of primers for each CD8-C2-20 variant was performed according to the Q5 SiteDirected Mutagenesis protocol. The PCR products were further used to set up the KDL reactions
of the Q5 Site-Directed Mutagenesis kit, and prior to bacterial transformation, each reaction was
treated with DpnI for 1 hour at 37 ºC to remove the parental CD8 C2-20 PCR template. Once it
was determined that the mutation was properly incorporated to the CD8-C2-20 constructs by
Sanger sequencing, the CD8-C2-20 variant genes were cut with NheI and KpnI from the PCR
generated constructs. The cut fragment was then cloned into an empty pcDNA3.1+ backbone to
ensure that the CD8-C2-20 variant minigenes had no additional mutations outside the C2-20
sequence that could had been introduced during the PCR amplification.
3.2.5 Transfections
CHOwt cells or HEK293 cells were plated overnight to have cells at 70% confluency in a 12well plate format for transfection the following day. Cells were transfected with Lipofectamine
2000 purchased from Life Technologies (Carlsbad, CA) or with XtremeGENE 9 from Roche
(Basel, Switzerland) according to the manufacturer’s recommendations. Lipofectamine 2000 was
used for the transfection of HEK293 cells with the D2R, AC2 and CD8-C2-20, Scr-CD8-C2-20,
CD8-βARKct or Venus constructs. A 1:2 DNA to Lipofectamine ratio and a 1:2:3 DNA ratio for
the D2R, AC2, and Venus or CD8 minigene combinations, respectively, were the optimal
parameters for these transfections. CHO cells were also transfected with Lipofectamine 2000 for
the ERK phosphorylation experiments in a 1:2 DNA to Lipofectamine ratio and a 1:2 DNA ratio
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of the D2R and Venus or CD8 minigene constructs. Xtreme GENE 9 was used instead for the
transfection of the HEK 293 cells with D2R, AC2 or the CD8-C2-20 variants in a 1:2 DNA to
XtremeGENE ratio and a 1:2:4 DNA ratio for the D2R, AC2, and Venus or CD8 minigene variant
combinations, respectively. Transfection of the DiscoveRx CHO cells stably expressing the
ProLink-tagged D2R and the enzyme acceptor-tagged β2-Arrestin (CHO-D2L) were also
transfected with XtremeGENE 9 in a 1:2 DNA to XtremeGENE ratio.
3.2.6 Gβγ-mediated AC2 potentiation
After 48-hour transfection, transfected HEK293 cells were washed with PBS, harvested using
cell dissociation buffer, and resuspended in serum-free Opti-MEM. The cells were centrifuged at
150 x g for 5 minutes, and the cell pellet was resuspended in Opti-MEM for a second centrifugation
step. Transfected cells were then counted, and the volume of the cell suspension was adjusted to
the desire cell concentration for plating in a low volume 384-well plate (Catalog # 784080) from
Greiner Bio-One (Kremsmünster, Austria). After 1-hour incubation at 37 ºC in 5% CO2, the cells
were treated with vehicle or 3 μM quinpirole followed by 1 μM PMA in the presence of 500 μM
3-isobutyl-1-methylxanthine (IBMX). Cells were treated with the indicated drugs for 1-hour at
room temperature before cAMP production was measured using the HTRF cAMP Gs assay kit
from Cisbio (Bedford, MA). Fluorescence signals from each well were measured with a Cytation
3 plate reader at 330 nm excitation wavelength and 620/665 nm emission wavelengths. Cyclic
AMP levels were determined by extrapolating the 620/665 fluorescence ratio from a cAMP
standard curve ran in parallel.
3.2.7 Heterologous sensitization
Transfected D2R and AC2/AC5 cells were harvested and plated as described above for the
Gβγ-mediated AC2 potentiation assays with the minigenes. After the 1-hour incubation at 37 ºC
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in 5% CO2, the cells were treated with 3 μM quinpirole for 2 hours prior the stimulation of AC2 or
AC5 activity with 1 μM PMA or 30 nM forskolin (FSK), respectively, in the presence of 1 μM
spiperone (D2R antagonist) and 500 μM IBMX. Cyclic AMP was measured as described above
after 1-hour stimulation with the respective AC2 and AC5 activators.
3.2.8 β2-arrestin recruitment (PathHunter β2-arrestin assay)
After 24-hour transfection with XtremeGENE, DiscoveRx CHO-D2L cells were harvested and
plated overnight in a low volume 384-well plate at 37 ºC in 5% CO2. Next day, cells were incubated
with increasing concentrations of quinpirole for 90 minutes at 37 ºC in 5% CO2. To detect β2arrestin recruitment after D2R activation, the PathHunter detection kit from DiscoveRx (Fremont,
CA) was utilized. The detection reagent was prepared according to the PathHunter kit’s protocol
and was kept protected from light. The detection reagent was added and incubated for 1-hour at
room temperature prior luminescence signal was measured with a Synergy4.
3.2.9 ERK Phosphorylation (AlphaLISA SureFire Ultra)
CHO cells transiently transfected with D2R and Venus, CD8-βARKct or CD8-C2-20 were
harvested and centrifuged twice at 150 xg for 5 minutes. Cells were plated in a regular volume
384-well plate and after 2-hour incubation at 37 ºC in 5% CO2, the cells were treated with 3 μM
quinpirole or 1 μM PMA for 10 minutes at room temperature. Phosphorylated ERK 1/2 mediated
by D2R and PKC activation was quantified using the AlphaLISA SureFire Ultra p-ERK1/2
(Thr202/Tyr204) assay kit. AlphaLISA SureFire Ultra lysis buffer was added to the wells and
incubated for 10 minutes at room temperature while shaking on an orbital shaker. According to
the kit’s manual, the acceptor reagents beads were added to each well and incubated with the cell
lysate for 1-hour protected from light followed by the addition of the donor beads.
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The plate was incubated overnight before the AlphaScreen signal was detected using a Perkin
Elmer EnSpire plate reader.

3.3

Results

3.3.1 An uncharacterized 20-mer segment derived from AC2 binds to Gβγ
Considering that Gβγ localizes at membranes and interacts with a large number of
transmembrane proteins, we wanted to evaluate whether juxtamembrane domains on the Nterminus or the two catalytic domains of AC2 interact with the Gβγ complex. In previous studies,
intracellular domains that display high degree of homology between AC2, AC4, and AC7, have
shown to interact with Gβγ subunits (Boran et al., 2011). Therefore, we performed a sequence
alignment between the 4 juxta membrane segments of the Gβγ-stimulated cyclases and determined
their sequence homology (Fig. 3.2). No significant sequence similarity was observed between the
domains on the N-terminus or the C1a domain of AC2, AC4, and AC7. The juxtamembrane region
on the C1b only showed strong homology between AC2 and AC4, and this shared binding domain
(578-602, AC2 numbering) has been previously reported to bind Gβγ subunits with low affinity
(Boran et al., 2011). Surprisingly, an uncharacterized juxtamembrane section on the C2a domain
exhibited the highest overall degree of homology among the fragments evaluated. This section on
the C2a domain displayed 65% identical and 85% similar sequence homology between AC2, AC4,
and AC7.
To explore the relationship between the homology of the C2a juxtamembrane region and Gβγ’s
binding interactions with AC2, AC4, and AC7, a 20-mer peptide derived from the juxtamembrane
region of the C2a domain of AC2 (C2-20) was synthesized for in vitro binding assays with Gβγ.
Specifically, we used surface plasmon resonance (SPR) to determine whether this uncharacterized
C2a segment interacts with Gβγ subunits.
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Figure 3.2 Sequence alignment of juxta membrane cytosolic domains of AC2, AC4 and AC7.
Amino acid sequences of the intracellular domains adjacent to the membrane of human AC2
(ADCY2), AC4 (ADCY4), and AC7 (ADCY7) were aligned with the EMBL-EBI Clustal Omega
software. The location of the aligned domains is indicated in the diagram by the red boxes and the
corresponding numbering. The overall score represents the sequence homology between AC2,
AC4 and AC7, and the scores reported for the AC4 and AC7 domains represent the sequence
similarity between each AC and AC2. Identical amino acids and amino acids with similar
properties between AC2, AC4 and AC7 are highlighted in grey and light blue, respectively.
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The C2-20 peptide was immobilized on the SPR chip and increasing concentrations of Gβγ were
applied (Fig. 3.3a). Kinetic analysis of the SPR binding curves indicated that the C2-20 peptide
binds to Gβγ with a binding affinity of approximately 2 nM.
Compared to the KD values reported by Boran et al for other Gβγ binding sites of AC2, the C2-20
peptide showed equal binding affinity to Gβγ as the PFAHL domain localized on the C1a domain,
but it exhibited higher binding affinity than the QEHA domain and the other juxtamembrane 578602 segment. Furthermore, the binding interaction between the C2-20 peptide and Gβγ was
specific given that a sequence-scrambled C2-20 peptide failed to bind to Gβγ (Fig. 3.3b), and the
C2-20 peptide did not bind to the Gαi subunit (data not shown).
3.3.2 Expression of a C2-20 peptide minigene inhibits Gβγ potentiation of AC2 activity
After having determined that the C2-20 peptide binds with high affinity to Gβγ, we examined
the ability of the C2-20 domain to modulate Gβγ-mediated potentiation of AC2 activity. Using a
minigene strategy, we designed a vector, CD8-C2-20, encoding for a N-terminal CD8
transmembrane domain—to localize the peptide at the membrane–followed by the C2-20 peptide
sequence. Given that most of the stimulatory effects of Gβγ on ACs are mediated by the pertussis
toxin-sensitive Gαi/o-proteins (Smrcka, 2008), the effect of the CD8-C2-20 minigene on Gβγ
signaling was examined in HEK293 cells transiently coexpressing AC2 and the Gαi/o-coupled
receptor, dopamine D2 receptor (D2R). Gβγ-mediated potentiation of AC2 activity also requires
the simultaneous activation of the cyclase either by Gαs-coupled receptors or by protein kinase C,
so transfected HEK293 cells were treated with the phorbol ester, PMA, in the presence or absence
of the D2R agonist, quinpirole (Watts and Neve, 1997).

77

Figure 3.3 The juxtamembrane C2a domain of AC2 binds to Gβγ
Surface plasmon resonance curves of immobilized C2-20 (A) or a sequence-scrambled C2-20
peptide (B) binding to increasing concentrations of Gβγ subunit. Fitted curves (black lines) were
calculated from the SPR data using Scrubber and the BIAevaluation software (Biacore). Data was
generated and analyzed by Dr. Chinmay Surve in Dr. Alan Smrcka’s lab.
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Expression of the CD8-C2-20 minigene abolished Gβγ-mediated potentiation of AC2
activity (Fig. 3.4), however, expression of a minigene with the scrambled amino acid sequence of
the C2-20 peptide, CD8-Scr/C2-20, had no effect on potentiation of PMA-stimulated AC2 activity.
In addition, the CD8-C2-20 minigene showed the same extent of inhibition of Gβγ-mediated AC2
potentiation as the positive control, the scavenger of Gβγ subunits, CD8-βARKct (Inglese et al.,
1994; Koch et al., 1994). No major differences were observed on the cAMP response to PMA
alone for the cells expressing CD8-C2-20, CD8-Scr/C2-20, or CD8-βARKct compared to the
Venus-transfected cells, which suggests that the inhibition of AC2 activity by the CD8-C2-20
minigene was only limited to the conditional activation induced by the Gβγ complex.
3.3.3 Central residues of the C2-20 sequence are critical for the inhibitory activity of
the CD8-C2-20 minigene
In order to identify the amino acids important for the inhibitory activity of the CD8-C2-20
minigene, several minigene variants were designed with triple-alanine mutations or a C-terminal
truncation within the peptide sequence of the C2-20 segment (Table 3.1). The ability of the CD8C2-20 minigene variants to inhibit Gβγ potentiation of PMA-stimulated AC2 activity was
examined in AC2 and D2R-transfected HEK293 cells, and the magnitude of Gβγ potentiation over
the PMA response for each transfection condition was compared to the responses of wild-type
CD8-C2-20 -expressing cells. Mutations within the central portion of the C2-20 sequence (EYY
4-6, CRL 7-9, and DFL 10-12) caused a substantial loss of the inhibitory activity of the CD8-C220 minigene by more than 50% (Fig. 3.5). The bell-shaped distribution of the mutations’ effects
on the inhibitory activity of the CD8-C2-20 minigene with a peak at the intermediate residues,
DFL 10-12, highlights the importance of this central portion for its inhibitory activity.
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Figure 3.4 Expression of a C2-20 minigene blocked the stimulatory effects of Gβγ on AC2 activity.
HEK293 cells were transiently transfected with human AC2, the D2R and Venus (transfection
control), CD8-βARKct, CD8-C2-20 minigene or a scrambled version of the CD8-C2-20 minigene.
After 48-hour transfection, cells were treated with 1µM PMA in the absence or presence of 3μM
quinpirole to induce Gβγ-mediated potentiation of AC2 activity. Data represents the average and
SEM of at least three independent experiments, each performed in triplicate. Statistical
significance was calculated using unpaired student's t-test. ns, not significant, *P < 0.05 compared
to the to the cAMP levels of the PMA alone.
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Table 3.1 Amino acid sequences of the CD8-C2-20 minigene variants and % inhibition of Gβγmediated potentiation of AC2 activity.
The position within the C2-20 sequence of the triple alanine substitutions or the C-terminal
truncation of the CD8-C2-20 minigene variants is highlighted in bold and underlined.
a
Percentage inhibition of Gβγ potentiation of AC2 activity following PKC activation. First, foldchange over PMA response was calculated to determine relative magnitude of Gβγ-mediated
potentiation for each transfection condition. Subsequently, percentage inhibition was calculated
relative to the Gβγ-mediated potentiation (set as 0% inhibition) and PMA alone responses (set as
100% inhibition) of Venus-transfected cells.
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Figure 3.5 CD8-C2-20 variants containing triple-alanine substitutions in the “middle” of the C220 domain displayed diminished inhibitory effects on Gβγ potentiation.
HEK293 cells were transiently transfected with human AC2, D2R and Venus, CD8-βARKct,
CD8-C2-20, or a CD8-C2-20 minigene variant containing a triple-alanine substitution or a cterminus truncation. Transfected cells were treated with 1 µM PMA in the absence or presence of
3 μM quinpirole to induce Gβγ-mediated potentiation of AC2. Fold-change over PMA response
was calculated to determine relative magnitude of Gβγ-mediated potentiation for each transfection
condition, and Gβγ-mediated response was reported relative to the magnitude of Gβγ-mediated
potentiation (set as 100%) and PMA alone responses (set as 0%) of Venus-transfected cells.
Statistical analysis was performed using one-way ANOVA followed by a Dunnett’s comparison.
**P < 0.01, ****P < 0.0001 compared to the % of Gβγ-mediated potentiation of the CD8-C2-20transfected cells.
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However, no variant completely rescued Gβγ-mediated potentiation which indicates that more
than one residue between Glu at position 4 and a Leu at position 12, are required for the inhibitory
effects of the C2-20 domain. To ensure that the reduction of the inhibitory activity was not due to
different expression levels of the CD8-C2-20 minigenes, protein expression levels of the CD8-C220 minigene variants and wild-type CD8-C2-20 were measured by Western blot using an anti-CD8
monoclonal antibody (data not shown). Surprisingly, the CD8-C2-20 variants that had a
diminished ability to block Gβγ-mediated stimulatory effects on AC2 activity were generally more
highly expressed compared to wild-type CD8-C2-20; thereby, the relative level of protein
expression does not account for the decreased inhibitory effects of the CD8-C2-20 variants.
3.3.4 CD8-C2-20 fails to inhibit Gβγ-mediated pathways triggered by D2R activation
A large and diverse array of proteins are modulated by free Gβγ subunits (Khan et al., 2013).
Several of these Gβγ effectors shared a common binding site (hot spot) on the top surface of Gβ
subunit (Davis et al., 2005; Scott et al., 2001), so the effector specificity of the Gβγ and C2-20
interaction was examined. In order to explore how the interaction of the C2-20 peptide domain
modulates Gβγ activity on other AC signaling events, the effects of the CD8-C2-20 minigene were
studied on heterologous sensitization of AC2 and AC5. Heterologous sensitization of adenylyl
cyclases is an adaptive cellular response developed after chronic activation of Gαi/o-coupled
receptors that causes an enhancement of AC activity (Brust et al., 2015a). The role of Gβγ subunits
has been previously shown to be essential for heterologous sensitization (Conley and Watts, 2013;
Ejendal et al., 2012; Nguyen and Watts, 2006), so the ability of the CD8 -C2-20 minigene to inhibit
this adaptive mechanism was assessed in HEK293 cells expressing D2R and AC2 or AC5. As it
had been previously shown, expression of CD8-βARKct completely abolished the sensitized
response of both AC2 and AC5 after PMA or forskolin activation, respectively. Somewhat
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surprisingly, expression of the CD8-C2-20 failed to suppress the enhancement of AC2 and AC5
activity (Fig. 3.6).
Next, the ability of the CD8-C2-20 minigene to interfere with the Gβγ activation of GRK2 and
subsequent β-arrestin recruitment to the D2R was examined. DiscoveRx CHO-D2L cells stably
expressing D2R and β2-arrestin tagged with the enzyme fragments of the β-galactosidase enzyme
were transiently transfected with CD8-C2-20, CD8-βARKct, or Venus. Using the Path Hunter
technology, β2-arrestin recruitment was readily detected after transfected cells were incubated
with increasing concentrations of quinpirole (Fig. 3.7). Expression of the CD8-C2-20 and CD8βARKct minigene partially attenuated β2-arrestin recruitment when compared to Venus
expression (Fig. 3.7b). The potency of quinpirole was similar for all transfection conditions (Table
3.2), suggesting that neither CD8-βARKct or CD8-C2-20 altered the ability of the agonist to bind
the receptor. The modest changes in the efficacy of quinpirole to recruit β2-arrestin when CD8βARKct and CD8-C2-20 minigenes are expressed presumably reflect a decrease of Gβγ-mediated
activation of GRK resulting in less β2-arrestin recruitment.
Another major signaling event initiated after GPCR activation is mitogen-activated protein
kinase (MAPK) ERK1/2 phosphorylation. Activation of the MAPK cascade by Gαi/o-coupled
receptors has been shown to be mediated by Gβγ subunits via at least three different mechanisms
(Khan et al., 2013). One pathway involves Gβγ-induced stimulation of the phosphatidylinositol 3kinase (PI3K) and the Src family kinase. A second mechanism is mediated by recruited β-arrestin
that functions as a scaffolding protein, and a third pathway occurs through transactivation of
receptor tyrosine kinases (RTKs) (Fig. 3.8a). The effects on Gβγ-induced ERK 1/2
phosphorylation were examined in CHO cells transiently expressing Venus, CD8-C2-20 or CD8βARKct after 10-minute activation of the D2R by quinpirole.
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A.

B.

Figure 3.6 CD8-C2-20 was unable to suppress heterologous sensitization of AC2 and AC5.
HEK293 cells were transiently cotransfected with human AC2/AC5, the D2R and Venus
(transfection control), CD8-βARKct or CD8-C2-20 minigene. After 48-hour transfection, cells
were pretreated with 3 μM quinpirole for 2-hours followed by the activation of AC2 with PMA
and AC5 with FSK in the presence of the D2R antagonist, spiperone. Data represents average and
SEM of three independent experiments conducted in triplicate. Statistical significance was
calculated using paired student's t-test. ns, not significant, *P < 0.05, **P < 0.01, compared to the
cAMP levels of the vehicle-treated cells.
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A.

B.

Figure 3.7 CD8-C2-20 attenuated β-arrestin recruitment following D2R activation.
(A) Schematic diagram of Gβγ-mediated recruitment of β-arrestin. After receptor activation (1),
Gβγ subunits recruit G-protein receptor kinases (GRKs) to the activated receptor (2) leading to
subsequent recruitment of β-arrestin (3). (B) PathHunter β-arrestin CHO cells from DiscoveRx
stably expressing the D2R were transfected with Venus (blue), CD8-βARKct (black), or CD8-C220 (red). After 24 hours transfection, the cells were incubated in the presence of increasing
concentrations of quinpirole, and β-arrestin recruitment was measured. Data is represented as mean
and SEM of relative fold-change over basal levels of luminescence emission of each transfection
condition. Fold change was calculated for at least four independent experiments conducted in
duplicates.
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Table 3.2 EC50 and Emax values for β-arrestin recruitment to the D2R in the Path Hunter β-arrestin
CHO cells.
EC50 and Emax values were calculated from the curve fits of the quinpirole dose-response curves of
Fig. 3.7b. a Relative fold-change of β-arrestin recruitment over the basal condition. Values reported
in the table correspond to the average and SEM of the EC50 and Emax values calculated for at least
four independent experiments.
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A.

B.

Figure 3.8 CD8-C2-20 did not prevent Gβγ-mediated activation of ERK phosphorylation.
(A) Gβγ subunits can promote ERK phosphorylation (4) by activating upstream effectors of the
MAPK cascade such as platelet-derived growth factor receptor (PDGFR) (1) and phosphoinositide
3-kinase (PI3K) (2), or by interacting with scaffold proteins such as β-arrestins (3) that also
facilitate MAPK pathway activation. (B) CHOwt cells transiently expressed the dopamine D2
receptor in combination with Venus, CD8-βARKct, or CD8-C2-20. ERK phosphorylation was
measured after 10-minute incubation with 3 μM quinpirole or 1 μM PMA (control) as indicated.
Data represents the mean values and SEM of three independent experiments performed in
duplicates. Statistical significance was calculated using paired student's t-test. ns, not significant,
*P < 0.05, **P < 0.01, ***P < 0.001 compared to the pERK levels of the vehicle-treated cells.
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Expression of CD8-βARKct completely blocked ERK 1/2 phosphorylation mediated by the D2R,
but expression of CD8-C2-20 failed to halt the stimulatory effects mediated by Gβγ on
phosphorylated ERK (Fig. 3.8b). However, no changes in total ERK levels (data not shown) or
PKC-induced ERK phosphorylation levels were observed for the different transfection conditions.

3.4

Discussion

The Gβγ complex is a versatile modulator of adenylyl cyclase activity by having inhibitory or
stimulatory effects depending on the AC isoform (Dessauer et al., 2017). Characterization of the
specific binding interactions between Gβγ and AC isoforms suggest that multiple sites within the
C1 and C2 domains of the cyclase cooperate to mediate the effects of the Gβγ complex (Diel et
al., 2006). In the present work, an additional binding site for Gβγ on the C2 domain of AC2 was
identified. This new Gβγ binding site on AC2, C2-20, resides next to the plasma membrane at the
beginning of the C2a region. It displays high degree of homology between the related AC isoform
family members that are conditionally activated by Gβγ subunits. SPR was to determine that the
C2-20 domain binds to Gβγ with high affinity (KD~2 nM). Expression of a minigene encoding an
N-terminal CD8 domain to localize the C2-20 peptide to the membrane reduced the stimulatory
effects of Gβγ on PMA-stimulated AC2 activity. The effects of the minigene were specific to the
C2-20 sequence considering that a scrambled version of the peptide sequence failed to abolish the
Gβγ effects on AC2 activity. Alanine-scanning mutagenesis of the central portion of C2-20
diminished the inhibitory action of the CD8-C2-20 minigene on Gβγ-mediated AC2 potentiation.
However, none of the variations incorporated were sufficient to abolish completely the inhibitory
action on Gβγ stimulatory effects suggesting multiple contact points with Gβγ subunits. The effects
of the C2-20 sequence display bias to Gβγ-mediated AC2 potentiation given that expression of the
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CD8-C2-20 minigene only attenuated β-arrestin recruitment and had no effects on Gβγ-mediated
heterologous sensitization of AC2 and AC5 activity or phosphorylation of ERK1/2.
The existence of multiple binding domains for Gβγ subunits on AC2 is particularly
intriguing. Until now, five binding sites distributed across the C1 and C2 catalytic domains of AC2
have been reported. The C2-20 domain identified herein to interact with Gβγ is located upstream
of the QEHA and KF loop binding regions also positioned within the C2 domain. From our results
and the SPR analysis performed by Boran et al., it appears that the C2-20 peptide has one of the
highest binding affinities for the Gβγ complex compared to the peptides derived from the QEHA
domain and the other three binding sites within the C1 domain. Similarly, the degree of homology
of the C2-20 region (85%) among the Gβγ-stimulated ACs is very high, and it is of about the same
extent as the sequence homology reported for the rest of the binding sites—except for the 578–
602 region that is only shared between AC2 and AC4 (Boran et al., 2011).
Boran et al. also examined the ability of the Gβγ-binding peptides within the C1 domain
to inhibit the effects on AC2 activity in vitro. Peptides derived from the 339-360 and 568-602
regions displayed inhibitory effects on Gαs-mediated stimulation of AC2 activity (Boran et al.,
2011). Expression of the CD8-C2-20 minigene did not alter the responses of AC2 to PMA. The
C2-20 domain is distant from the Gαs-binding sites and the PKC phosphorylation sites on AC2
(Berlot and Bourne, 1992; Shen et al., 2012), so the absence of effects on the stimulatory response
to PKC activation implies that this region only interacts with the Gβγ complex. Considering that
Gβγ effects are conditional to AC activation, and Gαs activates all AC isoforms, we used PMA to
selectively activate AC2 activity in HEK293 cells. Previous studies examining the ability of the
binding domains to inhibit the effects of the Gβγ complex on AC activity were done in vitro with
Sf9 membranes, purified Gαs and Gβγ subunits. Hence, the degree of inhibition for the C2-20
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peptide and the Gβγ binding domains on AC2 examined by Boran et al. cannot be adequately
compared given that the stimulatory and assay conditions were significantly different.
Nonetheless, our studies revealed that a minigene strategy could be used as an alternative approach
to explore the activity of these inhibitory peptides on Gβγ in intact cells.
Gβγ subunits interact with a large set of proteins that are involved in diverse cellular
processes (Khan et al., 2013). Protein-protein interaction studies on Gβγ and its effectors have
revealed that various binding motifs on the effector proteins interact with a “hot spot” interface on
the top surface of the Gβ subunit. Evidence to support the existence of the “hot spot” comes from
the ability of synthetic peptides—either part of phage-display peptide library screens or derived
from Gβγ effectors—to bind at the same surface of Gβ which prevents the interaction and inhibits
the activity of more than one Gβγ-mediated pathway (Davis et al., 2005; Scott et al., 2001). For
instance, when the QEHA domain of AC2 was characterized, it abolished potentiation of AC2 by
Gβγ subunits, but it also inhibited other Gβγ-mediated effects on AC1, β-adrenergic receptor
kinase (βARK), PLCβ3 and muscarinic K+ channels (Chen et al., 1995). Consequently, a BLAST
sequence similarity search was performed to determine whether other proteins contained similar
regions to the C2-20 domain of AC2. As expected, the top three hits for the BLAST search were
AC2, AC4 and AC7 (85% sequence similarity). They were followed by AC isoforms 5, 6 and 8,
which was not totally surprising due to the high sequence homology of the AC cytosolic/catalytic
domains. The juxtamembrane C2a domains of AC5, AC6 and AC8 displayed 50% sequence
similarity with the C2-20 domain sequence of AC2 (Fig. S3a). However, a closer evaluation of
the sequence similarity revealed little conservation between AC5, AC6, and AC8 with the central
portion of the C2-20 domain that based on our mutagenesis studies appears to be important for the
inhibitory effects of the minigene on Gβγ. Thus, the absence of these residues may prevent or
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disfavor the interaction of the juxtamembrane domains of AC5, AC6 and AC8 with Gβγ. No other
known Gβγ effector was found among the hits of the BLAST sequence, but a domain near the
membrane on the C-terminus of the orphan receptor GPR155 did show sequence homology (50%
sequence similarity) with several amino acids of the C2-20 domain (Fig. S3b). Although no
interaction between Gβγ and GPR155 has been previously reported, it is curious that both
homologous regions are positioned at similar locations on their respective membrane-bound
proteins.
The location of the C2-20 domain is perhaps the most interesting feature of this new Gβγbinding site. Analogous to the 564-602 domain within the C1b region of AC2, the C2-20 domain
is adjacent to the membrane and precedes the C2 catalytic domain. The crystal structure of the
mammalian AC catalytic domains in complex with Gαs and forskolin did not include the
juxtamembrane cytosolic sections (Tesmer et al., 1997). However, a crystal structure recently
solved for the cytosolic domains of a homologous membrane-bound mycobacterial AC indicates
that the regions preceding the catalytic domains adopt a helical structure (Vercellino et al., 2017).
Increasing evidence has emerged suggesting that these helical domains play an important role
mediating the effects of AC regulators. For instance, polymorphisms identified in patients with
familial dyskinesia and facial myokymia that are located within the helical domains of AC5 cause
an enhancement of the catalytic activity in response to Gαs (Chen et al., 2012). Also, a recent study
identified a 19-residue domain part of the juxtamembrane helical structure of adenylyl and
guanylyl cyclases that appears to be important for the dimerization of the catalytic domains. This
helical domain also referred as cyclase transducer element (CTE), exhibits high level of diversity
and it can engage in protein-protein interactions with other AC/GC helical domains (Ziegler et al.,
2017). Because the C2-20 domain is located N-terminally to the C2 catalytic domain of AC2, it
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is possible that one of the mechanisms by which Gβγ mediates an enhancement of the catalytic
activity in response to Gαs or PKC activation is by directly interacting with a helical element of
AC2. Although intriguing, future structural studies of this domain in AC2 or other mammalian
ACs and the catalytic core are required to support this hypothesis.
Expression of the CD8-C2-20 minigene did not have major effects on other Gβγ-mediated
pathways downstream of Gαi/o-coupled receptor activation. No inhibitory effects on heterologous
sensitization of AC2 and AC5 or ERK activation suggested, that unlike CD8-βARKct, the CD8C2-20 minigene does not sequester the Gβγ complex and arbitrarily nullify all Gβγ-mediated
events. Although Gβγ is important to mediate the sensitization paradigm (Ejendal et al., 2012), the
enhancement of AC activity after chronic Gαi/o coupled receptor activation does not appear to
involve a direct AC-Gβγ interaction (Watts and Neve, 2005). Thus, the inability of the CD8-C220 minigene to modulate heterologous sensitization of AC2 activity was not surprising, despite the
inhibitory effects on Gβγ-mediated potentiation of AC2 after acute activation of the D2R.
Following GPCR activation, the Gβγ complex plays a critical role in receptor
desensitization and subsequent signal termination. Interaction of Gβγ subunits with G proteincoupled receptor kinases (GRK) promotes phosphorylation of the GPCR’s C-terminus which leads
to β-arrestin recruitment and internalization of the receptor (Benovic et al., 1986; DebBurman et
al., 1996). CD8-C2-20 partially attenuated the efficacy of quinpirole to recruit β-arrestin, however
our control CD8-βARKct showed only a minimal reduction in β-arrestin recruitment. The modest
effects of CD8-βARKct were unexpected and without a positive control, the results for the CD8C2-20 are difficult to reconcile. Alternatively, the β-arrestin recruitment observed in the
PathHunter β-arrestin CHO cells could have been induced by other mechanisms besides Gβγmediated binding and recruitment of GRK2/3. Gβγ-independent translocation of GRK2 to the
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receptor has also been reported via phosphoinositide 3-kinase (PI3K), and in those experiments
GR2K-ct (βARKct) also failed to prevent receptor desensitization (Naga Prasad et al., 2001;
Vasudevan et al., 2013). Thus, a more direct detection method is required to validate the negative
effects of the C2-20 domain on the Gβγ-GRK interaction and subsequent β2-arrestin translocation
to the plasma membrane.
In conclusion, we have identified a new Gβγ-binding site on the C2a domain of AC2 that
is highly conversed between Gβγ-stimulated ACs, exhibited a high affinity for the Gβγ complex,
and could be used to selectively modulate Gβγ signaling in intact cells. These studies highlight
further the complexities associated with AC signaling and the unique ways in which AC isoforms
are modulated by Gβγ subunits. Considering that the physiological relevance for Gβγ regulation
of AC2 activity is not understood yet, the CD8-C2-20 minigene could be used as a tool to
selectively characterize the stimulatory effects of Gβγ on AC2, AC4 and AC7 activity.
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CHAPTER 4.
STRUCTURE ACTIVITY RELATIONSHIP STUDIES
FOR INHIBITORS OF TYPE 1 AND TYPE 8 ADENYLYL CYCLASE
ISOFORMS

Ca2+/calmodulin-stimulated adenylyl cyclase isoforms AC1 and AC8 are potential targets for
treating chronic pain, opioid dependence, and anxiety. In an effort to develop selective and potent
AC1 inhibitors, the objective of this study was to carry out a series of structure activity relationship
(SAR) studies on existing and novel selective inhibitors of AC1 and/or AC8 activity. First, we
performed SAR studies using both commercially available and novel synthesized analogs of the
selective AC1 inhibitor, ST034307. The SAR for the ST034307 analogs revealed structural
features that were important for the compound’s inhibitory activity as well as for the selectivity at
AC1. Several ST034307 analogs had inhibitory activity on both AC1 and AC8, and one ST034307
analog surprisingly showed modest selectivity for AC8 over AC1. Complementary to the SAR
analysis for ST034307, a 10,000-compound screen was also completed searching for novel
scaffolds with inhibitory activity on AC1. Two promising scaffolds were identified that had robust
AC1 inhibitory activity with IC50 values in the low micromolar range (2-10 µM). These two novel
scaffolds displayed AC1 selective or dual AC1/AC8 inhibition. Further SAR analysis for the class
of compounds that had shown inhibitory activity at both AC1 and AC8, generated analogs with
improved potency and efficacy at both Ca2+/calmodulin-stimulated cyclases. However, no
apparent trend was distinguished that would justify the improvement in selectivity or/and potency
of the analogs. The inhibitory mode of action of these two scaffolds was also examined on different
AC1 and AC8 stimulatory mechanisms (forskolin) using membrane preparations. In conclusion,
we have identified potent inhibitors of AC1/AC8 activity, and the SAR results suggest that the
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selectivity at AC1 or AC8 has a structural relationship; this information can be then applied to the
design and synthesis of more potent and selective AC inhibitors with drug-like properties.

4.1

Introduction

Cyclic AMP and Ca2+ are major secondary messengers inside the cell that transmit signals
intracellularly to coordinate various vital cellular responses. The understanding of the regulatory
mechanisms of the cAMP and Ca2+ pathways have indicated that these two pathways are not
independent, and cross-talk between them creates a dynamic signaling network that adds another
level of complexity that the cells use to fine-tune a response (Bruce et al., 2003). Crosstalk between
cAMP and Ca2+ is bidirectional, and it involves multiple different elements within each signaling
pathway that directly or indirectly orchestrate a signaling event.
Adenylyl cyclases are the enzymes that synthesize cAMP and depending on the AC
isoform, their catalytic activity is stimulated or inhibited by Ca2+ (Tang and Hurley, 1998). The
major role of transmembrane ACs is to integrate GPCR signaling from receptors coupled to Gαs
and Gαi, but the differences in Ca2+ responsiveness among AC isoforms is also a major regulatory
property that underlies isoform-specific cAMP responses (Sunahara et al., 1996). The structure of
transmembrane ACs comprise a cytosolic N-terminus, two helical-spanning domains and the C1
and C2 catalytic domains. There are ten different mammalian AC isoforms, of which nine are
membrane-bound (AC1-AC9), and one is cytosolic (sAC). The general mechanism of AC
activation promotes the dimerization of the catalytic domains of the cyclase to create the active
site of the enzyme at the C1-C2 interface (Tang and Hurley, 1998). Adenylyl cyclase isoforms 1
and 8 (AC1 and AC8) are stimulated by Ca2+ via the calcium-binding protein, calmodulin, whereas
the soluble AC is directly activated by the divalent cation (Steegborn, 2014). On the contrary,
AC2, AC4, AC7 and AC9 are Ca2+-insensitive, and AC5 and AC6 are inhibited by micromolar

96
concentrations of Ca2+ (Dessauer et al., 2017). Thus, the direct and selective regulatory effects Ca2+
has on AC isoform activity is a major component that can modulate intracellular cAMP levels.
Ca2+ stimulation of AC1 and AC8 activity is mediated by the direct interaction of the
cytosolic domains of the cyclase with calmodulin (Halls and Cooper, 2011). For AC1, the CaM
binding site was found in the C1b domain, and for AC8, two binding sites were characterized: one
at the N-terminus and the other at the C2 domain (Gu and Cooper, 1999; Levin and Reed, 1995).
Although the precise mechanisms of AC1/AC8 activation by CaM have not been elucidated, it is
clear that differential regulatory mechanisms coordinate the stimulatory effects of
Ca2+/Calmodulin on these two AC isoforms (Masada et al., 2012). Besides the difference in CaMbinding domains, the sensitivity to Ca2+ and the kinetics of catalytic activity in response to
Ca2+/Calmodulin also diverge between them. AC1 appears to be more sensitive to Ca2+ than AC8,
but the amount of cAMP produced by AC8, as compared to AC1, is greater in response to
Ca2+/Calmodulin (Masada et al., 2009). Furthermore, the CaM domains that bind and regulate AC
activity are not the same for AC1 and AC8 (Gu and Cooper, 1999; Macdougall et al., 2009; Vorherr
et al., 1993). Consequently, Ca2+/Calmodulin regulation of AC1 and AC8 activity does not appear
to be functionally redundant.
The Ca2+/Calmodulin-stimulated cyclases, AC1 and AC8, are highly expressed in the
brain, so they represent a signal integration point of the cAMP and Ca2+ pathways in the central
nervous system (Cali et al., 1994; Conti et al., 2007; Fagan et al., 1996). Indeed, AC1 and AC8
activity has been associated with memory and long-term potentiation. AC1-/- and AC8-/- doubleknockout mice displayed memory deficits in passive avoidance and contextual learning assays, but
single-knockout mice of either AC1 or AC8 exhibited modest or no impairment when performing
the memory tasks (Ferguson and Storm, 2004; Wong et al., 1999). Studies with AC1 or AC8
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single-knockout mice have also revealed that these two ACs also have isoform-specific functions.
Studies with transgenic AC1-deficient mice suggested that AC1 plays a role in chronic pain,
neurotoxicity, fragile-X syndrome and opioid dependence, whereas AC8-deficient mice showed
that AC8 mediates anxiety-like behaviors (Bernabucci and Zhuo, 2016; Sethna et al., 2017;
Vadakkan et al., 2006; Wei et al., 2002; Zachariou et al., 2008). Therefore, AC1 and AC8 have
emerged as interesting targets for the treatment of various CNS disorders due to their isoformspecific physiological roles.
Particularly, the opioid crisis has driven the surge for novel druggable targets to treat
chronic pain, whereby AC1 inhibitors represent a non-opioid based alternative option that bypasses
Gαi inhibition through the opioid receptor to decrease cAMP levels. It was with the discovery of
the first inhibitor of AC1 activity, NB001, that the active role of AC1 in pain mechanisms and the
therapeutic potential of AC1 inhibitors was demonstrated (Zhuo, 2012). NB001, in accordance
with the AC1 knockout studies, has elicited analgesic effects in various pain models and has
reduced opioid dependence (Corder et al., 2013; Wang et al., 2011a). However, major limitations
exist with this inhibitor since it lacks isoform-selectivity for AC1 over AC8, and its inhibitory
effects appeared to be indirect given that in membrane preparations the inhibitor failed to reduce
AC1 activity (Brand et al., 2013). Most recently, a selective AC1 inhibitor was identified that also
exhibited antiallodynic effects in a mouse model of inflammatory pain (Brust et al., 2017). The
ST034307 compound inhibited Ca2+-mediated AC1 activity with a similar IC50 value as NB001 in
the micromolar range, but it displayed much improved selectivity for AC1 over the rest of the
membrane-bound AC isoforms. In addition, ST034307 appeared to engage the target since it
displayed inhibitory effects on Gαs and calmodulin-mediated stimulation of AC1 activity in
isolated membranes.
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Hence, the objective of this research was to further optimize the pharmacological profile of
the existing AC1 inhibitors by two approaches. In the first approach, a structure-activity
relationship (SAR) analysis with commercially available and newly synthesized analogs of
ST034307 was performed to determine whether the potency and overall selectivity of the AC1
inhibitor could be optimized. In the second approach toward identifying AC1 inhibitors, a highthroughput screen of a 10,000-compound library against AC1 was completed, and two promising
scaffolds were identified that displayed robust AC1 inhibitory activity with IC50 values in the low
micromolar range (0.5-10 µM). These novel and diverse scaffolds revealed both AC1-selective
and dual AC1/AC8 inhibition. The AC1 and AC8 SAR analyses for ST034307 and the new
scaffolds indicate that AC1 and AC8 selective inhibition has a structural relationship; this
information can then be applied to the design and synthesis of more potent and selective AC
inhibitors to create more drug-like compounds

4.2

Methods

4.2.1 Compounds
Commercially available analogs of the ST034307 compound were purchased as dry powders
from Vitas-M laboratory (Champaign, IL), Enamine (Kiev, Ukraine), and TimTec (Newark, DE).
The newly synthesized ST034307 analogs were designed and synthesized in the laboratory of Dr.
Mingji Dai at the Department of Chemistry, Purdue University (West Lafayette, IN). Dry powders
were resuspended in cell culture grade DMSO from Sigma-Aldrich (St. Louis, MO) to make 10
mM compound stocks. The compounds for the hit validation of the Life Chemical scaffolds and
the counter-screen of the oxadiazole and pyrimidinone class of compounds were repurchased from
Life Chemicals. Depending on the solubility of the compounds, dry powders were resuspended in
DMSO to make a 10 mM or 50 mM stock solution. For the SAR analysis of the oxadiazole class
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of compounds, analogs of the five lead compounds were designed and synthesized in the laboratory
of Dr. Daniel Flaherty at the Department of Medicinal Chemistry and Molecular pharmacology,
Purdue University (West Lafayette, IN). All the synthesized oxadiazole analogs were resuspended
in DMSO to make 50mM stocks. The DMSO stock solutions were then aliquoted in
microcentrifuge tubes that were stored in a -20°C freezer.
4.2.2 Compound screening
The compound screen was completed at the Biomolecular Screening and Drug Discovery Core
Facility (BSDD), Purdue University (West Lafayette, IN) by Dr. Karin “Kaisa” Ejendal and Dr.
Larisa Avramova. In a brief summary, cryopreserved HEK293 cells stably expressing AC1 (HEKAC1) were counted and plated into a white opaque 384-well plate from Perkin Elmer (Waltham,
MA). Cells were incubated for 1-hour in a 37°C incubator supplemented with 5% CO2 to let the
cells adhere to the plate prior incubation with the compounds. Subsequently, the positive control
compound, ST034307, and the test compounds were added at a final concentration of 10 μM.
Following a 30-minute incubation at room temperature with the compounds, the Ca2+ ionophore
A23187 was added to the plates in the presence of the phosphodiesterase inhibitor, 3-isobutyl-1methylxanthine (IBMX). After 1-hour incubation with A23187 at room temperature, cAMP
accumulation was measured using the HTRF cAMP kit from Cisbio (Bedford, MA). The screen
was carried out on three separate days and a total of 10,240 test compounds were screened. The
percentage inhibition (%) was calculated by normalizing the cAMP levels of each of the compound
wells to the mean cAMP levels of the positive control, ST034307 (100% inhibition) and vehicle
(0% inhibition).
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4.2.3 Cyclic AMP accumulation assays
Cryopreserved HEK cells overexpressing human AC1, AC2, AC5 or AC8 were transferred to
a 15-mL Falcon tube and gently resuspended in prewarmed OptiMEM. The cells were centrifuged
for 5 minutes at 150x g, then the supernatant was discarded, and the cell pellet was resuspended in
10 mL for a second centrifugation step. Then, the cells were counted, plated in a Perkin Elmer
tissue culture–treated 384-well plate and incubated for 1-hour in a 37°C incubator supplemented
with 5% CO2. The test compound working solutions were prepared in prewarmed OptiMEM and
the serial dilutions for the dose response curves were prepared using a Precision 2000 automated
pipetting system. A 7-point dose response curve was generated for each test compound using a
three-fold serial dilution starting at 30 μM concentration. After the 1-hour incubation at 37°C, the
compounds were added and incubated for 30 minutes at room temperature. Next, in the presence
of IBMX, AC1 and AC8 activity was stimulated with 3 μM A23187, AC2 activity was induced
with 100nM PMA or AC5 activity was triggered with 1 μM forskolin. The Cisbio HTRF cAMP
reagents, d2-labeled cAMP and the cryptate-labeled antibody, were added in equal parts to all the
wells after 1-hour incubation with the stimulant at room temperature. Following 1-hour incubation
with the cAMP detection reagents, fluorescence at 620nm and 665nm wavelengths were measured
using a Synergy 4 or Cytation3 plate reader. Cyclic AMP accumulation per well was calculated by
extrapolating the fluorescence 620/665 ratio from a cAMP standard curve.
4.2.4 Cell Toxicity assay
The cell toxicity assays were done in parallel with the cAMP accumulation assays on the HEKAC1 cells at a single concentration of 30 μM compound, so the same protocol as the one described
above was followed to plate and treat the cells. After 1-hour incubation with 3 μM A23187, cell
viability was determined using the Cell-Titer GLO kit from Promega (Madison, WI) according to
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the manufacturer’s protocol. Following the addition of the Cell-Titer GLO reagent, the 384-well
plate was protected from light and placed on an orbital shaker at a low shaking speed for 20
minutes. Luminescent signal was measured with a Synergy 4. Percentage viability was calculated
by normalizing the luminescence counts of each of the compounds to the luminescence counts of
the vehicle (100% viability) and the Triton X-100 (0% viability) treated wells.
4.2.5 Cyclic AMP Membrane assays
Membranes from the stable pool HEK-ACΔ3/6 cell lines overexpressing AC1 or AC8 were
isolated as previously described (Brust et al., 2015b). The day of the assay, the cell membranes
were thawed on ice and resuspended in washing buffer containing 2 mM Tris, 1mM EGTA and
1mg/mL of BSA. The membrane pellets were spun down at 10,000 x g for 10 minutes at 4°C,
supernatant was discarded, and the centrifugation step was repeated two additional times.
Following the final wash, the membrane pellet was resuspended in membrane buffer containing
33mM HEPES, 0.1% Tween 20, and 1mM EGTA. The Pierce BCA Protein assay kit was used to
measure the protein concentration of the membrane suspension that was subsequently adjusted to
250 μg/mL for the AC1 membranes and 25μg/mL for the AC8 membranes. Membrane suspensions
were plated in a white opaque 384-well plate at 10 μL/well, followed by the addition of 5 μL of
compound at 120 μM (4x) concentration prepared in membrane buffer with no EGTA. Membrane
suspensions were incubated for 20 minutes with the respective compound or vehicle prior the
addition of 5 μL of increasing concentrations of forskolin prepared in stimulation buffer containing
(4x): 33mM HEPES, 0.1% Tween 20, 10 mM MgCl2, 1 mM ATP and 2mM IBMX at pH 7.4.
Cellular membranes were incubated with the stimulants for 45 minutes at room temperature and
cAMP accumulation was measured using the Cisbio HTRF cAMP detection kit as described
above.
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4.3

Results

4.3.1 Structure-Activity Relationship of ST034307 Analogs
ST034307 was discovered from the NDL-3000 natural derivatives library from TimTec as
a selective inhibitor of the Ca2+/calmodulin-stimulated cyclase AC1. ST034307 had no inhibitory
activity on the other closely related and Ca2+/calmodulin-stimulated cyclase AC8, but potentiated
the cAMP responses of the Ca2+-insensitive cyclase, AC2. To determine the functional groups
important for the inhibitory activity and selectivity of ST034307, a structure–activity relationship
(SAR) analysis for commercially available analogs of ST034307 was performed. HEK293 cells
stably expressing human AC1 (HEK-AC1) or AC8 (HEK-AC8) were pretreated with increasing
concentrations of the analogs prior to stimulation of AC1 and AC8 activity with the Ca2+ ionophore
A23187. The IC50 and % inhibition values of each analog on AC1 and AC8-expressing cells is
summarized in Table 4.1. All the ST034307 analogs that had a chromone scaffold but did not have
trichloromethane at the 2-position of the ring, were inactive on AC1 and AC8. Also, the chloro
substituent at position 6 of the chromone ring appeared to be irrelevant for the biological activity
of the inhibitor since compound 307-1 had the same potency and efficacy as ST034307. Instead,
analogs 307-2, 307-3 and 307-4 with substituents at position 6 and/or 7 of the ring displayed the
same potency as ST034307, but partial inhibition of AC1 activity. Several compounds that had a
flavone scaffold instead of the chromone showed inhibitory activity on both AC1 and AC8.
Analogs 307-5, 307-6 and 307-7 with a flavone scaffold and a hydroxy substitution at the 3position were less potent and efficacious on AC1 than ST034307, but inhibited AC8 activity by
50% at 30 μM concentration. Interestingly, analog 307-10 with two chloro substituents at the 6and 8-position, inhibited by 50% both AC1 and AC8 activity at 30 μM, but showed modest
selectivity for AC8 over AC1.
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Table 4.1 IC50 values and % inhibition of the commercially available ST034307 analogs.
The IC50 values were calculated from the dose response curves generated for each corresponding
compound in the HEK-AC1 and HEK-AC8 cells stimulated with the Ca2+ ionophore, A23187.
The % inhibition values correspond to the normalized cAMP responses at 30 μM concentration of
compound. Data represent the average of the calculated values of at least three independent
experiments, each conducted in duplicate. NIO (no inhibition observed).
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Further SAR studies were performed with ST034307 analogs that were designed based on the
knowledge provided by the preliminary data with the commercially available compounds. The
new ST034307 analogs primarily had substitutions at the 2-position of the chromone or had no
hydroxy group at the 3-position of the flavone scaffold. Table 4.2 summarizes the calculated IC50
and % inhibition values on AC1 and AC8 activity for the newly synthesized analogs. All the
analogs were inactive or exhibited lower than 50% inhibitory activity at AC1 and AC8. The cell
toxicity at 30 μM concentration was evaluated side-by-side with the cAMP assays for all the
ST034307 analogs tested, and those that exhibited more than 30% cell toxicity were not included
in the SAR comparisons/tables. Thus, the SAR studies revealed that the biological activity of
ST034307 is strongly dependent on a trichloromethyl group at the 2-position of the chromone, and
that ST034307 analogs also display a range of pharmacological profiles from partial inhibition of
AC1 activity to AC8 selective inhibition (Fig. 4.1).
4.3.2 High-throughput screening for new AC1 inhibitors
The SAR analysis of the ST034307 analogs did not provide sufficient information to generate
a strategy for lead optimization. Hence, a high-throughput screen of 10,000 compounds from the
Life Chemicals library was completed to identify new AC1 inhibitor scaffolds. Fig. 4.2 illustrates
the flow from the high-throughput screen to the hit compound selection and validation. The Life
Chemicals compounds were assayed at 10 μM concentration, and the ability of each to decrease
A23187-mediated cAMP responses was assayed in the HEK-AC1 cells. The Z’ value for the assay
was 0.6. The cAMP levels detected for the negative control, DMSO, and the positive control,
ST034307, were used as parameters to calculate the % inhibition of each compound. The %
inhibition cut-off to defined hits was 90%, so 480 compounds met the criteria, representing
approximately 5% of the whole library.
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Table 4.2 IC50 values and % inhibition of the newly synthesized ST034307 analogs.
The IC50 values were calculated from the dose response curves generated for each corresponding
compound in the HEK-AC1 and HEK-AC8 cells. The % inhibition values correspond to the
normalized cAMP responses at 30 μM concentration of each compound. Data represent the
average of the calculated values of at least three independent experiments, each conducted in
duplicate. *Same IC50 value and % inhibition reported for ST034307 in Table 4.1. NIO (no
inhibition observed).
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Figure 4.1 ST034307 analogs displayed a range of pharmacological profiles from partial
inhibition of AC1 activity to AC8 selective inhibition.
IC50 values and percent (%) inhibition at 30µM concentration of a series of representative
ST034307 analogs with different inhibitory activities on AC1 and/or AC8. The table values
correspond to the mean of the calculated values already reported in Table 4.1. NIO (no inhibition
observed).
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Figure 4.2 Overview of the steps involved in the drug discovery process of the two novel AC1
inhibitor scaffolds.
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Additional parameters were considered to select the hit compounds taken forward due to the
high hit rate. First, the list of 480 hit compounds was filtered for pan-assay interference
compounds, or PAINS, and more than 200 apparent hits containing PAINS-like structures were
excluded from further analysis (Baell and Walters, 2014; Baell and Nissink, 2018). Second, to
prioritize and decrease the number of compounds for follow-up, hits that shared a similar scaffold
were clustered and a total of nine groups were selected for further hit validation, each having at
least 8 hit compounds (Table 4.3).
4.3.3 Hit Validation of AC1 Inhibitor Scaffolds
Dose response curves were generated in the HEK-AC1 cells for two “representative”
compounds of each of the nine scaffolds. Cell toxicity of the compounds was also examined in
parallel with the cAMP assays at a single concentration of 30 μM. IC50 and % inhibition values
are reported in Table 4.3 for those compounds that were not toxic to the cells. Out of the nine
groups, five scaffolds were quickly discarded because they were either toxic to the cells (LC1,
LC6, LC7 and LC8), or they interfered with the fluorescence of the cAMP detection technology
(LC5). The compounds from the other 4 scaffolds, LC2, LC3, LC4 and LC7, showed IC50 values
in the micromolar range and had no major effects on cell viability—except for one of the
compounds of the LC4 group (F4385). Notably, the compounds from the LC2 and LC3 scaffolds
had IC50 values in the single-digit micromolar range, displayed no toxic effects after 2-hour
incubation period, and showed close to 100% inhibition of A23187-induced AC1 activity at 30
μM concentration. Hence, the LC2 and LC3 scaffolds also referred to as the oxadiazole and
pyrimidinone series, respectively, were selected as the hit compound scaffolds for further
validation and counter-screen.
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Table 4.3 IC50 values, % inhibition, and % viability of the two representative hit compounds from
the nine clustered scaffolds.
The IC50 values were calculated from the dose response curves generated for each corresponding
compound in the HEK-AC1 cells. The % inhibition and % viability values correspond to the
normalized cAMP responses (activity) or luminescence counts (viability) respectively at 30 μM
concentration of compound. Data represent the average and ±SEM of the calculated values of at
least three independent experiments, each conducted in duplicate. NIO (no inhibition observed).
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4.3.4 Counter screen against AC isoforms
Having determined that the oxadiazole and pyrimidinone scaffolds inhibited Ca2+/Calmodulinstimulated AC1 activity in a dose-dependent manner, an additional set of 10 hit compounds per
scaffold were repurchased as dry powders and included in the counter screen against the closely
related AC8 isoform and other representative ACs (i.e. AC2 and AC5). Dose-response curves were
generated for all hit compounds on AC1 and AC8-expressing cells to determine the selectivity of
the inhibitory effects on the Ca2+/Calmodulin-stimulated cyclases. The selectivity for other AC
isoforms was examined at single concentrations of 10 μM and 30 μM of compound for the Ca 2+insensitive and the Ca2+-inhibited cyclase, AC2 and AC5 respectively. The results/effects on AC1,
AC2, AC5 or AC8 activity of the oxadiazole and pyrimidinone class of compounds were
summarized in Table 4.4 and Table 4.5, respectively. The dose response curves on HEK-AC1 and
HEK-AC8 cells indicated the oxadiazole compounds have dual AC1 and AC8 inhibitory activity
on Ca2+-mediated stimulation. The IC50 values of these set of compounds range on AC1 from 2
μM to 11 μM, and on AC8 from 5 μM to 60 μM. At the highest concentration tested (30 μM), the
oxadiazole series inhibited AC1 activity close to 100% and AC8 activity by 70-80%. Compounds
F9097, F3324, F4465, F8509, F9110 and F9189 were equipotent on AC1 and AC8, whereas the
rest of the compounds showed modest selectivity for AC1 over AC8. The effect on AC5 of these
compounds was comparatively much less on forskolin-stimulated AC5 activity, and only
compound F8538 enhanced the AC5 response at 10 μM concentration. The structures of the 12
compounds of the oxadiazole series were significantly diverse, so no major conclusions could be
drawn that would explain the differences in potency or selectivity. According to the dose response
curves of the pyrimidinone series of compounds on AC1 and AC8, this scaffold appears to be
selective for AC1.

Table 4.4 IC50 values, % inhibition, and % viability of the oxadiazole hit compounds
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Table 4.5 IC50 values, % inhibition, and % viability of the pyrimidinone hit compounds.
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Tables 4.4. and 4.5 continued
Tables 4.4. and 4.5 IC50 values, % inhibition, and % viability of the oxadiazole and pyrimidinone
hit compounds.
The IC50 values were calculated from the dose response curves generated for each corresponding
compound in the HEK-AC1 and HEK-AC8 cells stimulated with A23187. The % inhibition and
% viability values correspond to the normalized cAMP responses (activity) or luminescence signal
(viability) respectively. Negative % inhibition values indicate an enhancement of AC activity over
the stimulant-induced cAMP responses. Data represent the average and ±SEM of the calculated
values of at least three independent experiments, each performed in duplicate. NIO (no inhibition
observed).
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The IC50 values on AC1 activity range between 0.5 μM and 10 μM, and the maximum
efficacy was 100% inhibition for all the pyrimidinone compounds at 30 μM concentration. The
pyrimidinone scaffold showed less than 50% inhibition on AC8 activity at 30 μM concentration,
and only for compounds F1003 and F5087 an IC50 value was calculated for AC8 inhibition.
Compound F5213 is the most potent AC1 inhibitor of the two scaffolds with an IC 50 value of 0.5
μM and at least 60-fold selectivity for AC1 over AC8. Similar to the oxadiazole series of
compounds, the pyrimidinone scaffold exhibited mixed effects on AC2 and AC5, potentiating the
activity of AC2 by 1 to 3-fold, but not having a significant effect on AC5 activity. Interestingly,
compound F1003 seems to inhibit AC2 and AC5 activity, but with much lesser potency than AC1.
The hit validation and counter screen with the oxadiazole and pyrimidinone class of compounds
has confirmed the inhibitory activity of these two scaffolds on AC1 activity. Both scaffolds exhibit
promising pharmacological profiles for AC1 or dual AC1/ AC8 inhibition. In addition, no other
targets were found in the SciFinder Scholar and PubChem databases for the pyrimidinone scaffold,
and only one study reported biological activity for the oxadiazole class of compounds as potential
anti-prostate cancer agents (Mochona et al., 2016). Hence, the two scaffolds are suitable candidates
for further hit expansion and lead optimization.
4.3.5 SAR analysis of the oxadiazole class of compounds
To understand the structural relationship of the dual AC1 and AC8 inhibition of the oxadiazole
class of compounds, a SAR analysis was carried out with newly synthesized analogs. Five hit
compounds, F8011, F8538, F9097, 9107 and F4036, were selected as the lead compounds to
generate the SAR. The derivatives that were designed for each lead compound had modifications
on the benzene substituent of the scaffold, whereas the direct substituents on the oxadiazole ring
were kept consistent. The IC50 and % inhibition values for the analogs and lead compounds were
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calculated from dose response curves generated on the HEK-AC1 and HEK-AC8 cells. In addition,
the effects on AC2 activity and cytotoxicity of the compounds were also assessed at one or two
high concentrations. Supplementary Tables S2-6 report the biological activity of the oxadiazole
derivatives and parent compounds at AC1, AC2, and AC8.
In general, the SAR studies with the derivatives of the lead compounds indicated that
compounds with a naphthalene tetra hydro substituent at the 5-position of the oxadiazole ring, such
as the parent compound F8538, tend to be more potent inhibiting AC1 activity than the other lead
compounds that had a different functional group at the same position. Furthermore, substituents
on the 3-, 4-, or 5-position of the benzene substituent increased the inhibitory activity of all the
oxadiazole class of compounds at both AC1 and AC8. In particular, analogs that had a benzene
ring or a trifluoromethyl group at the 2-position of the benzene substituent were more likely to be
active at both AC1 and AC8.
For the set of analogs of the F9097 lead compound, IC50 values range from 1.4 μM to 29 μM
for AC1, and 4 to 100 μM for AC8 (Table S2). No trend was observed for a position on the benzene
ring substituent that would improve the potency or selectivity of the parent compound, however a
substituent on the 2-position of the benzene ring (JK-246) was detrimental for the inhibitory
activity on both AC1 and AC8. Various analogs showed improved potency against AC1 and a
modest selectivity for AC1 over AC8 (7-fold), even though the parent compound appeared to be
equipotent. An interesting feature of the F9097 hit compound was its reduced stimulatory activity
on AC2; however, all analogs potentiated the activity of AC2 to the same extent that it was
observed for the other hit compounds.
Adding substituents to the benzene ring considerably improved the inhibitory activity of the
F8538 parent compound on AC8 (Table S3). For instance, compound JK-251 was equipotent for
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both Ca2+/calmodulin-stimulated cyclases with IC50 values of 1.2 μM (AC1) and 2 μM (AC8), and
it displayed almost complete inhibition of the AC activity at 30 μM concentration. The analogs of
the F8538 lead compound had IC50 values for AC1 between 1 μM to 26 μM, and for AC8 between
2 μM to 46 μM. Also, the resynthesized F8538 compound (DF-180) recapitulated the inhibitory
activity of F8538, showing only a 2-fold difference in the IC50 values. Almost all the analogs of
the F8538 series showed selectivity for AC1 over AC8, except for compound JK-265 that exhibited
a 5-fold selectivity for AC8 over AC1. Unfortunately, all the analogs potentiated AC2 activity,
and those that were the most potent at AC1 also strongly potentiated PMA-stimulated AC2
activity.
The resynthesized F9107 compound (DF-188) displayed the same IC50 value for AC1 but the
IC50 value for AC8 was 3-fold less potent. The inhibitory activity of the F9107 derivatives was
improved at both AC1 and AC8 compared to the parent compound (Table S4). Compound JK252 exhibited equipotent activity on both Ca2+/calmodulin-stimulated cyclases with an IC50 value
of 1.4 μM, and together with the JK-251 analog are the most potent AC1 and AC8 inhibitors of
the oxadiazole class of compounds. Compared to the other lead compounds and their
corresponding analogs, the F9107 set of derivatives displayed consistently the highest selectivity
for AC1 over AC8. Again, no major changes or trends were observed on the stimulatory effects of
the analogs on AC2 activity compared to the F9107 parental compound.
The analogs for F8011 and F4036 did not exhibit significant differences in activity with the
parental compounds, and resynthesized F8011(AK303) and F4036 (LH2-01) were slightly less
potent than the hit compounds repurchased from Life Chemicals (Table S5 and S6). Thus, the
efforts of the medicinal chemists were focused on the previously described lead compounds due
to the little information drawn from the preliminary set of F8011 and F4036 analogs.
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A total of 70 newly synthesized oxadiazole compounds were included in the SAR studies. Fig.
4.3 exemplifies the most potent derivatives on AC1 from the five lead compounds evaluated. The
SAR analysis established that the oxadiazole scaffold has dual inhibitory activity on AC1 and
AC8, and depending on the substituents on the benzene ring, various ranges of IC50 values for AC1
and AC8 were observed. Furthermore, the SAR analysis indicated that the selectivity of the
scaffold was predominantly for AC1 over AC8, but few analogs were equipotent or showed a
modest selectivity for AC8.
4.3.6 Inhibitory activity of the new AC1 scaffolds is selective to Ca2+/calmodulinstimulated AC activity
To further characterize the inhibitory properties of the oxadiazole and pyrimidinone scaffolds,
the ability to inhibit forskolin-mediated stimulation of AC1 and AC8 was examined in membrane
preparations. Given that forskolin stimulates AC activity of all membrane-bound isoforms except
for AC9, we used isolated membranes from a stable pool HEK-ACΔ3/6 cell line overexpressing
AC1 or AC8 to ensure that the changes in cAMP levels were only from the overexpressed cyclase.
Membranes were treated with increasing concentrations of forskolin in the presence or absence of
the inhibitors (Fig. 4.4). The selective AC1 inhibitor ST034307 reduced the efficacy of forskolinmediated activity in AC1 membranes but had no effect on the forskolin-induced cAMP responses
of the AC8 membranes. Instead, the oxadiazole compound JK-211 and the pyrimidinone
compound F5213 failed to inhibit forskolin-mediated responses in the AC1 and AC8 membranes,
suggesting that the inhibitory action of both scaffolds in cells is selective on Ca2+/calmodulinstimulated AC activity.
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Figure 4.3 Summary of the SAR analysis for the oxadiazole lead compounds
On the oxadiazole scaffold structure, an R indicates the sites that were modified on the benzene
ring substituent and/or the oxadiazole ring. The blue color structures designate the substituent on
the 5-position of the oxadiazole ring that was unmodified on the parent compound and its
respective analogs. The structure shown for each lead compound, corresponds to the most potent
analog at AC1, and the % values correspond to the inhibitory activity on AC1 or AC8 at 30 μM
concentration.
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AC1

AC8

Figure 4.4 Effects of AC1 inhibitors on forskolin-stimulated AC1 and AC8 activity in membrane
preparations.
Membranes isolated from HEK-ACΔ3/6 cells stably expressing AC1(A) or AC8 (B) were
incubated with vehicle (black) or 30 μM inhibitor (blue) for 20 minutes prior the stimulation with
increasing concentrations of forskolin in the presence of IBMX. After 1-hour incubation with the
stimulant, cAMP accumulation was measured. Data represents the mean and SEM of at least two
independent experiments conducted in duplicate.
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4.4

Discussion

The specific physiological roles of Ca2+/calmodulin-stimulated ACs, AC1 and AC8, have
motivated the development of selective AC1 inhibitors for the treatment of chronic pain and opioid
dependence. The discovery of AC1 inhibitors such as NB001 and ST034307 has demonstrated that
AC1 is a druggable target with high potential to be an alternative method other than opioids for
the effective treatment of chronic pain.
To further improve the potency and selectivity of ST034307, the starting point of the SAR
analysis was by obtaining commercially available ST034307 analogs. The broad spectrum of
inhibitory activities at both AC1 and/or AC8 of the analogs tested were the first indication that the
selectivity of ST034307 for AC1 over AC8 had a structural-basis. Notably, these limited set of
analogs revealed the crucial role of the trichloromethane group at the 2-position of the chromone
ring for the biological activity and selectivity of ST034307 at AC1. Further expansion of the SAR
with newly synthesized analogs also provided compelling data supporting the critical role of the
trichloromethane substituent. In addition, the SAR analysis suggested that substitutions at
positions 6 and 7 of the chromone ring affected the efficacy of the ST034307 analogs to inhibit
AC1 activity. Interestingly, the ST034307 analogs with a benzene ring substituent at the 2-position
of the chromone ring and a hydroxy group at position 3 displayed dual AC1 and AC8 inhibitory
activity. In particular, the hydroxy substituent appeared to improve the biological activity of these
chromone derivatives—also referred as flavones—at both AC1 and AC8. It is also worth noting
that compound 307-10 stood out from the rest of the ST034307 analogs because it displayed
modest selectivity for AC8 over AC1. The lack of activity at both AC1 and AC8 of the 307-11
compound with only a chloro substitution at position 6, suggests that the additional chloro
modification at position 8 may be responsible for the selectivity of compound 307-10 at AC8.
Hence, the preliminary SAR studies for the ST034307 analogs indicated that the inhibitory activity
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of the chromone scaffold on Ca2+/calmodulin-stimulated ACs has a structural relationship that can
be modified for tuning selectivity between AC1 and AC8. Nonetheless, further characterization of
the binding site for the ST034307 compound and its active analogs is also required to provide more
compelling data that confirms the structure-selectivity relationship.
The strong dependence of the inhibitory activity on the trichloromethane moiety of the
ST034307 compound and the limited evidence provided by the SAR to improve the potency and
selectivity of the chromone scaffold, motivated the search for new scaffolds with improved AC1
inhibitory activity. Two promising scaffold clusters, oxadiazole and pyrimidinone class of
compounds, were identified from the Life Chemicals library of 10,000 compounds that showed
either selective inhibitory activity at AC1 or displayed dual inhibitory activity at AC1 and AC8.
Despite the high hit rate (~5%) for the screen, reevaluation of the hit list by filtering to exclude
compounds with PAINS-like structures, considerably reduced the number of initial hits. Likewise,
clustering hit compounds with similar scaffolds enabled a fast validation of the promising scaffolds
and provided certain confidence on the scaffold’s activity. All the compounds part of the screening
library that had an oxadiazole or pyrimidinone scaffold showed up as hits, and these two scaffold
clusters contained the largest number of hit compounds among the nine scaffolds examined. Even
though the 12 compounds tested per scaffold in the counter screen displayed a wide range of
activities against AC1, AC2, AC5 and AC8, no SAR could be derived from the hit compounds due
to their structural diversity. The different pharmacological profiles of the oxadiazole class of
compounds suggest also a structural relationship between AC1 and AC8 selectivity—similar to
the one observed for the chromone scaffold. Additionally, structural features were identified
among the hit compounds that diminished the off-target effects on AC2 activity (i.e. F9097, F9110,
F9189, and F9346). Furthermore, F5213—a pyrimidinone derivative—with sub micromolar
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potency against AC1 coupled with its 60-fold selectivity for AC1 over AC8, makes it the most
potent inhibitor to date of Ca2+/calmodulin-stimulated AC1 activity.
The SAR campaign for the five lead compounds of the oxadiazole scaffold successfully led
to the identification of several analogs with improved potency and inhibitory efficacy than the
parent compound. The oxadiazole analogs, in general, were more potent on AC1 than AC8,
however no trend was observed for a functional group or a given position on the benzene ring that
would determine the potency and selectivity for either AC1 or AC8. Indeed, the effects a respective
substituent on the benzene ring had on the inhibitory activity of the analog, differed depending on
the functional group of the lead compound on the 5-position of the oxadiazole ring. For instance,
the ethyl substitution on the 4-position of the benzene ring had opposite effects on the F8538 and
F9097 lead compounds. For the F8538 analog, JK-251, the ethyl group improved the potency at
AC8, but for the F9097 analog, JK-235, the same substituent reduced the potency against AC8 by
5-fold. Several analogs derived from the lead compounds are worth noting. For example, the JK252 compound was equipotent against AC1 and AC8 with an IC50 value of 1.4 μM, whereas its
parent compound, F9107, was 5x more potent at AC1 than AC8 with IC50 values of 6 μM and
27μM respectively. Conversely, the F9097 parent compound was equipotent at Ca2+/calmodulinstimulated ACs, but several of its analogs displayed selectivity for AC1 over AC8. Additionally,
the reduced activity on AC2 of F9097 was not recapitulated by its analogs, suggesting that the
sulfamoyl moiety at position 4 of the benzene ring is potentially responsible for the diminished
activity on AC2 of hit compounds F9097, F9110, F9189 and F9346. Considering that the
oxadiazole compounds were consistently more selective for AC1 over AC8, the F8538 analog, JK265, is also particularly interesting because it appeared to be more selective for AC8 than AC1 (5fold). Overall, the oxadiazole class of compounds displayed dual activity at AC1 and AC8, and

123
the modifications evaluated in the SAR analysis indicated that substitutions at the 3-, 4- and 5positions of the benzene ring could modulate the activity/selectivity at AC1 or AC8.
Examining the inhibitory activity of the scaffolds on forskolin-mediated activity in HEKACΔ3/6-AC1 and HEK-ACΔ3/6-AC8 membrane preparations provided insightful information
about the mechanisms of action of the scaffolds. In a general overview, compounds inhibiting
cAMP production by competing with ATP for the active site should inhibit catalytic activity
regardless of the stimulatory mechanism, or those compounds that bind to the transition state such
as P-site inhibitors, their efficacy improves as the activity of the cyclase increments (Seifert et al.,
2012). Thus, the inability of the oxadiazole and pyrimidinone scaffolds to inhibit forskolintriggered cAMP responses in the isolated membranes indicate that the scaffolds are not P-site
inhibitors, do not bind to the active site of the cyclase or compete for the forskolin-binding site.
The lack of inhibitory activity on forskolin-mediated activation at first would imply that
the mechanism of inhibitory action of the two scaffolds is selective on Ca2+/calmodulin-mediated
stimulation of AC1 and/or AC8 activity. However, it also suggests that the inhibitory effects on
AC1 and AC8 activity are indirect, and the target of the scaffolds is calmodulin and not the cyclase.
A recent screen for inhibitors that would disrupt the protein-protein interaction between AC8 and
calmodulin, identified a set of FDA-approved small molecules that inhibited AC1 and AC8
activity, but were ultimately calmodulin-binders (Hayes et al., 2017). Considering the potential
indirect effects on calmodulin, a set of preliminary studies with the oxadiazole and pyrimidinone
scaffolds were recently completed to determine whether the compounds were binding CaM.
Comparison of the NMR spectra of
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N-labeled calmodulin in the presence and absence of the

scaffolds revealed that surprisingly both compounds directly bind calmodulin. The chemical shift
perturbations observed for the two scaffolds were significantly different, indicating the scaffolds
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have different binding mechanisms. Due to the dual inhibitory activity of the oxadiazole series,
calmodulin was a potential target for this series of compounds, but it was unexpected that the
pyrimidinone scaffold would be mediating its inhibitory effects via calmodulin since it exhibited
potent and selective inhibitory activity at AC1 over AC8. Hence, further characterization of the
AC1/8-CaM interactions is still required in order to establish the mechanism of action of the
inhibitors and potentially elucidate how calmodulin inhibition mediate selective effects on AC1
over AC8 activity.
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CHAPTER 5.

CONCLUSIONS AND FUTURE DIRECTIONS

Adenylyl cyclases are key integrators of extracellular and intracellular signal inputs. The
diverse mechanisms that regulate the catalytic activity of the membrane-bound ACs, together with
the distinct subcellular localization of the AC isoforms, enable the control of distinct cAMP
signaling events in an organized and dynamic manner (Arora et al., 2013).
To develop novel tools to characterize isoform-specific AC responses the work reported
herein first accomplished the development of a CRISPR/Cas9-based cell line with remarkably low
cAMP levels. Functional characterization of the HEK-ACΔ3/6 cell line demonstrated that all the
stimulatory and inhibitory mechanisms previously described in the literature for the membranebound ACs can be recapitulated in this cell model (Dessauer et al., 2017). The improved signal
window of the knockout cell line enabled the detection of distinct cAMP responses from all mAC
isoforms by different stimulatory mechanisms, which was particularly exciting for AC7 and AC9
given that they do not show robust enough responses in the parental HEK293 cells (Brust et al.,
2017). It also became more apparent with the HEK-ACΔ3/6 cells that AC isoforms don’t exhibit
the same cAMP responses to general activators of AC activity such as forskolin or Gαs, so by
having a cell model with low cAMP background, the specific isoform responses to forskolin and
Gαs can be appropriately evaluated and distinguished in HEK-ACΔ3/6 intact cells or membranes.
This becomes quite handy when trying to develop selective AC modulators because the HEKACΔ3/6 cell model, besides offering a platform to counter screen against all AC isoforms, it also
enables the evaluation of AC inhibitors’ activity on various stimulatory mechanisms. Furthermore,
the human genetic background and the capability to examine cAMP accumulation in live-cells of
our HEK-ACΔ3/6 cells, present some advantages to our knockout cellular model over the widely
used Sf9 insect system that also exhibits low cAMP background levels.
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Thus, the use of the HEK-ACΔ3/6 cells in combination with cAMP biosensors would be another
interesting approach to further assess AC isoform specific responses as a result of subcellular
localization or specific coupling with a GPCR or anchoring protein (Paramonov et al., 2015).
The comparison of the cAMP responses of the AC1wt and AC1 mutant constructs in the
HEK293 cells and the HEK-ACΔ3/6 cell line, demonstrated that the HEK-ACΔ3/6 cell model is
not only beneficial for ACs with low catalytic activity, but also for overactive ones. As it was
evidenced with the AC1-N878A mutant, the forskolin dose response curves in the absence and
presence of A23187 were different in the knockout and the parental HEK293 cell lines. Most
recently a set of AC3 variants were identified that linked loss in AC3 activity with obesity (Grarup
et al., 2018). Therefore, it would be interesting to pharmacologically characterize the responses to
various stimulatory mechanisms in the knockout cells of these insensitive AC3 variants as well as
other variants with enhanced AC3 activity to correlate the genetic findings with pharmacological
data that potentially could provide insightful information for the development of novel therapies
(Pitman et al., 2014).
For the work on chapter 3, it was startling to identify a sixth Gβγ binding site on AC2. SPR
analysis confirmed the interaction of Gβγ with the highly conserved C2a domain shared between
AC2, AC4, and AC7. Likewise, a minigene expressing an N-terminal CD8 membrane-anchoring
domain followed by the C2-20 peptide, blocked Gβγ-mediated potentiation of AC2 activity. The
identification of the C2-20 domain adds a third Gβγ binding site on the C2 catalytic domain. The
high binding affinity and degree of sequence homology between AC2, AC4, and AC7 of the C2a
region is similar to the one reported for the PFAHL domain (Boran et al., 2011). Considering that
the PFAHL region is critical for Gβγ’s stimulatory effects, and it requires an additional binding
site on the C2 domain in order to be functional, the C2-20 domain could be the other binding
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domain required to mediate with PFAHL the stimulatory effects of Gβγ (Diel et al., 2006).
Mutagenesis studies based on the CD8-C2-20 variants or domain swapping for instance with the
50% homologous C2a domain of the Gβγ-inhibited AC8, may allow to disrupt the role of the C2a
region on AC2 without affecting much the activity of the cyclase. However, it is important to keep
in mind that not all domains that interact with Gβγ mediate its stimulatory effects. QEHA binds
Gβγ, and it can inhibit various Gβγ-mediated signaling events, but it is not a required binding
domain for conditional stimulation of AC2 given that a chimera of AC2 that does not have the
QEHA binding site still gets stimulated by the Gβγ complex (Chen et al., 1995; Weitmann et al.,
2001). Therefore, the role of the C2-20 domain may be important for the AC2-Gβγ interaction, but
not to transduce the stimulatory effects of Gβγ on AC2 activity.
Our studies with the minigene are the first to examine the ability of Gβγ binding sites to
prevent Gβγ-mediated potentiation of PMA-stimulated AC2 activity in intact cells. All of the rest
of the studies with the other five Gβγ binding sites have evaluated in vitro the inhibitory effects of
the peptide domains on Gαs stimulation in isolated membranes (Boran et al., 2011). Therefore,
now that the HEK-ACΔ3/6 cell model was developed, it could be used to examine the inhibitory
effects of the minigene on Gαs-mediated activation of AC2, AC4, or AC7 activity, and to
determine whether it can block the Gβγ effects on AC4 and AC7. Evaluating the Gβγ-mediated
effects on both PMA and Gαs stimulation could provide insightful information that could justify
the existence of multiple binding sites. Depending on the stimulatory mechanism and the
corresponding induced-conformation of the catalytic domains, Gβγ by having multiple binding
sites on AC2 may recognize multiple conformations of activated AC2.
Targeting the AC isoform regulatory mechanisms mediated by G-proteins, Ca2+ or protein
kinases appears to be a reasonable strategy to develop selective AC isoform modulators.
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Ca2+/calmodulin-stimulated cyclases have emerged as potential targets for several CNS disorders,
driving ongoing efforts to identify selective AC1 and/or AC8 inhibitors (Brust et al., 2017; Hayes
et al., 2017). Hence, it was the goal of the work done in chapter 4 to improve the current
pharmacological profiles of the known AC1 inhibitors. In a first approach, a SAR analysis was
carried out for analogs of the selective AC1 inhibitor, ST034307. The limited set of commercially
available analogs immediately indicated that the trichloromethane at the 2-position of the
chromone ring is the functional group that determines the activity of the compound on AC1. The
inability to identify other substitutions that were comparable to ST034307 discouraged us to keep
expanding the SAR campaign for ST034307, so the Life Chemicals screen was our second strategy
to improve the current chemical moieties acting on AC1. Out of 10,000 compounds, two scaffolds
stood out after hit compound validation and counter-screens. The pyrimidinone series of
compounds displayed AC1 selective activity and are to-date the most potent inhibitors of
Ca2+/calmodulin-stimulated AC1 activity. The other scaffold, the oxadiazole class of compounds,
are dual inhibitors of AC1/AC8 and displayed a wide range of IC50 values, however they were
mostly AC1 selective.
Unfortunately, after a preliminary evaluation of the inhibitory activity of the scaffolds in
membranes and subsequent testing for calmodulin binding, it was determined that both scaffolds
were not engaging the target and the inhibitory effects on AC1/8 activity were indirect and
mediated by calmodulin inhibition. Further characterization at this point is required to determine
whether the calmodulin inhibition is selective for AC activation or if there any other calmodulin
targets that are also inhibited. Calmodulin is a small and flexible protein that interacts with more
than 300 proteins including critical kinases and phosphatases that modulate various cellular
processes. In order to take the oxadiazole and pyrimidinone scaffolds forward it is critical to
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determine potential off-target effects on primary CaM effectors such as CaMKII or calcineurin.
As it is the case for Gβγ, calmodulin might have distinct mechanisms of activation for various of
its targets, so selectivity could still be achieved.
The chemical shift observed for the oxadiazole series resembles the NMR spectra detected
for the calmodulin inhibitors identified in the screen of FDA-approved small molecules (Hayes et
al., 2017). Interestingly, the NMR spectra of the F5213 compound suggested a single and definite
interaction with CaM, so collaborators at the University of Iowa are in the process of assigning
peaks to the calmodulin residues on the F5213 spectra in order to determine the binding site of the
scaffold on the protein. Identifying the binding site and structure determination of the F5213 and
CaM interaction is key in the process of designing the analogs for the future SAR campaign of the
pyrimidinone class of compounds. Initially we thought unlikely that the pyrimidinone scaffold
could bind calmodulin since the scaffold displayed a 60-fold selectivity for AC1 over AC8.
However, the pyrimidinone scaffold could still achieve selectivity by targeting the distinct
mechanisms of activation or by disrupting the unique calmodulin binding sites that mediate the
interaction between CaM-AC1 and CaM-AC8. Consequently, further characterization of the
mechanism by which the pyrimidinone scaffold prevents AC1 activity without having a major
effect on AC8 needs to be explored. Protein-protein interaction studies with the catalytic domains
of AC1 and CaM could be employed to determine whether the inhibitors disrupt the AC1-CaM
interaction. Additionally, the action of both scaffolds on calmodulin might also explain the offtarget effects of the compounds on AC2 activity. AC2 is activated by protein kinase C which in
turn, is inhibited by the calmodulin-effector, CaMKII. Inhibition of calmodulin could inhibit
CaMKII and subsequently disinhibit PKC. Therefore, we are evaluating whether in the presence
of a PKC and CaMKII inhibitors the scaffolds still potentiate AC2 activity. Failure to potentiate
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AC2 activity in the presence of the inhibitors would support the hypothesis that the target of the
scaffold is calmodulin and the modulation of AC activity by these scaffolds are result of indirect
effects.
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APPENDIX A. SUPPLEMENTARY FIGURES

A.

B.

HEK-ACΔ6 cell line

A.

B.

HEK-ACΔ6 cell line

C. HEK-ACΔ3/6 cell line

Supplementary Figure 1. Genotypic characterization of HEK-ACΔ6 and HEK-ACΔ3/6 cell
lines
Schematic for the generation and characterization of the CRISPR/Cas9-based cell lines (A).
Genomic sequencing and predicted protein sequence alignment for the ADCY3 and/or ADCY6
edited genes in the HEK-ACΔ6 (B) and the HEK-ACΔ3/6 (C) cell lines. The sgRNA target
sequences are in bold, and the black triangles indicate the Cas9-mediated cleavage site upstream
of the PAM (box) sequence.
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Supplementary Figure 1 continued
The resulting indels for the ADCY6 and/or ADCY3 genes were determined by sequencing a PCR
product that contained the nuclease cleavage site from the genomic DNA of the clonal cell lines.
The black arrows show the mutation (deletion/insertion) introduced for each allele of the targeted
genes and the deleted/inserted base pairs are underlined. These indels caused a frame-shift on both
ADCY3 and ADCY6 genes that introduced a premature STOP codon as illustrated by the amino
acid sequence alignment between wild-type AC3 or AC6 and the predicted protein sequences of
the mutated genes. Amino acid sequence for the wild-type genes are in bold and aligned regions
with 100% identity are shaded in grey.
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Supplementary Figure 2. Cyclic AMP responses of AC1 mutants expressed in HEK293 and
HEK-ACΔ3/6 cells elicited by the calcium ionophore, A23187.
Cyclic AMP responses of HEK293 and HEK-ACΔ3/6 cells transiently transfected with Venus,
AC1-WT, or a AC1 mutant constructs stimulated with 3 μM A23187 for 1-hour. Data represents
the mean and SEM of at least three independent experiments conducted in duplicate.
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A.

B.

Supplementary Figure 3. Sequence alignment between C2-20 sequence from AC2 and top hits of
the BLAST search
Amino acid sequences of (A) human AC2 (ADCY2), AC4 (ADCY4), AC5 (ADCY5), AC6
(ADCY6), AC7 (ADCY7) and AC8 (ADCY8) or (B) human AC2 (ADCY2) and GPR155
(GP155) were aligned with the EMBL-EBI Clustal Omega software. The scores reported represent
the sequence similarity between each AC/receptor and AC2. Identical amino acids and amino acids
with similar properties are highlighted in grey and light blue, respectively.
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APPENDIX B. SUPPLEMENTARY TABLES

Supplementary Table S1. Primer sequences for site-directed mutagenesis of CD8 (C2-20)
variants
Forward and reverse primer sequences designed for Q5 Site-Directed Mutagenesis using the
NEBaseChanger tool from New England BioLabs. Lowercase letters indicate the base mismatches
incorporated to introduce the desired mutation.

Supplementary Table S2. IC50 values, % inhibition, and % viability of the F9097 analogs.
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Supplementary Table S2 continued
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Supplementary Table S3. IC50 values, % inhibition, and % viability of the F8538 analogs.

138

Supplementary Table S3 continued
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Supplementary Table S4. IC50 values, % inhibition, and % viability of the F9107 analogs.
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Supplementary Table S4 continued
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Supplementary Table S5. IC50 values, % inhibition, and % viability of the F8011 analogs.
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Supplementary Table S6. IC50 values, % inhibition, and % viability of the F4036 analogs.
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departmental shared instrumentation (plate readers, centrifuges, gel scanners) in the
Department of Medicinal Chemistry and Molecular Pharmacology.

•

Helped users troubleshoot problems that were experienced with instrumentation.

TEACHING ASSISTANT
Department of Medicinal Chemistry and Molecular Pharmacology,
Purdue University, West Lafayette, IN
•

August 2012 – May 2013

Teaching assistant for MCMP 204L/205L

RESEARCH VOLUNTEER
Department of Chemistry and Biochemistry
University of Minnesota, Duluth, MN

September 2011– May 2012

•

Undergraduate research assistant working with Ahmed Heikal, Ph.D., Adjunct Professor
Pharmacy Practice and Pharmaceutical Sciences.

•

Studied the effects of macromolecular crowding on the fraction of free and LDH-bound
NADH, employing Time resolving Anisotropy.

SUMMER UNDERGRADUATE RESEARCH ASSISTANT
Department of Chemistry and Biochemistry
University of Minnesota, Duluth, MN
•

Examined the interaction of cholesterol and lipid molecules in a Triton X-100 micellar
system by using the techniques Fluorescence correlation Spectroscopy (FCS) and Dual-Color
Fluorescence Cross-Correlation Spectroscopy (DCFCS).

TEACHER ASSISTANT
College of Saint Scholastica, Duluth, MN
•

June – August 2011

August 2010 – May 2012

Teaching assistant for CHML 1110/1120

Technical Skills
•

Cell-Based Assay Development for Small Molecule Drug Discovery (assay development,
experience with automated liquid handling systems and plate readers, lead optimization and
SAR development)

•

Cell culture of mammalian cell lines and iPSCs-derived neurons (transfection and
transduction of mammalian cells. stable cell line generation, production and handling of
adenoviral expression systems)
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•

Experience with cell-based assay technologies (reporter-based, FRET-based, luminescencebased, FACS, live-cell imaging, HTRF, sensors)

•

Gene Editing for target validation (CRISPR/Cas9 and RNA interference (siRNA))

•

Microscopy (confocal microscopy, fluorescence microscopy)

•

Molecular Biology (RNA and DNA isolation and analysis, PCR, gibson assembly, qPCR,
DNA cloning, vector construction, and gel electrophoresis)

•

Biochemistry (protein quantification, ELISA, SDS/PAGE, Western Blotting, and protein
expression)

•

Tissue processing and preparation for enzyme activity assays, RNA/DNA extraction or
protein quantification.

•

Additional skills (Microsoft Office, Adobe Photoshop, GraphPad Prism, Snapgene, Vector
NTI)

Awards and Honors
•

Graduate Student Travel Award—ASPET annual meeting at Experimental Biology (2018)

•

College of Pharmacy Graduate Student Travel Award— Purdue University (2018)

•

Neuroscience Collaborative Research Award—PIIN, Purdue University (2017)

•

Graduate Student Travel Award—ASPET annual meeting at Experimental Biology (2017)

•

Graduate Student Travel Award—ASPET annual meeting at Experimental Biology (2016)

•

Graduate Student Travel Award—ASPET annual meeting at Experimental Biology (2014)

Professional Society Memberships
American Society for Pharmacology and Experimental Therapeutics—ASPET (2013-Present)
Publications
•

Soto-Velasquez, M., Hayes, M.P., Alpsoy, A., Dykhuizen, E.C., and Watts, V.J., A Novel
CRISPR/Cas9-Based Cellular Model to Explore Adenylyl Cyclase and Cyclic AMP
Signaling. Mol. Pharmacol, (Accepted).

•

Frydrych, J., Skácel, J., Šmídková, M., Mertlíková-Kaiserová, H., Dračínský M.,
Gnanasekaran, R., Lepšík, M., Soto-Velasquez, M., Watts, V. J., Janeba, Z.. Synthesis of αbranched acyclic nucleoside phosphonates as potential inhibitors of bacterial adenylate
cyclases. ChemMedChem, (2018).

•

Hayes, M.P., Soto Velasquez, M., Fowler, C.A., Watts, V.J., Roman, D.L.. Identification of
FDA-Approved Small Molecules Capable of Disrupting the Calmodulin-Adenylyl Cyclase 8
Interaction through Direct Binding to Calmodulin. ACS Chem. Neurosci., (2017).
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•
•

Brust, T. F., Alongkronrusmee, D., Soto Velasquez, M.P., Ye, Z., Dai, M., van Rijn, R.M.,
Watts, V. J..
Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with
analgesic properties. Sci. Signal., (2017).

•

Rana, N, Conley, J.M., Leon, F., Cutler, S. J, Soto Velasquez, M.P., Watts, V. J., Lill, M.A..
Molecular Modeling Evaluation of the Enantiomers of a Novel Adenylyl Cyclase 2 Inhibitor.
J. Chem. Inf. Model., 57, 322–334 (2017).

•

Břehová, P., Šmídková, M., Skácel, J., Dračínský, M., Mertlíková-Kaiserová, H., Velasquez,
M. P. S., Watts, V. J., Janeba, Z.. Design and Synthesis of Fluorescent Acyclic Nucleoside
Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases. ChemMedChem, 11(22),
2534–2546 (2016).

•

Alfveby, J., Timerman, R., Soto Velasquez, M. P., Wickramasinghe, D. W. P. M., Bartusek,
J., Heikal, A. A. Time- and polarization-resolved cellular autofluorescence towards
quantitative biochemistry on living cells. Proc. of SPIE, 91980U–91980U–15 (2014).

